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Summary 
 
Despite advances in treatment, peritoneal dialysis (PD)-associated peritonitis 
remains a major cause of morbidity and mortality in PD patients. Given that 
peritonitis can be the proximate cause of technique failure and cause ultrafiltration 
failure at a later time, it is important to understand the peritoneal immune response, 
microbiology and outcomes of these infections. 
 
Data presented in this thesis have shown that leukocytes are recruited to the 
peritoneal cavity, starting with a rapid accumulation of neutrophils, which are later 
replaced by a population of mononuclear cells, including monocytes/macrophages 
and T cells during acute peritonitis. Of note, Vγ9/Vδ2 T cells are also recruited to the 
peritoneal cavity in the early stage, which implies a significant role of Vγ9/Vδ2 T 
cells as early responders in acute peritonitis.  
 
In patients with acute peritonitis, the capacity of the causative pathogen to produce 
(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), together with the 
infiltration of activated Vγ9/Vδ2 T cells are important risk factors and possible 
predictors of patient outcomes from infection. By performing a detailed 
immunological and microbiological analysis in PD patients on the first day of 
peritonitis, our findings provide proof of concept that acute bacterial infections 
indeed leave characteristic disease-specific ‘immune fingerprints’ of diagnostic and 
prognostic value. Local fingerprints not only discriminated between episodes of 
culture-negative and culture-positive PD-associated peritonitis but also predicted 
infections caused by Gram
−
 or Gram
+
 bacteria. 
 
HPMC play an important role in maintaining homeostasis of the peritoneal immunity. 
Our data revealed the regulation of Vγ9/Vδ2 T cells by HPMC and demonstrated 
that resting HPMC were potent suppressors of Vγ9/Vδ2 T-cell cytokine production 
and proliferation in the presence of HMB-PP.  
 
Collectively, these findings improve our insight into the complex cellular 
interactions in PD-associated peritonitis and peritoneal homeostasis, identify novel 
biomarkers of possible diagnostic and predictive value and highlight new avenues 
for therapeutic intervention. 
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1.1 Chronic kidney disease 
 
1.1.1 Definition and staging system 
Chronic kidney disease (CKD) is a worldwide public health problem. The National 
Kidney Foundation - Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) 
workgroup has defined CKD as the following (1): 
1) The presence of markers of kidney damage for ≥ 3 months, as defined by 
structural or functional abnormalities of the kidney with or without decreased 
glomerular filtration rate (GFR), that can lead to decreased GFR, manifest by either 
pathological abnormalities or other markers of kidney damage, including 
abnormalities in the composition of blood or urine, or abnormalities in imaging tests; 
or 2) the presence of GFR < 60 ml/min/1.73 m2 for ≥ 3 months, with or without 
other signs of kidney damage as described above.  
The staging system (Table 1.1) for CKD is intended to aid clinicians in the 
management of patients with CKD by identifying those with the most severe disease 
who are, therefore, at greatest risk for progression and complications. 
Table 1.1 Stages of chronic kidney disease 
 
Stage Description GFR (ml/min/1.73 m
2
) 
1 Kidney damage with normal or ↑GFR ≥ 90 
2 Kidney damage with mild ↓GFR 60~89 
3 Moderate ↓GFR 30~59 
4 Severe ↓GFR 15~29 
5 Kidney failure <15 (or dialysis) 
Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities 
in blood or urine tests or imaging studies. Adapted from (1). 
Once the patient has reached the stage of near end-stage renal disease (stage 5 with 
GFR less than 15 ml/min), signs and symptoms related to uraemia begin to occur, 
such as malnutrition, anorexia, nausea, vomiting, fatigue, sexual dysfunction, platelet 
dysfunction, pericarditis, and neuropathy. When these problems reach a critical stage, 
renal replacement therapy will be required. 
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1.1.2 Renal Replacement Therapy 
The 2006 K/DOQI guidelines recommend that patients with a GFR less than 30 
ml/min per 1.73 m
2
 should be educated about kidney failure and options for its 
treatment, including renal transplantation, peritoneal dialysis (PD) and haemodialysis 
(HD) (2). 
 
Renal transplantation is one of the treatment choices for end-stage renal disease 
(ESRD). A successful renal transplant improves the quality of life and reduces the 
mortality risk for most patients, when compared with maintenance dialysis (3). 
However, not all patients are appropriate candidates for a kidney allograft. 
Furthermore, there is a shortage of donated organs and the waiting list for 
transplantation is growing (4). As a consequence, most patients with ESRD receive 
maintenance dialysis to support their renal function. 
 
There are two types of dialysis: PD and HD. The choice between PD and HD is 
influenced by a number of considerations such as availability and convenience, 
medical factors, and socioeconomic and dialysis centre factors. Starting patients on 
PD as their initial treatment modality seems appropriate for many reasons. One 
reason is to take potential advantage of the better survival of PD patients compared 
with HD patients during the first 2 years of dialysis treatment (5). Other reasons to 
offer PD as the first-choice modality include the lower cost of therapy, convenience 
of home therapy, a flexible schedule, and increased freedom from the patient’s 
perspective (6). 
 
1.2 Peritoneal Dialysis 
 
1.2.1 General consideration 
Over the last thirty years, PD has become an alternative to HD for the treatment of 
ESRD that is widespread around the world. Its popularity has increased greatly, 
mainly because of its simplicity, convenience, and offering patients a home-based 
therapy. Studies comparing differences in patient mortality between PD and HD 
have shown conflicting results. The relative long-term outcome with PD compared to 
HD remains uncertain, but peritoneal dialysis may offer a slight advantage in 
younger, nondiabetic patients (7, 8). 
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1.2.2 Peritoneal dialysis technique 
PD requires a peritoneal dialysis catheter as the access to permit clean dialysis 
solution to enter the patient’s peritoneal cavity and let wastes and fluid drain out 
later (Figure 1.1). The transport of solutes and water between circulation and the 
dialysis solution in the peritoneal space is based on the ability of the peritoneal 
membrane to function as a dialyzing membrane. The dialysis solution in the 
peritoneal space typically contains sodium, chloride, calcium, and lactate or 
bicarbonate and is made hyperosmolar by the inclusion of a high concentration of 
glucose (9). 
 
 
Figure 1.1 This drawing shows a person having peritoneal dialysis.  
Taken from: Treatment Methods for Kidney Failure: Peritoneal Dialysis.  
National Institute of Diabetes and Digestive and Kidney Diseases.  
Available at: http://kidney.niddk.nih.gov/kudiseases/pubs/peritoneal. 
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1.2. 3 Physiology of peritoneal transport 
The peritoneal membrane is a complex membrane composed of the capillary 
endothelium, the interstitium, and the mesothelium (9). The transport of water and 
solutes across this membrane best fits the three-pore model that describes the 
presence of three different sized pores in the peritoneal membrane. Large pores that 
constitute less than 0.01% of the total number of pores are thought to represent clefts 
between endothelial cells that allow the transport of macromolecules such as 
proteins. Numerous small pores are responsible for the transport of lower molecular 
weight solutes such as urea and creatinine, while ultra-small pore water channels 
(aquaporin-1) allow the movement of water only (10). 
 
In PD, solute transport across the peritoneum occurs by the processes of diffusion 
and ultrafiltration. Diffusion varies directly with the magnitude of the concentration 
gradient and inversely with the size of the solute. During the course of a PD dwell, 
smaller solutes such as creatinine and urea diffuse down a concentration gradient 
from the peritoneal capillary blood into the PD solution. The concentration gradient 
across the membrane is highest in the beginning of the dwell. Thus, the removal of 
small solutes such as urea is maximal in the beginning, and falls progressively 
during the course of the dwell. Diffusion becomes more restricted as molecular 
weight increases. Glucose, lactate, and calcium will diffuse in the opposite direction, 
from dialysate to the blood. 
 
Ultrafiltration occurs as a result of an osmotic pressure gradient between the dialysis 
solution and the peritoneal capillary blood. The dialysis solution is made hypertonic 
usually by the addition of high concentrations of glucose. Ultrafiltration is maximal 
at the beginning of a dwell when the osmotic pressure gradient is highest. The 
osmotic pressure gradient will decrease over time due to the dilution of the glucose 
by ultrafiltrate and by the diffusion of glucose from the peritoneal cavity into the 
bloodstream. Fluid removal is maximized by using more hypertonic dialysis 
solutions or by doing more frequent exchanges.  
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During ultrafiltration, solutes present in body fluids will be transported by solvent 
drag, which is called convection, contributing to overall solute clearance. Water and 
solutes are also constantly being absorbed from the peritoneal cavity into the 
lymphatic system and this will counteract both solute and fluid removal (9). 
 
1.2.4 Peritoneal equilibration test (PET) 
In clinical practice, a patient's peritoneal membrane transport function can be 
assessed by measuring the creatinine equilibration curve and the glucose absorption 
curve during a standardized peritoneal equilibration test (9). The standardized four-
hour PET involves a 2-L 2.5% dextrose dwell with dialysate samples taken at 0, 2, 
and 4 hours and a plasma sample at 2 hours. Net fluid removal is also measured 
along with the ratio of dialysate glucose at 4 hours to dialysate glucose at time zero. 
Patients are classified principally into one of four transport categories: high, high-
average, low-average, and low. 
 
High transporters will have the fastest equilibration of creatinine, but ultrafiltration 
will not be as great due to rapid absorption of glucose and dissipation of the osmotic 
gradient. High transporters also tend to have higher dialysate protein losses. In 
contrast, low transporters will have less complete equilibration of creatinine, but will 
have good net ultrafiltration due to the slower absorption of glucose into the 
bloodstream. Thus, high transporters tend to do better on regimens that have frequent, 
short-dwell exchanges, such as automated peritoneal dialysis (APD), whereas low 
transporters tend to do better on regimens with long-dwell exchange, such as 
continuous ambulatory peritoneal dialysis (CAPD) or continuous cyclic peritoneal 
dialysis. Patients with average transport rates can effectively be treated with either 
short- or long-dwell exchange techniques. 
 
1.2.5 Modalities of PD 
Chronic peritoneal dialysis is divided into CAPD and APD. CAPD typically 
involves four 2.0- to 2.5L dwells daily, with each lasting 4–8 hours. In APD, 3-10 
dwells are instilled nightly using an automated cycler. In the daytime, the patient 
usually carries a dwell, which is drained each night before cycling recommences. 
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1.3 Acute peritonitis  
PD associated peritonitis remains a major cause of morbidity and mortality in PD 
patients. Although less than 4% of peritonitis episodes result in death, peritonitis is a 
“contributing factor” to death in 16% of deaths on PD. Moreover, severe and 
prolonged peritonitis can lead to peritoneal membrane failure. It is a major cause for 
the switch from PD to HD, especially within the first 1 to 2 years of initiating PD (6, 
11-15).  
 
1.3.1 Diagnosis 
Peritonitis is thought to occur most often by touch contamination at the time of 
catheter connection, but may also occur associated with exit site/tunnel infection or 
by transmural migration of bacteria across the intestinal wall. Patients with 
peritonitis usually present with cloudy peritoneal fluid and abdominal pain. When a 
patient presents with these complaints, the peritoneal fluid should be drained and the 
effluent sent for white blood cell (WBC) count and differential, Gram stain, and 
culture. The diagnosis of peritonitis is supported by the presence of WBC count 
more than 100/μl of PD effluent with at least 50% polymorphonuclear neutrophil 
cells (14).  
 
1.3.2 Microbiology 
Infections due to Gram-positive bacteria are most common (50-70% of episodes) 
compared to infections with Gram-negative bacteria (20–25%) or fungi (2–3%). 
Infection with mycobacteria is rare (16, 17). The proportion of Gram-negative  
peritonitis is increasing and such infections are becoming more severe with poor 
outcome (18). Among Gram-positive bacteria, coagulase-negative staphylococcus is 
the most common species, followed by Staphylococcus aureus and Streptococcus 
species. Enterococcus and Corynebacterium are less common. The most common 
Gram-negative organisms are Pseudomonas, Escherichia coli, and Klebsiella (13, 
15). Peritonitis with multiple organisms or anaerobes should raise the concern of 
intra-abdominal pathology and lead to abdominal computed tomography scans and 
surgical evaluation. 
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1.3.3 Culture-negative peritonitis 
Culture-negative peritonitis is defined as the presence of cloudy dialysate and/or 
abdominal pain in the presence of a WBC count of more than 100/μl of PD effluent 
with at least 50% polymorphonuclear neutrophil cells, with no microbiological 
growth at 72 hours. Most cases of culture-negative peritonitis result from recent 
antibiotic exposure, suboptimal sample collection/culture methods or unusual 
organism (e.g., mycobacteria, or mycoplasm). However, noninfectious causes such 
as chemical peritonitis or chylous ascites or effluent eosinophilia (19) should also be 
considered, especially when peritonitis fails to respond to empirical antibiotic 
therapy (14, 20).  
 
In keeping with the International Society for Peritoneal Dialysis recommendations, 
the rate of culture-negative peritonitis in a centre should not be greater than 20% of 
episodes when standard culture technique using blood-culture bottles is adopted (14). 
Using large-volume culture (e.g., culturing the sediment after centrifuging 50 mL of 
effluent) could further improve the recovery of micro-organisms (21). There is not 
enough evidence for recommending the use of novel techniques such as broad-
spectrum polymerase chain reaction with RNA sequencing for the diagnosis of 
peritonitis (22, 23).  
 
1.3.4 Treatment of PD peritonitis 
Patients who present with signs and symptoms of peritonitis are usually treated 
empirically with antibiotics covering both Gram-positive and Gram-negative 
organisms. Gram-positive organisms may be covered by vancomycin or a 
cephalosporin, and Gram-negative organisms by a third-generation cephalosporin or 
aminoglycoside. The choice of antibiotics should take into account the patient's 
infection history and the centre's history of resistant organisms (14). Antibiotics are 
usually administered by the intra-peritoneal route and can be given by intermittent or 
continuous dosing. Most patients will show considerable clinical improvement 
within 48 hours of starting antibiotic therapy. Final antibiotic therapy is guided by 
culture results and sensitivities. Treatment is continued for a total of 2 weeks, while 
more severe infections due to Staphylococcus aureus, Pseudomonas, or multiple 
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Gram-negative organisms are treated for 3 weeks. If there is no clinical improvement 
after 48 hours, cell counts and cultures should be repeated.  
 
Refractory peritonitis is defined as failure to respond to appropriate antibiotics 
within 5 days and is usually managed by catheter removal. Other indications for 
catheter removal are fungal peritonitis, relapsing peritonitis, peritonitis in the setting 
of severe exit site or tunnel infection, and infection due to multiple enteric organisms 
in the setting of a surgical abdomen (14). 
 
1.4 Inflammation in peritoneal dialysis 
 
1.4.1 Anatomy of the peritoneal cavity 
The peritoneum is a serosal membrane that lines the peritoneal cavity. It has a 
surface area that is found to correlate with body surface area and typically ranges 
from 1 to 2 m
2
 in an adult (24). It is divided into two portions: (a) the visceral 
peritoneum, which lines the gut and other viscera, and (b) the parietal peritoneum, 
which lines the walls of the abdominal cavity (9). During peritoneal dialysis, the 
parietal peritoneum takes the major part of peritoneal transport, since only about 
20~30% of the visceral peritoneum is in contact with the dialysis solution at a given 
time (25). 
 
1.4.2 Peritoneal membrane histology 
The peritoneal membrane is lined by a monolayer of mesothelial cells (MC). 
Mesothelial cells are active cells involving the structural and functional alteration of 
the peritoneum. They can coordinate inflammation, host defence, contributing to 
solute transport, and wound healing (26). Beneath the mesothelium is the interstitium, 
which contains collagen, fibroblasts, peritoneal capillaries and lymphatics (27, 28).  
 
During PD, peritoneal cells are repeatedly exposed to a non-physiological 
hyperosmotic and hyperglycemic solutions with low pH environment. Long-term 
exposure to the bio-incompatible PD solutions results in denudation of the 
mesothelium, submesothelial compact zone thickening, hyalinizing vasculopathy, 
and an epithelial-to-mesenchymal transition (EMT) of MC (26, 29-31). The fibrotic 
process in the peritoneal membrane develops following acute and chronic release of 
Chapter 1: Introduction 
 
10 
 
PD-related inflammatory mediators.  
 
1.4.3 Chronic inflammation in PD patients 
Chronic inflammation is common in PD patients. The inflammatory status of PD is 
affected by reduced renal excretion of cytokines, dialysis procedure and 
comorbidities including chronic heart failure and coronary heart disease (32). 
Inflammation in PD patients is associated with a poor prognosis. Noh et al. 
demonstrated that elevated serum C-reactive protein level is associated with 
increased mortality of CAPD patients (33). Continuing exposure of bio-incompatible 
PD solutions, glucose degradation products, advanced glycation end-products, 
peritonitis, and uraemia all contribute to peritoneal inflammation (30, 34), which is 
characterized by increased vascular permeability, activation and expansion of the 
peritoneal macrophage population, recruitment of infiltrating cells to sites of injury, 
release of pro- and anti-inflammatory mediators, and increased matrix protein 
synthesis and tissue remodelling (26). 
 
Major cell types involving the inflammation in PD patients include macrophages and 
mast cells, together with mesothelial cells, fibroblasts, and endothelial cells. Figure 
1.2 summarises the cellular system known to contribute to PD-induced changes and 
includes the cytokines and chemokines produced.  
 
1.4.4 Peritoneal Macrophages 
Macrophages are the predominant cell type found in peritoneal cavity and play an 
important role in the first line of defence against invading microorganisms. During 
PD, reported peritoneal macrophage numbers are variable ranging from 20% to 95% 
(35, 36). Peritoneal macrophages from CAPD patients are activated with increased 
expression of Fc and C5a receptors, and human leukocyte antigen (HLA)-DR, which 
are important in host defence (37). Macrophages can release prostaglandin-E2 (PGE-
2), interleukin (IL)-1β, IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), 
and tumour necrosis factor (TNF)-α following stimulation of bacteria and thereby 
modulate the intraperitoneal inflammation (34, 38). In addition, CD206
+
 and 
CD163
+ 
M2 macrophages were found in peritoneal effluent, which may participate 
in human peritoneal fibrosis through the stimulation of fibroblast cell growth and 
CCL18 production (39).  
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Figure 1.2 Cellular system of inflammatory response, including production of cytokines and 
chemokines, upon exposure to peritoneal dialysis fluid.  
Dotted lines indicate activation of peritoneal cells; straight lines indicate production of cytokines and 
growth factors. IL = interleukin; PGE2 =prostaglandin E2; VEGF = vascular endothelial growth 
factor; FGF-2 = basic fibroblast growth factor; TGF-β = transforming growth factor beta; TNF-α = 
tumour necrosis factor alpha; NOS = nitric oxide synthase; ROS = reactive oxygen species; VCAM = 
vascular cell adhesion molecule; ICAM = intercellular adhesion molecule; MCP-1 = monocyte 
chemoattractant protein 1. Taken from (40). 
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1.4.5 Mesothelial Cells  
By secreting numerous cytokines/chemokines, growth factors, matrix proteins, and 
intracellular adhesion molecules, along with their ability to present antigens to 
lymphocytes, mesothelial cells play a critical role as immunomodulators during 
peritoneal injury and inflammation (26). Mesothelial cells express HLA-DR and 
intercellular adhesion molecules and secrete IL-6, IL-8, RANTES (regulated upon 
activation, normal T-cell expressed and secreted), and MCP-1 on exposure to 
bacterial products and inflammatory cytokines (41-45).  
 
Toll-like receptors (TLR) play a critical role in innate immune responses by 
specifically recognizing molecular patterns from a wide range of microorganisms, 
including bacteria, viruses, parasites and fungi (46). Recognition of bacterial 
pathogens by the peritoneum is mediated in part by TLR that induce inflammation 
by triggering nuclear factor kappa B and signalling transduction pathways, leading to 
the induction of inflammatory cytokines (46-48). Although human peritoneal 
mesothelial cells (HPMC) respond to TLR1/2, TLR2/6 and TLR5 ligands in a 
similar manner to murine cells, there are no cell surface TLR4 or responses to 
lipopolysaccharides (LPS) detected in it, unlike reports from murine cells (47-49). 
 
Chronic exposure of human mesothelial cells to glucose degradation products 
resulted in a dose-dependent inhibition of cell growth, cell viability, IL-6 and 
fibronectin release, and increased synthesis of transforming growth factor beta 
(TGF-β) and vascular endothelial growth factor (30, 34). During PD, HPMC can 
undergo EMT with a down-regulation of E-cadherin and an induction of snail 
expression. In addition, profibrotic factor TGF-β and inflammatory cytokines may 
induce a complete transition of mesothelial cells, which may play an important role 
in peritoneal fibrosis leading to failure of peritoneal membrane function (29). 
Treating the cultured HPMC with bone morphogenic protein 7 (BMP-7), an intrinsic 
antifibrotic protein and member of the TGF-β superfamily, blocks high glucose or 
TGF-β1-induced EMT (50, 51). Aguilera et al. also demonstrated that EMT reversal 
of mesothelial cells by rapamycin, a mammalian target of rapamycin (mTOR) 
inhibitor (52). 
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In summary, extrinsic factors and PD fluid characteristics activate macrophages and 
mesothelial cells, which produce inflammatory cytokines and growth factors. 
Thereafter, these factors activate fibroblasts, endothelial cells, and mast cells, which 
secrete angiogenic and fibrotic cytokines and growth factors, playing an important 
role in tissue remodelling after long-term PD (Figure 1.2) (40). 
 
1.5 Immune responses in acute peritonitis 
 
1.5.1 Progression from innate to adaptive immunity 
Peritonitis is an inflammatory process that involves all the components of the 
immune system (Figure 1.3). Immune responses are frequently categorized as innate 
and adaptive responses on the basis of the time course kinetics and contributing cells 
and mediators. The innate response involves mainly monocytes, neutrophils, or 
natural killer cells, and are readily activated following engagement of non-clonal 
receptors referred to as pattern recognition receptors such as TLR, which rapidly 
initiate cytokine production upon recognition of conserved microbial or endogenous 
danger signals. 
 
Adaptive immune cells have functions that are similar to those of innate cells, but 
they can give stronger responses after repeated exposure to a given eliciting agent 
due to immunological memory. T cells and B cells are characterized by the 
expression of clonally variable antigen receptors that are built up from rearranged 
gene segments (53). The establishment of immunological memory implies expansion 
of T and B cells, specific for the eliciting antigen, after engagement of clonally 
distributed T cell receptors (TCR) and B cell receptors. Clonally expanded T and B 
cell populations acquire a restricted set of effector functions that are presumably best 
suited for clearance of the eliciting agent at a given time point in a given tissue (54). 
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Figure 1.3 Immune responses in acute peritonitis.  
The initial reaction against invading pathogens is usually made by cells of innate immunity (upper 
left). Unlike other T cells, γδ T cells are able to react against antigens without presentation on antigen 
presenting cells. Pathogens in the peritoneal fluid are drained to the lymphatic system and accumulate 
in lymph nodes, where their antigens are presented to T cells by dendritic cells (DC) (upper left). DC 
may migrate from the peritoneum to the lymph node to present antigens that they have processed. 
Stimulated T helper (TH) cells and cytotoxic T lymphocytes (CTL) differentiate, proliferate, and 
migrate from lymph nodes to the peritoneum. Taken from (55). 
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1.5.2 Recruitment of mononuclear cells during peritonitis  
During acute peritonitis, leukocytes are recruited to the peritoneum, starting with a 
rapid accumulation of neutrophils, which are later replaced by a population of 
mononuclear cells, including macrophages and lymphocytes (Figure 1.4) (56). This 
represents the transition from the innate immunity to adaptive immunity, which play 
an important role in the clearance of infection. IL-6 and its soluble receptor (sIL-6R) 
have been showed to be involved in controlling this pattern of leukocyte recruitment. 
The CXC chemokines, such as IL-8 (CXCL8), can stimulate the recruited 
neutrophils to release sIL-6R. In turn, the sIL-6R/IL-6 complex attenuates IL-8 
production by HPMC, ensuring clearance of neutrophils, and simultaneously 
promoting the secretion of the CC chemokines, such as MCP-1 and RANTES, which 
increase the recruitment of monocytes and lymphocytes (57). 
 
In addition to the effects of sIL-6R/IL-6 complex in regulation of the transition to 
mononuclear cell dominance during peritonitis, mononuclear cells positively 
regulate their recruitment by secretion of interferon gamma (IFN-γ) and by 
expression of CD154 (CD40 ligand). The expression of CD40, a member of the 
tumour necrosis factor receptor family, was shown to be present on HPMC (Figure 
1.3) and was elevated on exposure to inflammatory cytokines. The ligation of CD40 
and IFN-γ synergize to up-regulate RANTES secretion from HPMC (58). In a mouse 
model, CD40 in peritoneal mesothelial cells increased and CD154 expression was 
induced in peritoneal leukocytes after induction of peritonitis. Peritoneal 
macrophages were the main peritoneal leukocyte population to express CD154 (59). 
In a human study, a positive correlation between CD154 levels and mononuclear 
dominance, suggest that CD40–CD154 ligation plays an important role in the 
transition to mononuclear predominance in the late phase of peritonitis (60). 
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Figure 1.4 IL-6 and sIL-6R signalling in the regulation of leukocyte trafficking. 
The regulation of leukocyte trafficking in the peritoneal cavity is mediated by proinflammatory 
cytokine– driven activation of IL-6/sIL-6R trans-signalling mediated through control of STAT3 
activation that results in differential control of chemokine secretion and polymorphonuclear 
neutrophils (PMN) apoptosis. Taken from  (56) 
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1.6 The role of peritoneal αβ T cells 
 
In the normal peritoneal cavity, 5-10% of the leukocytes are lymphocytes. In PD 
patients, wide ranges of lymphocyte percentages in PD effluent have been found 
between 2% and 84% (35, 36). The majority of lymphocytes in both patients’ 
peripheral blood and peritoneal effluent are T cells. Compared to patients’ peripheral 
blood, more B cells are found in PD effluent (61). Several studies from PD effluent 
have reported the presence of activated lymphocytes, which suggests that some 
degree of local activation exists continuously in a patient’s peritoneum (35, 61, 62). 
Although peritoneal lymphocytes are activated, they appear to be functionally 
impaired, with a significantly lower IL-2 production than is seen with peripheral 
lymphocytes (61). 
 
1.6.1 TCR signal transduction and T cell subsets 
Most mature T cells express T cell receptors composed of α/β protein heterodimers 
which are non-covalently linked to the signal-transducing CD3 complex. 
Engagement of TCR leads to the activation of Src family protein tyrosine kinases 
resulting in the phosphorylation of CD3 immunoreceptor tyrosine-based activation 
motifs and recruitment of Zeta-chain-associated protein kinase 70 (ZAP-70)  
followed by numerous downstream signals and leading to T cell activation (53). αβ T 
cells are further divided into subsets based on expressed co-receptors or distinct 
patterns of cytokine production. CD4
+
 T cells recognize via their TCR peptides 
derived from exogenous antigens and presented in the context of major 
histocompatibility complex (MHC) class II molecules. In contrast, CD8
+ 
T cells 
recognize their cognate antigenic peptides generated endogenously, e.g. during viral 
infection via presentation by MHC class I molecules (63). It is obvious that CD4
+
 T 
cells are functionally heterogeneous and comprise distinct subpopulations (Figure 
1.5). There are at least 4 well-characterized CD4
+
 T cell populations that can be 
distinguished on the basis of cytokines and the expression of specific transcription 
factors: T helper 1 (TH1) cells produce IFN-γ as a key cytokine and express the 
transcription factor T-bet; T helper 2 (TH2) cells produce IL-4, IL-5 and IL-13 under 
the control of the transcription factor GATA-3; T helper 17 cells produce IL-
17(TH17)  and express the transcription factor RORγt; and regulatory T cells (Treg) 
which inhibit immune responses and express the transcription factor FoxP3. 
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However, there is substantial plasticity in the lineage commitment of CD4
+
 T cells, 
pointing to the importance of the local microenvironment for the functional CD4
+
 T 
cell development (64). Another T cell subpopulation is the γδ T cells, which 
contribute to anti-infective and tumour immune responses and regulate local immune 
surveillance (65).  
 
 
 
Figure 1. 5 Differentiation of naive CD4
+
 T cells into Tregs or Effector T cells.  
Cytokines and transcription factors that promote the differentiation of naive T cells into Tregs or 
effector T cells are shown. The transcription factors T-bet, GATA3, or RORγt are required for the 
differentiation of naive T cells into Th1, Th2, or Th17 cells, respectively. nTreg, natural Treg; iTreg, 
induced Treg; RA = retinoic acid. Taken from (66) 
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1.6.2 TH1 and TH2  
T Helper cells provide help to B cells, CD8
+
 cytotoxic T cells, and activating the 
cells of the innate immune system. They also play critical roles in the pathogenesis 
of autoimmunity, asthma, allergy and cancer (64). The differentiation of the CD4
+
 T 
cell lineage into effector cells underlies successful adaptive immune responses aimed 
at distinct categories of pathogens. The first paradigm for this functional 
diversification was the description of TH1 and TH2 CD4
+
 effector subsets by 
Mosmann and Coffman in 1986 (67). TH1 cells were thought to be responsible for 
delayed type hypersensitivity, activating macrophages via release of IFN-γ and 
enabling them to kill intracellular pathogens. TH2 cells were considered the classical 
helper T cells providing help to B cells to generate class switched antibodies (68). 
 
In the peritoneum, TH cells are one of the most important cell populations. PD 
associated peritonitis is predominantly the type 1 immune response, characterized by 
early induction of TNF-α, IL-1β, IL-12, and IL-18, followed by elevation of IFN-γ 
(69, 70). Wang et al. demonstrated that local IL-12 and IL-18 production is part of a 
protective early immune to PD associated peritonitis. High levels of IL-12 and IL-18 
in PD effluent during the early phase of peritonitis correlated with a predominant 
type 1 immune response and favourable outcome (70). 
 
1.6.3 Regulatory T cells   
CD4
+
CD25
+
 Treg are vital for the preservation of immune tolerance. It has been 
shown that these cells suppress proliferation and cytokine production of naive 
CD4
+
CD25
–
 T cells, differentiated CD4
+
 T cells, CD8
+
 T cells, and natural killer 
cells in vitro and in vivo. They suppress immune responses through several 
mechanisms including the secretion of immunosupressive cytokines, cell-cell contact, 
and by modulating the function of antigen presenting cells (71). Besides thymic-
derived Treg (natural or nTreg), it was shown that naive T cells in the periphery 
could acquire immunosuppressive properties and become induced Treg (iTreg). 
Absence of Foxp3, a forkhead/winged-helix transcriptional factor, results in 
widespread autoimmunity and absence of Treg. However, over-expression of Foxp3 
results in immunosuppressive functions. Accordingly, Foxp3 was designated as the 
Treg master regulator (64, 66, 71). 
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Thymic-derived Treg (natural or nTreg): The CD4
+
CD25
+
 Treg represent 5-10% of 
all peripheral CD4
+
 T cells. These cells develop in the thymus and then enter the 
peripheral tissue. It was observed that CD4
+
CD25
+
 T cells remained fairly constant 
in the peripheral blood and significantly increased in the peritoneal fluid 24 hours 
and 48 hours after elective surgery of the gastrointestinal tract (72). In a mouse 
model, adoptive transfer of in vitro stimulated CD4
+
CD25
+
 T cells significantly 
improved survival of infected mice. Furthermore, the effect on survival was 
accompanied by improved peritoneal bacterial clearance, enhanced peritoneal mast 
cell recruitment, and TNF-α production (73). 
 
Induced Treg: Naive CD4
+ 
T cells in the periphery can acquire Foxp3 expression and 
Treg function in several experimental settings such as in vitro antigenic stimulation 
of naive T cells in the presence of TGF-β (74-76). It remains to be determined 
whether Treg induced from naive T cells in the periphery are functionally stable in 
vivo and to what extent they contribute to the peripheral pool of Foxp3
+
 Treg (66).  
 
1.6.4 TH17 
TH17 cells are a subset of CD4
+
 helper T cells characterized by producing IL-17 and 
express the lineage specific transcription factors, RORγt (77).  In healthy individuals, 
less than 1% of CD4
+
 T cells in peripheral blood are Th17 cells (78, 79). TH17 cells 
might be actively recruited to and/or expanded in the pathological site, and their 
tissue localization could be important for TH17 cell-associated pathology. Supporting 
the idea of active recruitment, the chemokine receptor CCR6 and the integrin CD49, 
which are molecules implicated in TH17 tissue trafficking, are highly expressed on 
TH17 cells in human blood and tissues (79, 80). Although TH17 cells form a distinct 
TH lineage under specific conditions in vitro, it is emerging that TH17 cells exhibit 
plasticity in some in vivo settings (68) and the cytokine profile of TH17 cells may be 
altered in tissues. For example, human TH17 cells may express IL-4 (81), IFN-γ (78) 
and Foxp3 (82) in different pathological environments. Although the precise role and 
underlying mechanisms of TH17 cells in tissues in human disease are unclear relative 
to other effector T cell subsets, it is thought that the plasticity could be important for 
TH17 cell-associated pathology and -mediated immunity (68).  
 
 
Chapter 1: Introduction 
 
21 
 
1.6.5 CD8
+
 Cytotoxic T cells (CTL) 
Cytotoxic T cells that express the CD8 co-receptor and recognize peptide–MHC 
class I complexes have a key role in clearing viral infections. During a primary 
immune response to pathogens, naive CD8
+
 T cells expressing pathogen-specific T 
cell receptors clonally expand and differentiate into effector CD8
+
 T cells that 
control the primary infection. This differentiation process produces effector CTL that 
can destroy virally infected cells through the targeted secretion of perforin and 
granzymes from lytic granules. After the primary infection is cleared there is a 
contraction phase when most of the effector CTL die by apoptosis. However, an 
effective immune response also produces a stable population of antigen-specific long 
lived memory CD8
+
 T cells that can respond rapidly to clear secondary infections 
(83). T cells from the normal human peritoneum contain high frequencies of TH2-
type CD8
+
 T cells (84). A previous study showed that a progressively decreasing 
CD4/CD8 ratio in PD effluent correlates with the persistent expression of TGF-β1 in 
the dialysate and may play a pathogenetic role in the evolution of peritonitis, 
peritoneal equilibration test deterioration and peritoneal fibrosis. The pattern of the 
CD4/CD8 T cell ratio in PD effluent may predict the outcome of peritonitis in CAPD 
patients (85). 
 
1.7 The role of peritoneal γδ T Cells  
Many reports indicate that γδ T cells play an important role in anti-infective and anti-
tumour immune responses and regulate chronic inflammation (65). γδ T cells, which 
express γδ TCR instead of the αβ TCR found on classic T cells, constitute 
considerable variation (0.2-20%) of the CD3
+
 T cells in human blood. Vγ9/Vδ2 T 
cells, Vγ2/Vδ2 T cells according to alternative nomenclature, are the major subset 
(50-95%) of the peripheral blood γδ T cells population (86-88). Unlike classical αβ T 
cells, Vγ9/Vδ2 T cells recognize nonpeptide ligands such as pyrophosphate antigens 
produced in the course of isoprenoid synthesis (89), alkylamines (90) and several 
synthetic aminobisphosphonate (91). The pyrophosphate antigens may be autologous 
(isopentenyl pyrophosphate, IPP) or microbial ((E)-4-hydroxy-3-methyl-but-2-enyl 
pyrophosphate, HMB-PP) (87). This recognition is mediated by the TCR and is not 
restricted by MHC molecules (92). 
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Figure 1.6 2-C-methyl-D-erythritol 4-phosphate (MEP) and mevalonate pathways for 
isoprenoid biosyntheiss.  
Genes for MEP enzymes are also termed ispC (dxr), ispD (ygbP), ispE (ychB), ispF (ygbB), ispG 
(gcpE), and ispH (lytB). Taken from (89). 
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1.7.1 Antigen presentation to γδ T Cells: HMB-PP 
HMB-PP is an intermediate of the non-mevalonate pathway of isoprenoid 
biosynthesis (Figure 1.6) that is found in many microbes, but not in higher 
eukaryotes including humans, and triggers Vγ9/Vδ2 T-cell responses at sub-
nanomolar concentrations. Bacteria that possess the non-mevalonate pathway and 
hence produce HMB-PP represent some of the most detrimental human pathogens, 
such as the causative agents of tuberculosis, diphtheria, typhoid, plague and cholera 
(Table 1.2). HMB-PP is also produced by numerous commensal species in the 
mucosal flora and in faeces (87). Notable exceptions of clinical relevance that do not 
produce HMB-PP are Gram-positive enterococci, streptococci and staphylococci as 
well as Gram-negative Legionella. 
 
Although Vγ9/Vδ2 T cells also recognize multiple compounds of highly variable 
structure, HMB-PP is 10,000 times more potent than any other physiological 
compound such as IPP and dimethylallyl pyrophosphate, substances often used in γδ 
T cell culture experiments and which might derive locally from necrotic or 
transformed host tissues (93). This allows efficient detection by human Vγ9/Vδ2 T 
cells of infected tissues, which produce minute amounts of microbial 
phosphoantigens, and prevents them from being activated by normal tissue cells that 
express basal levels of the weakly stimulatory mammalian metabolites. (54, 87, 94) 
 
1.7.2 HMB-PP: an unconventional pathogen-associated molecular pattern 
HMB-PP resembles classical pathogen-associated molecular patterns (PAMP) (95). 
It is: (1) an invariant metabolite produced by numerous Gram-positive and Gram-
negative bacteria; (2) an essential metabolite in bacteria that synthesise isoprenoid 
precursors exclusively via non-mevalonate pathway, but not by higher eukaryocytes; 
and (3) specifically recognized by human and non-human primate γδ T cells (94). 
The molecular mechanism for the recognition of HMB-PP by Vγ9/Vδ2 T cells 
remains unclear. However, cell–cell contact with accessory cells is required for 
efficient Vγ9/Vδ2 T cell activation, and basically any nucleated human cell type is 
capable of acting as feeder cells (96, 97). Although the Vγ9/Vδ2 TCR is essential for 
the recognition of HMB-PP (and related compounds) (98), there is no evidence for a 
direct binding of soluble HMB-PP to the TCR (94).  
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Table 1.2 HMB-PP-producing capacities across a variety of microbial pathogens. Adapted from 
(94).  
 
HMB-PP
+
   
Gram
–
 bacteria Gram
+
 bacteria Other bacteria 
Acinetobacter baumannii Bacillus anthracis Ehrlichia chaffeensis 
Enterobacter aerogenes Clostridium difficile Mycoplasma penetrans 
Escherichia coli Corynebacterium diphtheriae Treponema pallidum 
Francisella tularensis  Listeria monocytogenes  
Haemophilus influenzae  Mycobacterium tuberculosis  
Helicobacter pylori  Propionibacterium acnes  
Klebsiella pneumoniae   
Neisseria meningitidis   
Pseudomonas aeruginosa  Protozoan parasites 
Salmonella enterica   Plasmodium falciparum 
Shigella dysenteriae   Toxoplasma gondii 
Vibrio cholera   
Yersinia pestis   
HMB-PP
–
   
Gram
–
 bacteria Gram
+
 bacteria Other bacteria 
Legionella pneumophila Enterococcus faecalis Borrelia burgdorferi 
 Staphylococcus aureus Mycoplasma genitalium 
 Streptococcus pneumoniae Rickettsia prowazekii 
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1.7.3 Effector functions of γδ T cells 
γδ T cells have a broad array of effector functions that reflect their involvement in 
diverse physiopathological processes. They can kill infected, activated or 
transformed cells, through pathways that involve the engagement of death-inducing 
receptors, such as CD95 (also known as FAS) and TNF-related apoptosis-inducing 
ligand receptors (TRAIL-R), and the release of cytotoxic effector molecules, such as 
perforin and granzymes (99, 100). Moreover, they contribute to pathogen clearance 
directly through the production of bacteriostatic or lytic molecules, such as 
granulysin and defensins (100, 101).  
 
1.7.4 Differentiation of Effector/Memory γδ T cells 
It is well established that circulating naive αβ T cells use CD62L and CCR7 to 
migrate to lymph nodes (102). They also express the CD45RA isoform and the 
costimulatory receptor CD27, which are switched off  after primary antigen 
encounter (103). Conversely, experienced T cells consist of central memory (TCM) 
(CD45RA
－
CCR7
+
), effector memory (TEM) (CD45RA
－
CCR7
－
), and CD45RA
+
 
effector memory cells (TEMRA) (CD45RA
+
CCR7
－
) (102, 104).  
 
Similarly, Francesco et al. showed that the expression of CD45RA and CD27 
antigens defines four subsets of human Vδ2 T cells with distinctive 
compartmentalisation routes (105). CD45RA
+
CD27
+
 Vδ2 T cells showed 
characteristics of naive cells with expression of CD45RO
－ 
and expressed the lymph 
node homing receptors CCR7 and CD62L (106). These cells did not express 
receptors for inflammatory chemokines such as CCR2, CCR5, CCR6, and CXCR3 
(107). CD45RA
－
CD27
+
 Vδ2 T cells shared chemokine receptor expression with 
naive cells since they still express high levels of CD62L and CCR7, but about 25% 
of these cells also expressed CCR5 and CXCR3. Despite expression of CCR7 and 
CD62L, CD45RA
－
CD27
+
  Vδ2 T cells had the CD45RO+ memory phenotype, thus 
resembling central memory αβ T cells (102). CD45RA
－
CD27
－
 Vδ2 T cells showed 
an effector phenotype, having down-regulated CD62L and CCR7. But they 
expressed high levels of receptors for inflammatory chemokines and were CD45RO
+
. 
These results identify three subsets of human peripheral blood Vδ2 carrying distinct 
homing receptors. Of note, in inflammatory sites only two Vδ2 subsets were detected, 
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which were effector CD45RA
－
CD27
－
 subset and CD45RA
+
CD27
－
phenotype. The 
latter one resembles a subset of terminally differentiated CD8 memory T cells (105, 
108). Additionally, Vδ2 T cells collected from these inflammatory fluids expressed 
CCR5 and CXCR3, but were virtually negative for CCR7 and CD62L expression. 
 
1.7.5 Antigen-Presenting γδ T Cells (γδ T-APC) 
Antigen-stimulated human Vγ9/Vδ2 T cells take up and process antigen, and either 
present it on MHC-II, or cross-present it on MHC Class-I. These cells activated via 
the TCR and certain cytokines upregulate co-stimulatory molecules (CD80, CD86, 
CD40) and adhesion receptors (CD11a, CD18, CD54) and can turn naïve CD4
+
 and 
CD8
+ αβ T cells into effector cells (Figure 1.7). αβ T cells differentiation induced by 
γδ T cells led to T helper cell response with a predominant pro-inflammatory 
cytokine (IFN-γ, TNF-α) profile  (109, 110).  
 
 
Figure 1.7 Antigen processing and presentation in Antigen-Presenting γδ T Cells (γδ T-APC).  
Exogenous antigens are taken up by endocytosis and are directed to MHC I or MHC II loading 
pathways. Activation of γδ T cells by HMB-PP leads to upregulation of costimulatory molecules, 
adhesion molecules, and the lymphoid homing chemokine receptor CCR7. Activated cells release 
cytokines such as IFN-γ and TNF-α, thus creating a proinflammatory microenvironment favouring the 
generation of CD4
+ 
Th1 cells and cytotoxic CD8
+ 
T cells. Taken from (111). 
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1.7.6 HMB-PP dependent interaction between γδ T cells, neutrophils and 
monocytes in acute microbial infection 
Human blood Vγ9/Vδ2 T cells, monocytes and neutrophils share a responsiveness 
toward inflammatory chemokines and are rapidly recruited to sites of infection. 
Monocytes provide ‘feeder’ qualities for optimum stimulation of Vγ9/Vδ2 T cells 
with HMB-PP but that they also receive reciprocal differentiation signals. In an in 
vitro model, monocytes activated by HMB-PP stimulated γδ T cells undergo a rapid 
and substantial differentiation program toward an APC phenotype (112). Further 
study from the same group demonstrated that Vγ9/Vδ2 T cells also provide potent 
survival signals resulting in neutrophil activation and the release of the neutrophil 
chemoattractant CXCL8 (IL-8). In turn, Vγ9/Vδ2 T cells readily respond to 
neutrophils harbouring phagocytosed bacteria, as evidenced by expression of CD69, 
IFN-γ and TNF-α. This response is strictly dependent on the ability of these bacteria 
to produce the microbial metabolite HMB-PP and requires cell-cell contact of 
Vγ9/Vδ2 T cells with accessory monocytes through lymphocyte function-associated 
antigen-1, and results in a TNF-α dependent proliferation of Vγ9/Vδ2 T cells (113). 
The antibiotic fosmidomycin, which inhibits the first enzymatic step in the non-
mevalonate pathway, not only has a direct antibacterial effect on most HMB-PP 
producing bacteria but also possesses immediate anti-inflammatory properties by 
inhibiting Vγ9/Vδ2 T cell responses in vitro (Figure 1.8) (113). 
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Figure 1. 8 HMB-PP dependent interaction between γδ T cells, neutrophils and monocytes in 
acute microbial infection.  
Local secretion of inflammatory chemokines leads to extravasation of neutrophils, monocytes and γδ 
T cells toward the site of infection. Upon phagocytosis of invading microbes, neutrophils release 
traces of HMB-PP into the microenvironment where it becomes ‘visible’ to γδ T cells. γδ T cells 
recognize HMBPP in the context of a yet unidentified presenting molecule ‘X’ and contact-dependent 
signals provided by monocytes. Crosstalk between the three different cell types triggers the 
production of pro-inflammatory cytokines such as TNF-α, which drives local γδ T cell expansion, and 
chemokines such as CXCL8, which recruits further neutrophils to the site of infection. Activated γδ T 
cells also provide survival and activation signals such as TNF-α for newly arriving neutrophils and 
monocytes. This γδ T cell-driven inflammatory reaction can be interrupted at various check-points as 
demonstrated in the present study. Taken from (113). 
 
Collectively, γδ T cells play a unique role in the modulation of innate and adaptive 
immunity, protective immunity against extracellular and intracellular pathogens, 
tumour surveillance, tissue healing and epithelial cell maintenance (86). Vγ9/Vδ2 T 
cells are rapidly activated by microbial phosphoantigens and produce cytokines 
including TNF-α and IFN-γ. Soon after activation, γδ T cells acquire the capacity to 
take up and process antigen and to present it to CD4
+
 and CD8
+
 T cells, and thereby 
help to initiate peptide-specific αβ T cell responses (110). In general, it appears that 
human Vγ9/Vδ2 T cells display a wide range of functional activities, referred to pro-
inflammatory cytokine production, potent killer cell activity, regulatory (suppressive) 
functions (114), and antigen-processing and -presenting capacity. 
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1.8 Scope of this thesis 
 
Peritoneal infection and associated inflammation remain frequent complications in 
PD patients. Key to developing improved approaches for infection prevention and 
therapy is a detailed understanding of the peritoneal immune response that 
contributes to infection resolution and long-term membrane damage and treatment 
failure. Peritonitis is a local inflammatory disorder, characterized by the recruitment 
and infiltration of leukocytes as essential elements of the immune response. 
Although T cells are present in high numbers and are recognized as likely major 
regulators of peritoneal inflammation, a comprehensive analysis of peritoneal T cell 
subsets has not been attempted, and little is known with respect to the functional 
characteristics of αβ and γδ T cell subsets and the correlation with clinical outcome 
in PD patients. 
 
The specific aims for each investigative chapter are as follows: 
 
Chapter 3: Clinical outcome analysis and characterisation of local immune responses 
including γδ T cells, CD4+ T cells, and CD8+ T cells in PD-associated bacterial 
peritonitis. 
 
Chapter 4: To identify immunological signatures in PD-associated peritonitis to 
predict the nature of the causative pathogen and to discriminate among culture-
negative, Gram
+
 and Gram
−
 episodes. 
 
Chapter 5: Identification of the regulation of human γδ T-cell responses to HMB-PP 
by methothelial cells through an in vitro cell-culture model. 
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2.1 Ethics statement 
 
This study was conducted according to the principles expressed in the Declaration of 
Helsinki and under local ethical guidelines (Bro Taf Health Authority, Wales). 
Patient sampling was approved by the South East Wales Local Ethics Committee 
under reference numbers 04WSE04/27 (PD effluent) and 96/1730 (omentum). All 
patients provided written informed consent for the collection of samples and 
subsequent analysis. 
 
2.2 Patient information and data collection 
 
The Cardiff study population included 43 adult patients with end stage renal disease, 
who were receiving PD at the University Hospital of Wales, Cardiff, UK, and were 
treated with acute peritonitis (52 episodes) between September 2008 and January 
2012. 15 stable patients without infection in the previous 3 months were included in 
this study as non-infected controls. In addition, microbiological and survival data 
were obtained from all 739 adult patients who received PD between 1987 and 2008 
at the University Hospital of North Staffordshire, Stoke-on-Trent, UK; and all 2,542 
Australian adult patients from the Australia and New Zealand Dialysis Transplant 
(ANZDATA) Registry who received PD between 2003 and 2008. Diagnosis of acute 
peritonitis was based on the presence of abdominal pain and cloudy peritoneal 
effluent with > 100 WBC/mm3. The day of the first appearance of leukocytes in the 
effluent was defined as day 1 post-infection. Infections were grouped into culture-
positive and culture-negative episodes, according to the result of the microbiological 
analysis of the effluent. Bacteria identified in culture-positive infections were 
grouped into Gram
+
 and Gram
－
 species, or into HMB-PP
+
 and HMB-PP
－
 species, 
based on the presence or absence of HMB-PP in the microbial metabolism (89, 94). 
Cases of fungal infection or unrecorded culture results were excluded and endpoints 
of outcome analyses were 90
th
 day mortality and technique failure (catheter removal, 
transfer to haemodialysis, and/or patient death).  
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2.3 Leukocyte isolation from PD fluid 
 
All general reagents, unless otherwise stated, were analytical grade and purchased 
from BD Bioscience (Oxford, UK), Beckman Coulter Ltd. (High Wycombe, UK), 
eBioscience (Hatfield, UK), Fisher Scientific UK Ltd. (Loughborough, UK), 
Invitrogen/Life Technologies Ltd (Paisley, UK), Nalgene/Thermo Fisher Scientific 
(Roskilde, Denmark), Miltenyi Biotec Ltd. (Bisley, UK), R&D Systems (Abingdon, 
UK), Sigma-Aldrich Co. Ltd. (Dorset, UK).  
 
2.3.1 Total leukocyte isolation 
PD effluent (mean drained volume 2146 ± 632 ml, range 930-3540 ml ) was 
collected from patients after 4-10 hour dwell and total bag weight was recorded. 
Samples were collected on ice to reduce adhesion of cells to the PD bag and excess 
cellular changes. Following collection, the PD effluent was aliquoted into 500 ml 
centrifuge tube (Corning Inc., New York, USA) and centrifuged at 2000 rpm (953g) 
at 4°C for 20 minutes. The cell-free supernatant was subsequently stored at -70°C 
until assayed. The cell pellets were re-suspended in 50 ml phosphate buffered saline 
(PBS) (Invitrogen). Cell counts were performed using a dual chamber Neubauer 
haemocytometer (Assistent, Sondheim, Germany). The suspension was re-
centrifuged at 1300 rpm (403g) at 4°C for 8 minutes and the pellet was re-suspended 
in PBS at 2-3 ×10
7
 cells/ml.  
 
2.3.2 Mononuclear cells isolation from total leukocytes 
Mononuclear cells were isolated by discontinuous Percoll (Sigma-Aldrich) gradient. 
Percoll was adjusted to isotonicity by the addition of 9 parts (v/v) of Percoll to one 
part (v/v) of 1.5 M NaCl. Two concentrations of Percoll in medium were prepared 
(54% and 79%, prepared with 0.9% saline) (115, 116). 10 ml 79% Percoll was 
placed in the bottom of a 50 ml centrifuge tube (Corning Inc., New York, USA), 
then layered with 20 ml 54% Percoll, followed by 10 ml of total leukocyte 
suspension (up to 300 x 10
6
 cells). The 50 ml tube was centrifuged at 1100 rpm 
(294g), at 18°C for 20 minutes with minimal acceleration and no brake. The 
mononuclear cell layer formed at the interface of the 54% Percoll layer was aspirated 
in to a 50 ml tube and washed with PBS (x 2 times), which was centrifuged at 1300 
rpm (403g), at 4°C for 8 minutes. The cell pellet was re-suspended in PBS at 1-2 × 
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10
7
 cells/ml. Some cells were resuspended in freezing buffer (section 2.13.1) at 5-10 
× 10
6
 cells/ml in cryo-tubes (Greiner Bio-One Ltd., Gloucestershire, UK), which 
were immediately frozen in an isopropanol freezing container (Nalgene, Thermo 
Fisher Scientific) and stored at –70°C overnight. Frozen cells were transferred to 
liquid nitrogen containment.  
 
2.4 Leukocyte isolation from peripheral blood 
 
2.4.1 Peripheral blood mononuclear cells (PBMC) 
Venous blood was collected from consenting healthy laboratory volunteers in a tube 
containing 20U/ml of Heparin and 15mM of EDTA (Fisher Scientific UK Ltd). 
PBMC were isolated by layering 20 ml of whole blood over 20 ml of Ficoll-Paque 
(Axis-Shield, Oslo, Norway) and centrifuged at 1680 rpm (687g), at 18°C for 20 
minutes with minimal acceleration and no brake. The mononuclear cell layer formed 
at the interface of Ficoll-Paque was aspirated into a 50 ml tube and washed twice 
with PBS, which was centrifuged at 1300 rpm (403g), at 4°C for 8 minutes. The cell 
pellet was re-suspended in PBS or medium depending on the experiment design.  
 
2.4.2 Purified leukocytes using magnetic column 
PBMC were re-suspended in 1 ml MACS buffer (section 2.13.2) in a 15 ml Falcon 
tube and blocked with 1% human normal immunoglobulin (KIOVIG, Baxter, 
Thetford, UK) for 10 minutes on ice. Following incubation, 2.5 μl anti-Vγ9 TCR PE-
Cy5 monoclonal antibody (mAb) (1:400) (Immu360; Beckman-Coulter) was added 
and incubated for 15 minutes on ice in the dark. Following incubation, the cells were 
washed once with MACS buffer and re-suspended in 400 μl MACS buffer. 80 μl 
Anti-PE microbeads (1:5) (Miltenyi Biotec) were added and the cells were incubated 
for 15 minutes at 4℃ in the dark. Following incubation, the cells were washed once 
with MACS buffer and re-suspended to 2 ml. The cells were subjected to magnetic 
separation using LS columns (Miltenyi Biotec). Vγ9+ T cells (>98%) were purified 
from PBMC using positive selection. Thereafter, the pass-through fraction (non- 
Vγ9+ leukocytes) was used to purify Monocytes (>95%) with anti-CD14 microbeads 
(Miltenyi Biotec). Again, the pass-through fraction (Vγ9
－
CD14
－
 leukocytes) was 
used to purify αβ T cells (90%) using pan T-Cell isolation kit (Miltenyi Biotec).  
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2.5 Leukocyte isolation from omental specimens 
Omental tissues from consenting patients undergoing elective abdominal surgery, 
but not undergoing CAPD, were collected from surgery in a sterile plastic receptacle 
containing approximately 50ml of sterile PBS solution and stored at 4°C. The tissue 
(about 10 g) was processed immediately to obtain single-cell suspensions. Omental 
samples were minced and incubated with 10 ml Krebs Ringer bicarbonate buffer 
(section 2.13.3) with 2 mg/mL collagenase D (Roche, Welwyn, UK) and 4% (w/v) 
bovine serum albumin (BSA) (Sigma-Aldrich), shaking in a water bath at 180 rpm, 
at 37°C for 60 min. Samples were washed with Krebs Ringer bicarbonate buffer with 
1% BSA (washing buffer), which was centrifuged at 1300 rpm (403g), at 4°C for 8 
minutes. After centrifugation, the cells were re-suspended in 5 ml washing buffer 
and passed twice through a 40 μm nylon mesh (BD Bioscience). The cell 
suspensions were centrifuged at 1300 rpm (403g), at 4°C for 8 minutes and the cell 
pellet was lysed with 10 ml RBC lysis buffer (eBioscience) for 5 min at room 
temperature. After adding 10ml of complete RPMI medium (section 2.13.4), the cell 
suspensions were centrifuged at 1300rpm for 8 minutes. The cell pellet was then re-
suspended in 1 ml complete RPMI.  
 
2.6 Mesothelial cell culture 
Human peritoneal mesothelial cell isolation and culture were performed with the 
assistance of Dr. Ann Kift-Morgan (Institute of Infection & Immunity, Cardiff 
University) as previously described (117). In brief, omental tissues from consenting 
patients undergoing elective abdominal surgery, but not undergoing CAPD, were 
collected from surgery in a sterile plastic receptacle containing approximately 50ml 
of sterile PBS solution and stored at 4°C. The tissue was gently manipulated to 
remove as much blood and unwanted surface material as possible. Twenty ml of 
0.05% trypsin-EDTA (Invitrogen) solution was aliquoted into 50 ml tubes. The 
tissue was dissected into pieces by two scalpels using a crossover motion. Each piece 
of tissue was placed into a tube with 20 ml of 0.05% trypsin-EDTA solution. The 
tube was sealed with a screw cap and placed on a rotating wheel in the 37°C 
incubator for 15 minutes. The tubes were than centrifuged at 1300 rpm (403g) for 8 
minutes at 15°C. Supernatant was carefully removed using a syringe and the bottom 
of the tube was tapped vigorously to loosen the pellet and make re-suspension easier 
and more efficient. Twenty ml of 10% foetal calf serum (FCS) supplemented M-199 
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medium (Invitrogen, section 2.13.5) was added and rinsed around the tube to re-
suspend and wash all the pelleted cells. The tubes were centrifuged at 1300 rpm 
(403g) for 8 mins at 15°C. The supernatants were removed and replaced with an 
appropriate volume of fresh 10% FCS supplemented M-199 medium. Cells were 
detached and re-suspended gently using a syringe. 5 ml of cells were syringed into a 
fresh T25 flask (NUNC, Thermo Scientific) and left to stand for 1 min. Cells were 
incubated at 37°C and observed frequently. After 1-2 days, cells were pooled into a 
T75 flask (NUNC, Thermo Scientific) with 10% FCS supplemented M-199 medium 
(digestion 1). Medium was replaced every 3 days (passage 1) and incubated to reach 
confluence. HPMC cultures were incubated at 37°C in a humidified 5% CO2 
atmosphere. All experiments performed with cells of the second passage cultured in 
a 96 well plate (NUNC, Thermo Scientific). Prior to assays, HPMC from a second 
passage were growth arrested for 48 h by culture in serum-free M-199 medium (49).  
 
The culture supernatants of HPMC were collected from HPMC (~ 6 × 10
3
 cells/well) 
cultured in a 96 well plate using complete RPMI (200μl/well) for 20 hours. For 
exosome-depletion experiments, the culture supernatants of HPMC were subjected to 
serial centrifugations: 2,000 g, 20 min, to remove dead cells; 10,000 g, 20 min, to 
remove cell debris; 100,000 g, 1 hour, to remove most exosomes (Optima-Max 
ultracentrifuge, Beckman Coulter); 200,000 g, 1 hour, to remove all exosomes 
(Optima-Max ultracentrifuge, Beckman Coulter). 
 
2.7 Co-cultures of γδ T cells, monocytes and mesothelial cells  
Unless indicated otherwise, γδ T cells (0.5 × 106 cells/well) stimulated with 0-100 
nM HMB-PP (Table 2.3) were co-cultured for 20 hours in complete RPMI-1640 
medium with autologous monocytes or allogeneic mesothelial cells at the indicated 
ratios in an incubator maintained at 37°C with a humidified environment containing 
5% CO2. Proliferation assays (Section 2.10) using γδ T cells that had been pre-
labelled with carboxyfluorescein diacetate, succinimidyl ester (CFSE) (Molecular 
Probes/Invitrogen) were incubated for 4 days. Controls included cultures of  γδ T 
cells alone in the absence or presence of HMB-PP (93).  
 
Cell-free supernatants derived from mesothelial cells cultured in complete RPMI-
1640 medium after 24 hours were incubated with γδ T cells alone or a co-culture of 
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monocyte-γδ T cells (1:1) at a dilution of 1 in 2 (50%). Blocking reagents used were 
10 μM SB431542 (Sigma-Aldrich), 10 ng/ml TGF-β1–neutralizing antibody (clone 
141322, R&D Systems), and 10 ng/ml IL-10 receptor α-mAb (R&D Systems).   
Recombinant human TGF-β1 (R&D Systems), IL-10 (Miltenyi Biotec), activin A 
(R&D Systems) and follistatin-288 (R&D Systems) were used at indicated 
concentrations (Table 2.3). 
 
2.8 Culture of CD3
+ 
T cells with supernatants of primary 
mesothelial cells 
CD3
+ 
T cells (90%) were purified using Pan-T Cell isolation kit (Miltenyi Biotec) 
and magnetic column (section 2.4.2). CD3
+ 
T cells were cultured in the presence of a 
1 in 2 (50%) dilution of supernatants derived from mesothelial-cell culture and 
complete RPMI-1640 or further stimulated with anti-CD3/CD28 beads (Invitrogen) 
at a cell-to-bead ratio of 4:1 for 20 hours.  
 
2.9 Flow cytometry 
Cells were acquired on an eight-colour FACSCanto II (BD Biosciences) and 
analyzed with FloJo 7.6 (TreeStar).  
 
2.9.1 Staining for surface markers  
Prior to staining, the cells were washed once with PBS. The cell pellet (up to 3 × 10
6
 
Cells) was stained by adding 3 μl live/dead stain (fixable Aqua; Invitrogen) and 
incubated at room temperature for 15 minutes in the dark. Following incubation, the 
cells were washed with PBS and re-suspended in FACS buffer (section 2.13.6). 1% 
human normal immunoglobulin (KIOVIG, Baxter) was added and the cells were 
incubated for 15 minutes on ice in the dark. Following incubation, the cells were 
washed with FACS buffer and stained for surface markers by adding cocktails of 
mAbs (Table 2.1), together with appropriate isotype controls, for 20 minutes on ice 
in the dark. 
Cells of interest were gated based on their appearance in side scatter and forward 
scatter area/height, exclusion of live/dead staining (fixable Aqua; Invitrogen) and 
surface staining: CD3
-
 CD14
-
 CD15
+
 neutrophils, CD3
-
 CD14
+
 CD15
-
 monocytes, 
and CD3
+
 CD14
-
 CD15
- 
T cells. T cell subsets were identified as CD3
+ 
CD4
+ 
CD8
- 
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helper T cells, CD3
+ 
CD4
- 
CD8
+ 
cytotoxic T cells, and CD3
+ Vγ9+ or CD3+ Vδ2+ γδ T 
cells (Figure 2.1).  
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V
E
/D
E
A
D
CD4
C
D
8
CD3
V
δ2
Viable 
CD3+ cells
 
 
Figure 2.1 Flow diagram of gating strategies.  
SSC/FSC-A/H: side scatter and forward scatter area/height; LIVE/DEAD: live/dead staining (fixable 
Aqua; Invitrogen). 
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2.9.2 Staining for intracellular cytokines 
For detection of intracellular cytokines, 10 μg/ml brefeldin A (Sigma) was added to 
cell cultures 4 hours prior to harvesting. To stimulate global cytokine production, 
cells were stimulated with phorbol myristate acetate (PMA, 50 ng/ml) and 
ionomycin (1 μg/ml) (both from Sigma). Cells were then stained with live/dead stain 
and for surface marker expression (Section 2.9.1). After washing in PBS (x 2 times), 
surface-stained cells were incubated in 100 μl fixation buffer (eBioscience) for 15 
minutes at room temperature in the dark. Cells were subsequently washed once with 
PBS and once with permeabilisation buffer (eBioscience) and then re-suspended in 
50 μl of permeabilisation buffer containing fluorochrome-conjugated mAbs directed 
against various cytokines. Cells were incubated with antibodies for 15 minutes at 
room temperature in the dark, then washed twice with PBS, re-suspended in 200 μl 
of FACS buffer and analyzed on a flow cytometer.  
 
2.9.3 Staining for transcription factors 
For detection of transcript factors, cells were stained for surface marker expression 
(Section 2.9.1). After washing twice in FACS buffer, surface-stained cells were 
incubated in 100 μl Fixation/Permeabilisation solution (eBioscience) for 30 minutes 
at 4°C in the dark. Cells were subsequently washed once with FACS buffer and once 
with permeabilisation buffer (eBioscience) and then re-suspended in 50 μl of 
permeabilisation buffer containing 2% mouse serum (Jackson Immunoresearch, 
Newmarket Suffolk, UK) for 10 minutes at 4°C in the dark. Fluorochrome-
conjugated mAbs directed against various transcription factors (Table 2.2) were 
incubated with cells for 30 minutes at 4°C in the dark. Cells were subsequently 
washed once with Fixation/Permeabilisation solution (eBioscience) and once with 
FACS buffer, re-suspended in 200 μl of FACS buffer and analysed by flow 
cytometry. 
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2.10 Assessment of γδ T-cell proliferation 
 
Purified γδ T cells were suspended in PBS to a concentration of 1-2 × 106 cells/ml. 
Cells were labelled with 1 μM carboxyfluorescein diacetate succinimidyl ester 
(CFSE; Molecular Probes/Invitrogen) at 37°C for 10 minutes in dark. Thereafter, 
cells were washed 3 times in cold RPMI. Labelled γδ T cells were incubated in 
different experimental conditions for 4 days and were analyzed by flow cytometry. 
 
2.11 Culture supernatants and effluent samples 
 
All samples were measured in duplicate. Cell-free peritoneal effluents were analyzed 
on a SECTOR Imager 600 (Meso Scale Discovery, Maryland, USA) for TNF-α, 
GM-CSF, IFN-γ, IL-1β, IL-2, IL-6, IL-10, IL-12p70, CXCL8 (IL-8), soluble IL-6 
receptor (sIL-6R), and MMP3. In addition, IL-17, IL-22 and CXCL10 in peritoneal 
effluents were measured in duplicate on a Dynex MRX II reader, using commercial 
enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems). TGF-β1 was 
measured in duplicate on a Dynex MRX II reader, using a commercial ELISA kits 
(eBioscience). 
 
2.12 Statistical analysis 
 
Statistical analyses were performed using SPSS 16.0 and GraphPad Prism 4.0 
software. Descriptive statistics are expressed as means ± standard error of the mean 
(SEM) unless otherwise stated. All variables were tested for normal distributions 
using the Kolmogorov-Smirnov test. Differences between unpaired groups were 
analyzed using the Student’s t-test for normally distributed data or Mann-Whitney 
U-test for non-parametric data. Differences between paired groups were analyzed 
using the paired t-test or Wilcoxon signed-rank test, as indicated in the tables. 
Categorical data were tested using the Chi-square test. Discrimination was assessed 
using the area under the receiver operating characteristic curve (AUROC), which 
was compared using a nonparametric approach. The AUROC analysis was also 
performed to calculate cutoff values, sensitivity, and specificity. Finally, cut-off 
points were calculated by acquiring the best Youden index (sensitivity + specificity 
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− 1). Cumulative survival curves as a function of time were generated using the 
Kaplan-Meier approach and compared using the log-rank test. Predictive biomarkers 
were assessed using univariate analysis; statistically significant (p<0.05) variables 
from the univariate analysis were included in a multivariate analysis. Multiple 
logistic regression analyses were conducted based on forward and/or backward 
elimination of data, as indicated in the tables. All statistical tests were two-tailed; 
differences were considered statistically significant as indicated in the figures and 
tables: 
*
, p<0.05; 
**
, p<0.01; 
***
, p<0.001.  
 
2.13 Reagents 
 
2.13.1 Freezing medium 
50% v/v foetal calf serum and 10% dimethylsulfoxide were added to RPMI-1640, 
and stored at 4°C. 
 
2.13.2 MACS buffer 
5 mM EDTA and 2% v/v foetal calf serum were added to sterile PBS, and stored at 
4°C. 
 
2.13.3 Krebs Ringer bicarbonate buffer 
118 mM NaCl (6.9g/L), 24.8 mM NaHCO3 (2.08g/L), 1.2 mM KH2PO4 (0.16g/L), 
4.8 mM KCl (0.358g/L), 1.25 mM CaCl2 (0.139g/L), 1.2 mM MgSO4 (0.14g/L), 10 
mM HEPES (2.3831g/L) (all from Sigma-Aldrich), dissolved in distilled water and 
adjusted to pH 7.35-7.45. 
 
2.13.4 Complete RPMI medium 
2 mM L-glutamine, 1% sodium pyruvate, 50 mg/ml penicillin/streptomycin and 10% 
foetal calf serum were added to RPMI-1640 (Invitrogen). 
 
2.13.5 FCS supplemented M-199 medium 
Earle's buffered Medium 199 (Invitrogen) was supplemented with penicillin (100 
U/ml), streptomycin (100 μg/ml), L-glutamine (2 mM; Invitrogen), transferrin 
(5μg/ml), insulin (5μg/ml), hydrocortisone (0.4μg/ml; all from Sigma-Aldrich) and 
10% v/v foetal calf serum (Invitrogen). 
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2.13.6 FACS buffer 
2% v/v foetal calf serum (Invitrogen), 0.04% v/v sodium azide (Fisher Scientific) 
were added to sterile PBS, and stored at 4°C. 
 
Table 2.1 Fluorochrome conjugated antibodies for surface marker staining 
Antigen Conjugate Clone Isotype Company Final 
concentration 
CD3 Pacific blue UCHT1 Mouse IgG1,κ  BD Bioscience 1:100 
CD3 FITC SK7 Mouse IgG1,κ  BD Bioscience 1:50 
CD3 PE SK7 Mouse IgG1,κ  BD Bioscience 1:50 
CD3 APC HIT3a Mouse IgG2a,κ  BD Bioscience 1:20 
CD3 APC-H7 SK7 Mouse IgG1,κ  BD Bioscience 1:100 
CD4 APC-H7 SK3 Mouse IgG1,κ  BD Bioscience 1:60 
CD8 APC RPA-T8 Mouse IgG1,κ  BD Bioscience 1:40 
CD8 PE-Cy7 SK1 Mouse IgG1,κ  BD Bioscience 1:200 
CD14 PE-Cy7 61D3 Mouse IgG1,κ  eBioscience 1:160 
CD15 APC HI98 Mouse IgM  BD Bioscience 1:5 
CD19 APC SJ25C1 Mouse IgM  eBioscience 1:40 
CD25 Cy M-A251 Mouse IgG1,κ  BD Bioscience 1:10 
CD25 PE-Cy7 M-A251 Mouse IgG1,κ  BD Bioscience 1:40 
CD27 FITC M-T271 Mouse IgG1,κ  BD Bioscience 1:40 
CD40 PE mAB89 Mouse IgG1,κ Beckman Coulter 1:20 
CD45 FITC HI30 Mouse IgG1,κ BD Bioscience 1:10 
CD45RA APC HI100 Mouse IgG1,κ eBioscience 1:10 
CD56 PE-Cy7 B159 Mouse IgG1,κ BD Bioscience 1:50 
CD62L Cy DREG-56 Mouse IgG1,κ BD Bioscience 1:15 
CD69 FITC FN50 Mouse IgG1,κ BD Bioscience 1:20 
CD86 FITC 2331; 
FUN1 
Mouse IgG1,κ BD Bioscience 1:40 
Vδ2 PE B6.1 Mouse IgG1,κ BD Bioscience 1:100 
Vγ9 PC5 Immu360 Mouse IgG1,κ Beckman Coulter 1:400 
HLA-DR APC-H7 L243  BD Bioscience 1:40 
CCR4 PE-Cy7 1G1 Mouse IgG1,κ BD Bioscience 1:20 
CCR5 PE 2D7 Mouse IgG2a,κ BD Bioscience 1:10 
CCR6 PE 11A9 Mouse IgG1,κ BD Bioscience 1:80 
CCR7 PE-Cy7 3D12 Rat IgG2a, κ BD Bioscience 1:100 
CCR9 APC 248601 Mouse IgG1,κ R&D systems 1:25 
CXCR3 FITC 49801.111 Mouse IgG1,κ R&D systems 1:20 
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Table 2.2 Fluorochrome conjugated antibodies for intracellular marker staining 
Antigen Conjugate Clone Isotype Company Final 
concentration 
IFN-γ FITC B27 Mouse IgG1 BD Bioscience 1:100 
IFN-γ eFluor 450 4S.B3 Mouse IgG1 eBioscience 1:100 
TNF-α APC 6401.1111 Mouse IgG1 BD Bioscience 1:20 
IL-4 PE 3010.211 Mouse IgG1 BD Bioscience 1:20 
IL-17 Alexa488   64DEC17 Mouse IgG1 eBioscience 1:10 
FoxP3 FITC 236A/E7 Mouse IgG1 eBioscience 1:10 
 
 
 
Table 2.3 Soluble mediators and blocking antibodies 
Reagent Supplier 
SB431542 Sigma-Aldrich 
TGF-β1–neutralizing antibody clone 141322, R&D Systems 
Recombinant Human TGF-β1 R&D Systems 
Recombinant Human IL-10 Miltenyi Biotec 
Recombinant Human Activin A R&D Systems 
Recombinant Human Follistatin-288 R&D Systems 
human IL-10 receptor α mAb R&D Systems 
HMB-PP A gift from Dr. Hassan Jomaa, Universitätsklinikum 
Giessen und Marburg, Germany 
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3.1 Introduction 
 
Bacterial infection remains a leading cause of morbidity and mortality worldwide, 
not the least due to the alarming spread of antibiotic-resistant pathogens that is 
posing an enormous challenge on clinical practice, biomedical research and public 
healthcare (118). In urgent cases such as acute PD-associated peritonitis in patients, 
antimicrobial treatment is largely empirical since therapeutic intervention has to 
commence before the nature of the causative pathogen is known, and 
microbiological culture results usually only become available within 1-3 days.  
Moreover, in many cases no organism can be identified, for instance if a patient is 
already on antibiotics, if sample collection and/or culture techniques are inadequate, 
or if the type of organism is unusual or fastidious (e.g. Mycobacterium spp.) (14, 19, 
119). Depending on the centre, rates of culture-negative peritonitis may vary from 0-
50 % (20, 120). 
Positive identification of the causative pathogen is not only crucial in order to guide 
and refine patient management with respect to the choice of antibiotic treatment; it 
also provides important clues as to the underlying inflammatory mechanisms and 
how to manipulate them to resolve infection. The innate immune system has evolved 
to survey the body constantly for potentially hazardous structures, and responds to 
PAMP that are invariant among a broad range of organisms and allow self/non-self 
discrimination (121, 122). However, different types of pathogens carry different 
types of PAMP, and hence interact with different components of the immune system. 
One such PAMP is bacterial endotoxin or LPS that is present in Gram-negative 
organisms but absent from Gram-positive organisms, and it is well-established that 
episodes of Gram-negative and Gram-positive sepsis present with different clinical 
signs and may have different clinical outcomes (123). As recently highlighted by 
Llewelyn and Cohen it is becoming increasingly clear that the nature of the infection 
is a major determinant of outcome, and future interventions may well have to focus 
on subgroups of patients with different forms of infection (124). Key to developing 
effective treatment strategies is therefore a more detailed understanding of the 
inflammatory response in acute infection. Such an understanding may then facilitate 
the use of appropriate biomarkers to both aid diagnosis and predict treatment 
outcome (57, 112, 125, 126).  
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In the present study, in order to identify potentially useful diagnostic and prognostic 
biomarkers of inflammation severity and outcomes from bacterial infection, we have 
performed a detailed analysis of immune responses in PD patients on the first day of 
presentation with acute peritonitis. The peritoneal cavity in PD serves as unique 
window to inflammatory scenarios that can be prospectively observed in vivo. It 
affords easy, continuous access to all relevant cellular components and humoral 
mediators, and allows us to examine how treatment and the type of infection 
modulate these processes. We know of no other experimental model that gives such 
direct insight into human immune responses in a similarly clinically relevant and 
non-invasive manner. Our findings indicate that a combination of microbiological 
characteristics and immunological parameters predict clinical outcome, and also 
suggest novel targets for of therapeutic intervention in acute bacterial peritonitis.  
 
3.2 Aims  
The aims of this Chapter were: 
1) To characterize local immune responses in PD associated peritontitis 
including the phenotype, effector/memory status, cytokine profile and 
migration properties of peritoneal T cell subsets 
2) To investigate whether the dichotomy between HMB-PP+ and HMB-PP− 
pathogens in their potential to trigger γδ T cells occurs under physiological 
conditions in vivo. 
3) To investigate whether the occurrence of clinical complications in PD 
patients depends on the capacity of the causative pathogen to produce HMB-
PP. 
4) To identify potentially useful prognostic biomarkers of inflammation severity 
and outcomes from PD-associated peritonitis 
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3.3 Results 
 
In order to study local immune response, we recruited 52 episodes of acute 
peritonitis from PD patients who were admitted at the University Hospital of Wales, 
Cardiff, UK. Pre-treatment effluent samples from day 1 of the infection (i.e. the day 
of presentation with a ‘cloudy bag’) were subjected to a contemporary 
immunological analysis by multi-colour flow cytometry and multiplex ELISA. 
Effluent samples from 15 non-infected age and sex-matched stable PD patients 
served as the control group. 
 
3.3.1 Acute peritonitis is characterized by a significant peritoneal influx of 
immune cells 
To assess the distribution of immune cells during acute peritonitis, we collected 
serial samples of peritoneal effluent from PD-associated peritonitis patients. During 
acute peritonitis, leukocytes are recruited to the peritoneal cavity, starting with a 
rapid accumulation of CD15
+
 neutrophils, which are later replaced by a population 
of mononuclear cells, including CD14
+
 monocytes/macrophages and CD3
+
 T cells. 
While peritoneal leukocytes in stable patients comprised mainly of 
monocytes/macrophages and T cells, acute peritonitis was dominated by a massive 
recruitment of neutrophils. Of note, γδ T cells were also recruited to the peritoneal 
cavity in the early stage (Figure 3.1).   
% of total cells Vδ2+ T cells (% of CD3+)
CD3+
CD14+
CD15+
 
Figure 3.1 Dynamic changes of peritoneal leukocyte subpopulations during acute peritonitis. 
Serial samples of peritoneal effluents were collected from patients with acute peritonitis. Data are 
shown as frequencies of CD15
+
 neutrophils, CD14
+
 monocytes/macrophages and CD3
+
 T cells in total 
cells, and frequencies of Vδ2+ T cells in CD3+ T cells. Data shown are representative from 3 
independent peritonitis episodes. 
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3.3.2  Monocyte/Macrophage activation 
   
Macrophages are the predominant cell type found in the peritoneal cavity and play 
an important role in the first line of defence against invading microorganisms. To 
examine the activation status of monocytes/macrophages in different conditions, we 
isolated leukocytes from peripheral blood of age-matched healthy donors or PD 
effluents of non-infected (stable) PD patients or PD patients with acute peritonitis on 
day 1 (Table 3.1). The expression of the APC markers CD40, CD86 and HLA-DR 
on monocytes/macrophages (CD14
+
) was analyzed. Data are shown in Figure 3.2. 
 
Of note, the expression levels of CD86 on peritoneal monocytes from stable and 
peritonitis patients were lower compared to circulating monocytes.  Further analysis 
of peritonitis samples on day 1 showed that the expression levels of CD86 on 
peritoneal monocytes were lower in HMB-PP
+
 peritonitis compared to HMB-PP
– 
peritonitis (Figure 3.2B). 
 
 
 
Table 3.1 Characteristics of samples analyzed in the present study. 
 
 
PBMC from  
healthy donors 
Stable Peritonitis 
Total number 5 15 52 
Age (mean ± SD) 53.8 ± 2.7 60.4 ± 17.8 65.5 ± 14.0 
Women (%) 20 40 35.5 
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% CD40+ % CD86+ % HLA-DR+
P=0.06
*
CD86+
HMB-PP － HMB-PP＋
*
A
B
***
***
 
 
Figure 3.2 Expression of APC markers on monocytes/macrophages.  
(A) Expression of CD40
+
, CD86
+
 or HLA-DR
+
 on monocytes/macrophages (CD14
+
) in peripheral 
blood of healthy donors (PB) or stable PD effluents (stable), or PD effluents of peritonitis patients on 
day 1 (Inf.). (B) Expression of CD86
+
 on monocytes/macrophages in PD effluents of PD-associated 
peritonitis on day 1, depending on whether or not the causative pathogen was capable of producing 
the microbial metabolite HMB-PP. Statistical differences between patient groups were analyzed using 
the Student’s t-test. Error bars indicate SEM. 
＊
, P<0.05; 
＊＊＊
, P< 0.001. 
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3.3.3 Peritoneal T-cell activation  
To define the activation properties of peritoneal T cells, leukocytes were isolated 
from PD effluents of stable PD patients or PD patients with acute peritonitis on day 1. 
Peripheral blood of age-matched healthy donors was used as controls. Cells were 
analyzed for the expression of CD25 (a late activation marker) and CD69 (an early 
activation marker) on CD4
+
, CD8
+
 and γδ T cells. Data are shown in Figure 3.3.  
 
Our results demonstrate that all three subsets of peritoneal T cells from PD effluents 
of stable patients expressed higher levels of CD69 in comparison with circulating T 
cells. Furthermore, the expression of CD25 on peritoneal γδ T cells was significantly 
higher compared to circulating γδ T cells. When we looked at the activation status of 
peritoneal T cells from peritonitis samples, both CD25 and CD69 expression levels 
were higher compared to circulating T cells. The peritoneal CD4
+ 
T cells from 
peritonitis patients expressed higher levels of CD25 than stable PD patients. 
Interestingly, the expression of CD69 on peritoneal CD8
+ 
T cells was lower in 
peritonitis patients compared to stable PD patients. 
 
Further analysis of peritonitis samples on day 1 demonstrated no significant 
difference in the expression of these markers on CD4
+
, CD8
+ 
or γδ T-cell between 
culture-negative and culture-positive peritonitis, or between HMB-PP
+
 and HMB-
PP
–
 peritonitis (data not shown). 
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Figure 3.3 Expression of the activation markers CD25 and CD69 on T cells.  
Expression of CD25 or CD69 on CD4
+
, CD8
+
 or γδ T cells (Vδ2+) in peripheral blood of healthy 
donors (PB) or stable PD effluents (stable), or PD effluents of peritonitis patients on day 1 (Inf.). 
Statistical differences between patient groups were analyzed using the Student’s t-test. Error bars 
indicate SEM. 
＊
, P<0.05; 
＊＊
, P<0.01, 
＊＊＊
, P< 0.001. 
 
Chapter 3: Outcome analysis and immune responses 
 
51 
 
3.3.4 Peritoneal T-cell memory subsets 
A previous study demonstrated that the peritoneal cavity is enriched in cells with 
effector/memory T cells, which were able to mount a TH1-polarized response to 
recall antigens, and that these responses were greater in peritoneal T cells compared 
with circulating T cells (126). To investigate the potential role of peritoneal memory 
T cells in peritoneal inflammation in more detail, we characterized the phenotype of 
peritoneal T-cell subsets.  
 
CD4
+
 T cells were identified as naïve T cells (CD45RA
+
CCR7
+
), central memory 
(CD45RA
－
CCR7
+
), effector/memory (CD45RA
－
CCR7
－
), and CD45RA
+
 
effector/memory cells (CD45RA
+
CCR7
－
) (102, 104). Figure 3.4A illustrates the 
different subsets of CD4
+
 T cells in peripheral blood of healthy donors or PD 
effluents of stable or peritonitis on day 1 samples. In comparison with circulating 
CD4
+
 T cells, the frequencies of peritoneal naïve CD4
+ 
T cells decreased and 
effector/memory CD4
+
 T cells increased significantly in both stable and peritonitis 
patients. Effector/memory CD4
+
 T cells were the most predominant subset in the 
peritoneal cavity of either stable or peritonitis patients. No significant differences in 
the proportion of CD4
+ 
T-cell memory subsets between stable and peritonitis patients 
were noted. Further analysis of peritonitis samples demonstrated no significant 
difference in the proportion of CD4
+ 
T-cell subsets between culture-negative and 
culture-positive peritonitis, or between HMB-PP
+
 and HMB-PP
–
 peritonitis (data not 
shown). 
 
We also characterized the potential memory status of γδ T cells with antibodies 
against the surrogate memory markers CD45RA and CD27 (105). In comparison 
with circulating γδ T cells, the frequencies of peritoneal CD45RA+CD27+ Vδ2+  T 
cells decreased in peritonitis patients and CD45RA
－
CD27
－
Vδ2+ T cells increased in 
both stable and peritonitis patients. CD45RA
－
CD27
+Vδ2+ T cells were the most 
enriched subsets in the peritoneal cavity of either stable or peritonitis patients (Figure 
3.4B). No significant differences in the proportion of γδ T-cell memory subsets 
between stable and peritonitis patients were noted. Further analysis of peritonitis 
samples demonstrated no significant differences in the proportion of γδ T-cell 
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subsets between culture-negative and culture-positive peritonitis, or between HMB-
PP
+
 and HMB-PP
–
 peritonitis (data not shown). 
 
 
CD45RA+
CCR7+
CD45RA－
CCR7+
CD45RA－
CCR7－
CD45RA+
CCR7－
% of CD4+ T cells
CD45RA+
CD27+
CD45RA－
CD27+
CD45RA－
CD27－
CD45RA+
CD27－
% of Vδ 2+ T cells
A
B
*
***
P=0.06
*
***
P=0.05 
***
**
Peripheral blood
Stable
Peritonitis
Peripheral blood
Stable
Peritonitis
 
 
Figure 3.4 Expression of memory markers on CD4
+ 
or Vδ2+ T cells.  
(A) CD4
+ 
T-cell memory subsets in peripheral blood of healthy donors or PD effluents of stable or 
peritonitis samples on day 1. (B) Vδ2+ T-cell memory subsets in peripheral blood of healthy donors or 
PD effluents of stable or peritonitis samples on day 1. Statistical differences between patient groups 
were analyzed using the Student’s t-test. Error bars indicate SEM. 
＊
, P<0.05; 
＊＊
, P<0.01, 
＊＊＊
, P< 
0.001. 
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3.3.5 APC markers on γδ T cells 
Since antigen-stimulated human Vγ9/Vδ2 T cells can take up and process antigen, 
and up-regulate co-stimulatory molecules (109), we also examined the expression of 
APC markers CD40, CD86 and HLA-DR on γδ T cells. Although peritoneal γδ T 
cells expressed low level of CD40 and CD86 in either stable or peritonitis patients, 
the expression levels of these two markers were not significantly higher in 
comparison with circulating γδ T cells in the present study. The expression of HLA-
DR on peritoneal γδ T cells from stable or peritonitis patients was higher in 
comparison with circulating γδ T cells.  
 
Further analysis of peritonitis samples on day 1 demonstrated no significant 
differences in the expression of these markers on γδ T-cells between culture-negative 
and culture-positive peritonitis, or between HMB-PP
+
 and HMB-PP
–
 peritonitis (data 
not shown). 
% CD40+ % CD86+ % HLA-DR+
***
**
 
 
Figure 3.5 Expression of APC markers on γδ T cells.  
(A) Expression of  CD40
+
, CD86
+
 or HLA-DR
+
 on γδ T cells (Vγ9+) from peripheral blood of healthy 
donors (PB) or stable PD effluents (stable), or PD effluents of peritonitis patients on day 1 (Inf.). 
Statistical differences between patient groups were analyzed using the Student’s t-test. Error bars 
indicate SEM. 
＊＊
, P<0.01; 
＊＊＊
, P< 0.001. 
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3.3.6 Migration properties of peritoneal T cells  
Infections trigger the local production of inflammatory chemokines, which control 
the composition of the cellular infiltrate. A change in local chemokines is an 
essential factor in the transition from the neutrophil-driven immediate response to 
the T and B cell-driven later response to infection. Effector T cells in the peripheral 
blood express distinct combinations of receptors for inflammatory chemokines such 
as CXCR3 and CCR5. Enhanced expression of these receptors enable effector 
memory T cells to enter inflammatory sites (127). CCR6 mediates the homing of 
both helper T cells and dendritic cells to the gut mucosal lymphoid tissue (128). 
Previous studies have also shown that CCR6 is a specific marker for Th17 cells and 
regulatory T cells distinguishing them from other helper T cells (129, 130). To 
define the migration properties of peritoneal T cells, cells were isolated from 
peripheral blood of healthy donors or PD effluents of stable patients, or peritonitis 
patients on day 1, and were analyzed for the expression of different chemokine 
receptors on CD4
+
, CD8
+
 and γδ T cells. Data are shown in Figure 3.6.  
 
The peritoneal γδ T cells from peritonitis patients expressed similar levels of CCR5 
and showed up-regulation of CCR6 and down-regulation of CXCR3 in comparison 
with circulating γδ T cells. The peritoneal CD4+ and CD8+ from peritonitis samples 
also had similar expression patterns of these markers.  Further analysis of peritonitis 
samples demonstrated no significant differences in the expression of these markers 
on CD4
+
 or CD8
+ 
or γδ T cells between culture-negative and culture-positive 
peritonitis, or between HMB-PP
+
 and HMB-PP
–
 peritonitis (data not shown). 
 
Effector T-cell entry into intestinal mucosae requires cellular adhesion receptors on 
T cells such as CCR9 and integrin α4β7 (131, 132). T cells measured in this study 
did not express CCR9 (data not shown). 
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PB stable Inf. PB stable Inf. PB stable Inf.
 
 
Figure 3.6 Migration properties of CD4
+
, CD8
+
 and γδ T cells.  
Cells were taken from peripheral blood of healthy donors (PB) or stable PD effluents (stable), or PD 
effluents of peritonitis patients on day 1 (Inf.). The expression of CCR5, CCR6 and CXCR3 on CD4
+
, 
CD8
+
 and γδ T cells (Vγ9+) were analyzed. Statistical differences between patient groups were 
analyzed using the Student’s t-test. Error bars indicate SEM. 
＊
, P<0.05; 
＊＊
, P<0.01, 
＊＊＊
, P< 0.001. 
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3.3.7 Characterization of helper T-cell subsets in PD patients 
To characterize different helper T-cell subsets in PD patients, cells from peripheral 
blood and PD effluents of stable PD patients or PD effluents of peritonitis patients 
on day 1 were isolated by centrifugation. Cells were stimulated with PMA (50 ng/ml) 
and ionomycin (1 μg/ml) in the presence of brefeldin-A (10 μg/ml) for 4 hours 
before intracellular cytokine staining. Immunofluorescent staining of intracellular 
cytokines was used to detect the percentage of T cells producing IFN-γ (TH1), IL-4 
(TH2) or IL-17 (TH17). Regulatory T cells (Treg) were identified by anti-CD25 and 
anti-Foxp3 antibodies.  
 
The CD4
+
 T cells showed a predominant IFN-γ production, manifested as 37.7 ± 4.9 
% positive intracellular staining (Figure 3.7 upper panels, stable patients), indicating 
that the majority of peritoneal CD4
+
 T cells of stable PD patients were TH1 cells. 
This pattern of cytokine production was the same in CD8
+
 T cells and γδ T cells in 
stable PD patients. Peritoneal T cells in peritonitis patients were characterized by an 
increase in the percentage of TH2 cells, as well as TH2-type CD8
+
 T cells and IL-4 
producing γδ T cells, without a significantly different percentage of TH1 cells in 
comparison with T cells in stable PD effluents (Figure 3.7). 
 
In order to evaluate the pattern of T-cell subsets in acute PD peritonitis patients, we 
further divided peritonitis samples into culture-negative or culture-positive 
peritonitis. Higher frequencies of TH1 and lower frequencies of TH2 and Treg were 
found in culture-positive peritonitis on day 1 (Figure 3.8). Further analysis of culture 
positive peritonitis samples demonstrated no significant differences in the proportion 
of helper T-cell subsets between HMB-PP
+
 and HMB-PP
–
 peritonitis (data not 
shown). 
 
Low frequencies of IL-17
+
 T cells could be identified within peritoneal T 
lymphocytes yet without significant differences among different subgroups. 
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Figure 3.7  Helper T-cell subsets in PD patients. 
Frequency (%) of IFN-γ+ (TH1), IL-4
+ 
(TH2), or IL-17
+
 (TH17) T cells in peripheral blood (PB) and PD 
effluents of stable PD patients (stable), or PD effluents of peritonitis patients on day 1 (Inf.). Cells 
from peripheral blood and PD effluents of stable PD patients were processed freshly. Data from 
peritonitis samples were obtained from frozen samples. Statistical differences between patient groups 
were analyzed using the Student’s t-test or the Mann-Whitney U test, depending on normal 
distribution test using the Kolmogorov-Smirnov test. Error bars indicate SEM. 
＊
, P<0.05; 
＊＊
, P<0.01, 
＊＊＊
, P< 0.001.  
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Figure 3.8 Helper T-cell subsets in acute peritonitis patients. 
Frequency (%) of IFN-γ+ (TH1), IL-4
+ 
(TH2), IL-17
+
 (TH17) or Foxp3
+
CD25
+
 (Treg) T cells in PD 
effluents from PD-associated culture-negative (neg) or culture-positive peritonitis (pos) on day 1. 
Cells were processed from frozen samples. Statistical differences between patient groups were 
analyzed using the Student’s t-test or Mann-Whitney U test, depending on normal distribution test 
using the Kolmogorov-Smirnov test. Error bars indicate SEM.  
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3.3.8 Culture-positive episodes of peritonitis are associated with poorer clinical 
outcome.   
We next assessed the clinical outcome after episodes of acute peritonitis. Two 
episodes in the above study were not included due to unavailable data of the 90
th
 day 
outcome when analyzing the data (Table 3.2). Although not reaching statistical 
significance due to the relatively small number of patients recruited to this study, 
cumulative survival curves as a function of time suggested that episodes of culture-
positive peritonitis were associated with poorer outcome compared with culture-
negative cases (Figure 3.9, top panels).  In order to validate this pattern of clinical 
outcome observed in the Cardiff cohort, we analyzed patient and technique survival 
with respect to the infecting organism in two larger and entirely independent, well-
defined patient cohorts (Table 3.2). Out of all patients from the ANZDATA registry 
who were receiving PD in Australia between 2003 and 2008, a total of 2,424 patients 
with first-time episodes of peritonitis were included in the present analysis and 
grouped according to the result of organism culture into culture-negative and culture-
positive infection, excluding cases of fungal infection. A parallel analysis was 
conducted in a total of 412 patients who were treated at the University Hospital of 
North Staffordshire, Stoke-on-Trent, UK, between 1987 and 2008, among whom 385 
cases of first-time peritonitis occurred, again excluding cases of fungal infection. In 
both cases, and in agreement with the data from Cardiff, episodes of culture-positive 
peritonitis were associated with poorer outcome compared with culture-negative 
peritonitis (Figure 3.9, middle and bottom panels). 
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Table 3.2 Characteristics of PD patients with acute peritonitis for outcome analysis. 
 
 
Cardiff 
(UK) 
Stoke-on-
Trent 
(UK) 
ANZDATA 
(Australia) 
Total number 50 385  2,424 
Age (mean ± SD) 65.5 ± 14.2 57.0 ± 16.0 58.5 ± 16.8 
Women (%) 38.0 43.1 44.8 
Days on PD (mean ± SD) 1163.8 ± 949.1 532.0 ± 581.9 738.8 ± 502.5 
90
th
 day mortality (%) 6.0 8.8 1.8 
90
th
 day technique failure (%) 22.0 19.0 16.8 
Culture-positive infections (%) 72.0 61.5 85.8 
HMB-PP
+
 organisms among 
positively identified species (%) 
41.7 26.4 38.6 
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Figure 3.9 Culture-positive peritonitis are associated with poor clinical outcome.   
Cumulative patient survival (left) and cumulative technique survival (right) of patients with acute 
peritonitis, grouped into culture-negative (dotted lines) or culture-positive infections (solid lines). Top, 
PD patients admitted at the University Hospital of Wales, Cardiff, with acute peritonitis. Middle, 
Australian PD patients from the ANZDATA registry with first-time peritonitis.  Bottom, PD patients 
with first-time peritonitis treated at the University Hospital of North Staffordshire, Stoke-on-Trent, 
UK.  Comparisons were made using log-rank tests. 
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3.3.9 Culture-positive episodes of peritonitis are associated with more severe 
peritoneal inflammation.   
 
In order to identify a possible correlation between inflammatory responses and the 
ensuing clinical outcome, we measured several pro-inflammatory 
cytokines/chemokines. Peritoneal levels of TNF-α, IL-1β, IL-2, IL-6, IL-10, IL-22, 
sIL-6R, and MMP-3 in culture-positive patients were significantly or marginally 
significantly higher compared with culture-negative patients and stable non-infected 
PD patients (Figure 3.10), indicative of a local inflammatory response in those 
patients (57, 112, 125). This was confirmed by a detailed leukocyte subset analysis 
revealing that during culture-positive peritonitis a larger proportion of the infiltrating 
immune cells were CD15
+
 neutrophils whereas a smaller proportion were CD14
+
 
monocytes/macrophages (Figure 3.11). Total numbers of all major peritoneal 
leukocyte populations (neutrophils, monocytes/macrophages, and CD4
+
, CD8
+
 and 
V2+ T cells) were elevated in culture-positive when compared to culture-negative 
peritonitis, revealing that in general this patient group experienced a more severe 
peritoneal inflammatory response. 
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Figure 3.10 Culture-positive episodes of peritonitis are associated with higher levels of pro-
inflammatory cytokines/chemokines. 
Peritoneal levels (pg/ml) of TNF-α, IL-1β, IL-2, IL-6, IL-10, IL-22, sIL-6R, and MMP-3 in stable PD 
patients and in patients with PD-associated culture-negative (neg) or culture-positive peritonitis (pos) 
on day 1.  Statistical differences between patient groups were analyzed using the Student’s t-test or 
Mann-Whitney U test, depending on normal distribution test using the Kolmogorov-Smirnov test. 
Error bars indicate SEM. 
＊
, P<0.05; 
＊＊
, P<0.01, 
＊＊＊
, P< 0.001. 
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Figure 3.11 Culture-positive peritonitis are associated with more infiltrating leukocytes. 
Frequency (%) and total numbers of peritoneal neutrophils (CD15
+
), frequency and total number of 
peritoneal monocytes/macrophages (CD14
+
), frequency of peritoneal T cells (CD3
+
), and total 
numbers of helper T cells (CD4
+
), cytotoxic T cells (CD8
+), and γδ T cells (Vδ2+), in stable PD 
patients and in patients with PD-associated culture-negative (neg) or culture-positive peritonitis (pos) 
on day 1. Statistical differences between patient groups were analyzed using the Student’s t-test or 
Mann-Whitney U test, depending on normal distribution test using the Kolmogorov-Smirnov test. 
Error bars indicate SEM. 
＊
, P<0.05; 
＊＊
, P<0.01, 
＊＊＊
, P< 0.001. 
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3.3.10 Episodes of peritonitis caused by HMB-PP producing bacteria are 
associated with poor clinical outcome.   
We speculated that patient and technique survival might depend on the capacity of 
the causative pathogen to produce the V9/V2 T-cell activator HMB-PP. Our 
analysis of the three independent patient cohorts demonstrated that infections with 
HMB-PP
+
 bacteria were indeed associated with worse outcomes, while HMB-PP
–
 
bacteria (Enterococcus, Staphylococcus, Streptococcus) caused milder symptoms 
(Figure 3.12, top panels). 
In order to rule out that the pattern observed in our study was not just due to 
differences in the Gram staining, as reported by previous investigators (15, 18, 119, 
133-137), we divided the group of HMB-PP
+
 bacteria further into Gram
+
 and Gram
–
 
species. Our outcome analysis demonstrated that even within the Gram
+
 group, 
bacteria capable of producing HMB-PP were associated with worse outcomes 
compared to HMB-PP
–
 pathogens, suggesting that the HMB-PP producing capacity 
of the causative pathogen might be of predictive value for the clinical outcome from 
bacterial peritonitis (Figure 3.12). 
Infections caused by HMB-PP
–
 pathogens had only marginally increased odds ratios 
in relation to culture-negative infection. In contrast, infections caused by HMB-PP
+
 
pathogens were characterized by odds ratios of 3.4-7.4 in relation to culture-negative 
infections, for 90
th
 day technique failure and 90
th
 day mortality (Table 3.3). Of note, 
both Gram
+
 HMB-PP
+
 and Gram
–
 HMB-PP
+
 bacteria contributed to the increased 
risk of technique failure although the number of episodes caused by Gram
+
 HMB-
PP
+
 species such as Bacillus and Corynebacterium was too low to reach statistical 
significance in the Stoke-on-Trent database. 
Chapter 3: Outcome analysis and immune responses 
 
66 
 
0 10 20 30 40 50 60 70 80 90
30
40
50
60
70
80
90
100
Gram+HMBPP-
Gram-
Gram+HMBPP+
Techniqe survival days (stoke)
P
e
rc
e
n
t 
s
u
rv
iv
a
l
0 10 20 30 40 50 60 70 80 90
60
70
80
90
100
Survival days (stoke)
P
e
rc
e
n
t 
s
u
rv
iv
a
l
T
e
c
h
n
iq
u
e
 s
u
rv
iv
a
l 1.0
0.9
0.8
0.7
0.4
P
a
ti
e
n
t 
s
u
rv
iv
a
l
1.0
0.9
0.8
0.7
0.6
days days
p<0.05 p<0.01
0 10 20 30 40 50 60 70 80 90
T
e
c
h
n
iq
u
e
 s
u
rv
iv
a
l 1.0
0.9
0.8
0.7
0.3
P
a
ti
e
n
t 
s
u
rv
iv
a
l
1.0
0.9
0.8
0.7
days days
0 10 20 30 40 50 60 70 80 90
0 10 20 30 40 50 60 70 80 900 10 20 30 40 50 60 70 80 90
Stoke-on-Trent, UK (n=220)
Cardiff, UK (n=36)
0.4
0.5
0.6
0.6
0.6
0.5
0.3
HMB-PP ̶
HMB-PP +
HMB-PP ̶
HMB-PP +
Gram + HMB-PP --
Gram + HMB-PP +
Gram + HMB-PP --
Gram + HMB-PP +
Gram -- HMB-PP +
Gram -- HMB-PP + 
0 10 20 30 40 50 60 70 80 90
30
40
50
60
70
80
90
100
Technique survival days (AZD)
P
e
rc
e
n
t 
s
u
rv
iv
a
l
0 10 20 30 40 50 60 70 80 90
95
96
97
98
99
100
Survival days (AZD)
P
e
rc
e
n
t 
s
u
rv
iv
a
l
Gram + HMB-PP --
P
a
ti
e
n
t 
s
u
rv
iv
a
l
1.00
0.99
0.98
0.97
0.96
0.95
T
e
c
h
n
iq
u
e
 s
u
rv
iv
a
l 1.0
0.9
0.8
0.7
0.4
days days
0 10 20 30 40 50 60 70 80 90 0 10 20 30 40 50 60 70 80 90
ANZDATA, Australia (n=1,964)
Gram -- HMB-PP +
0.3
0.5
0.6
Gram + HMB-PP +
Gram + HMB-PP --
Gram + HMB-PP + 
Gram -- HMB-PP + 
＊＊
＊＊＊
＊
＊
＊＊＊
 
Figure 3.12 Episodes of peritonitis caused by HMB-PP producing bacteria are associated with 
poor clinical outcome. 
Cumulative patient survival (left) and cumulative technique survival (right) of patients with acute 
bacterial peritonitis, grouped into infections with HMB-PP deficient (dotted lines) or HMB-PP 
producing pathogens (solid lines). Top, PD patients admitted at the University Hospital of Wales, 
Cardiff, with acute peritonitis. Middle, Australian PD patients from the ANZDATA registry with 
first-time peritonitis. Bottom, PD patients with first-time peritonitis treated at the University Hospital 
of North Staffordshire, Stoke-on-Trent, UK.  Comparisons were made using log-rank tests. 
＊
, P<0.05; 
＊＊
, P<0.01, 
＊＊＊
, P< 0.001, compared to Gram
+
HMB-PP
－ 
peritonitis. 
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Table 3. 3 Odds ratios for risk of technique failure and patient mortality within 90 days after 
infection, depending on the causative pathogen. Comparisons were made using multinomial 
logistic regression.  
90
th
 day technique failure 
 
Stoke-on-
Trent 
(UK) 
p value 
ANZDATA 
(Australia) 
p value 
ANZDATA
+ Stoke-on-
Trent 
combined 
p value 
Reference: 
culture-negative  
1.0  1.0  1.0  
HMB-PP
–
 2.0 * 0.8 n.s. 1.0 n.s. 
HMB-PP
+
 7.4 *** 3.4 *** 4.1 *** 
Reference: HMB-PP
–
  1.0  1.0  1.0  
Gram
+ 
HMB-PP
+
 3.1 n.s. 2.0 0.066 2.1 * 
Gram
–
 HMB-PP
+
 3.8 *** 4.3 ** 4.0 *** 
       
90
th
 day mortality       
Reference: 
culture-negative  
1.0  1.0  1.0  
HMB-PP
–
 2.1 n.s. 2.3 n.s. 1.3 n.s. 
HMB-PP
+
 6.3 *** 5.4 * 2.8 ** 
Reference: HMB-PP
–
  1.0  1.0  1.0  
Gram
+ 
HMB-PP
+
 2.9 n.s. 2.8 n.s. 2.4 n.s. 
Gram
–
 HMB-PP
+
 3.0 * 2.4 ** 2.2 ** 
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3.3.11 Infections caused by HMB-PP producing bacteria are characterized by 
elevated frequencies of local  T cells.   
V9/V2 T cell specifically respond to the microbial metabolite HMB-PP, an 
essential metabolite in the majority of Gram
+
 (Bacillus, Clostridium, 
Corynebacterium, Mycobacterium) and Gram
–
 bacteria (E. coli, Klebsiella, 
Pseudomonas, Salmonella) (87, 94). We therefore speculated that infections by 
HMB-PP producing bacteria directly lead to increased infiltration and activation of 
local  T cells.  In a total of 33 peritonitis episodes examined on the first day of 
infection, we did not see any significant differences in the numbers and frequencies 
of peritoneal neutrophils, monocytes/macrophages, and CD4
+
 or CD8
+
 T cells, 
regardless of the HMB-PP status of the causative pathogen. However, the 
frequencies of peritoneal V9/V2 T cells were elevated in HMB-PP+ infections 
compared to HMB-PP
–
 infections (Figure 3.13), suggesting increased infiltration 
and/or proliferation in response to HMB-PP released by bacteria. Although CD69 
expression on peritoneal V9/V2 T cells was higher compared to circulating 
counterparts, there were no significant difference in the expression of CD69 on 
V9/V2 T cells between HMB-PP+ and HMB-PP– peritonitis (Figures 3.3 and 3.13). 
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Figure 3.13 Infections caused by HMB-PP producing bacteria are characterized by elevated 
frequencies of local γδ  T cells.   
Total numbers of peritoneal neutrophils (CD15
+
), monocytes/macrophages (CD14
+
), and T cells 
(CD3
+
), and total numbers and frequencies of γδ T cells (Vδ2+), and expression of CD69 on 
peritoneal γδ T cells in patients with PD-associated peritonitis on day 1, depending on whether or not 
the causative pathogen is capable of producing the microbial metabolite HMB-PP. Statistical 
differences between patient groups were analyzed using the Student’s t-test. Error bars indicate SEM. 
＊
, P<0.05. 
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3.3.12 Frequencies of peritoneal  T cells predict clinical outcome in peritonitis 
patients.   
Analysis of all immunological parameters determined in the present study identified 
elevated frequencies of peritoneal Vγ9/Vδ2 T cells were associated with technique 
failure within 30 and 90 days after infection (Table 3.4).  Similarly, expression of the 
activation marker HLA-DR by peritoneal Vγ9/Vδ2 T cells on the day of admission 
might be associated with increased 90
th
 day mortality. Other parameters such as 
numbers and frequencies of neutrophils, monocytes, CD4
+
 or CD8
+
 T cells, the 
activation status of monocytes, or soluble factors in the effluent did not reach 
statistical significance (data not shown).   
Although some subsets of CD4
+
 (TEM and TEMRA) or γδ T cells (naïve) reached 
significant differences in the outcome analysis, inconsistent results among different 
markers (CCR7, CD27 or CD62L vs. CD45RA) made these data difficult to interpret. 
Moreover, low expression of CD25 on CD8
+
 T cells makes CD25 a poor marker for 
predicting outcome, even though its expression on CD8
+
 T cells reached a significant 
difference. 
While preliminary in nature due to the limited number of patient samples analyzed, 
our observations imply that positive identification of the causative pathogen to 
produce HMB-PP together with elevated frequencies of γδ T cells might be negative 
predictors of clinical outcome.   
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Table 3.4 Identification of day 1 predictive immune markers for clinical outcome in PD-
associated peritonitis patients (means ± SEM). 
 
30
th
 day technique failure Survivors (46) Non-survivors (4) p value 
Vδ2+ (% of CD3+ T cells) 2.6 ± 0.4 7.0 ± 1.4 ** 
CCR7
+
CD45RA
+(% of Vδ2+ T cells) 2.5 ± 0.7 8.7 ± 4.4 * 
CD62L
－
CD45RA
－ 
(% of CD4
+
 T cells) 51.1 ± 3.1 25.6 ± 6.6 * 
    
90
th
 day technique failure Survivors (39) Non-survivors (11) p value 
Vδ2+ (% of CD3+ T cells) 2.1 ± 0.2 5.9 ± 1.4 * 
Vδ2+ T cells (∙106) 0.7 ± 0.3 1.3 ± 0.4 * 
CCR7
－
CD45RA
+
(% of CD4
+
 T cells) 8.2 ± 1.8 3.3 ± 1.0 * 
CD27
－
CD45RA
+
(% of CD4
+
 T cells) 5.5 ± 1.3 2.0 ± 0.8 * 
CD25
+
(% of CD8
+
 T cells) 2.6 ± 0.5 1.2 ± 0.2 * 
    
90
th
 day mortality Survivors (47) Non-survivors (3) p value 
Vδ2+ T cells (∙106) 0.9 ±0.3 0.16 ± 0.12 * 
HLA-DR
+
 (% of V2+ T cells) 12.1 ± 1.7 40.6 ± 4.3 *** 
CD62L
－
CD45RA
+ 
(% of CD4
+
 T cells) 3.0 ± 1.2 6.1 ± 0.4 * 
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3.4 Discussion 
The number of patients developing end stage renal failure is increasing year upon 
year, and in the UK is expected to double over the next ten years (138, 139). Patients 
generally benefit most if they commence treatment with PD as the most efficacious 
and cost-effective part of an integrated program of renal replacement therapy. 
Currently however, the median treatment time on PD is only 2.5-3.5 years, with the 
major reason for cessation remaining recurrent or severe episodes of peritonitis (140). 
If we are to limit the susceptibility to infection and the detrimental impact of 
prolonged inflammation on peritoneal membrane longevity, we need to better 
understand the processes causing deleterious alterations to the local immune 
response.   
To realize the activation status of monocytes/macrophages, we measured the 
expression of APC markers including CD40, CD86 and HLA-DR. Peritoneal 
monocytes/macrophages from peritonitis patients on day 1 were unable to express 
high levels of HLA-DR or the costimulatory molecules CD40 and CD86 compared 
to circulating monocytes from healthy donors. In addition, the expression of CD86 
on peritoneal monocytes/macrophages from stable and peritonitis patients was 
significantly lower than that on circulating monocytes. Further analysis of peritonitis 
samples showed that the expression of CD86 was even lower in HMB-PP
+
 peritonitis 
compared to HMB-PP
– 
peritonitis. Clinical observations have shown that HLA-DR 
expression was significantly decreased both in patients with severe sepsis and septic 
shock (141). Down regulation of HLA-DR and CD86 on circulating monocytes were 
also showed in patients with indeterminate clinical form of Chagas disease (142). 
Compared to cells from controls, CD40L-activated monocytes from septic patients 
with Gram-negative organisms showed significantly reduced production of TNF-α, 
IL-1β, and IL-12 and were unable to express high levels of CD80 and CD86 
molecules (143). This could be the explanation for our observation of down-
regulation of CD86 on peritoneal monocyes in HMB-PP
+
 peritonitis, which were 
mostly Gram-negative infections in this study. Pathogens such as Salmonella (144) 
have been showed to develope immune evasion strategies (e.g. ubiquitination) to 
down-regulate expression of MHC class II molecules on APCs. 
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Consistent with previous studies (35, 61, 62), our data show that some degree of 
local activation is present in the peritoneal cavity of stable PD patients evidenced by 
enhanced expression of  CD69 on CD4
+
, CD8
+
 and γδ T cells and higher CD25 
expression on γδ T cells in comparison with their counterparts in blood. The 
peritoneal T cells from peritonitis patients on day 1 were also activated with 
enhanced expression of both CD25 and CD69 on all three T cell subsets compared to 
circulating T cells. Of note, the levels of CD69 expression were much higher than 
those of CD25 expression on activated T cells.  Since CD69 is generally regarded as 
an early activation surface maker expressed on lymphocytes and CD25 is a relatively 
late marker (145, 146), the collecting time point of peritonitis samples might be one 
of the reasons for this difference. On the other hand, CD25 is an important marker of 
some Treg sub-populations. Many of the peritoneal CD4
+
CD25
+
 cells may be Tregs 
rather than activated T cells.  
 
Because CCR7 and CD62L are essential for homing to lymph nodes (106) and 
human naïve T cells can be identified by the expression of the CD45RA isoforms 
(147), staining of T cells with antibodies to CD45RA and CCR7 revealed three 
subsets of CD4
+
 T cells: one naïve CD45RA
+
CCR7
+
; and two memory subsets, 
CD45RA
－
CCR7
+
 (TCM) and CD45RA
－
CCR7
－
(TEM). Both naïve and TCM cells 
expressed high levels of CD62L, whereas the TEM cells expressed lower CD62L. 
Within CD8
+
 T cells, an extra subset of CD45RA
+
CCR7
－
 cells (TEMRA) was 
identified (102). Accordingly, our results confirmed that effector/memory (CD45RA
－
CCR7
－
) CD4
+
 T cells were the most predominant subsets in the peritoneal cavity in 
stable PD effluents as shown before (126). In parallel, analysis of γδ T-cell memory 
subsets characterized with antibodies against CD45RA and CD27 (105) 
demonstrated that CD45RA
－
CD27
+ Vδ2+ T cells were the most enriched subsets in 
peritoneal cavity either in stable or peritonitis samples on day 1. However, in 
comparison with circulating γδ T cells, the frequencies of peritoneal 
effector/memory CD4
+
 T cells and CD45RA
－
CD27
－
Vδ2+ T cells increased in 
peritonitis patients. Conversely, the frequencies of naïve CD4
+
 T cells and 
CD45RA
+
CD27
+ Vδ2+  T cells decreased in peritonitis patients.   
 
There are a number of chemokine receptors and adhesion molecules involved in 
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lymphocyte migration to secondary lymphoid organs or tissues under homeostatic or 
inflammatory conditions (102). The peritoneal γδ T cells from peritonitis patients on 
day 1 expressed similar level of CCR5 but showed up-regulation of CCR6 and 
down-regulation of CXCR3 in comparison with their counterparts in blood. The 
peritoneal CD4
+
 and CD8
+
 T cells from peritonitis samples expressed these markers 
in a similar pattern. It has been reported that CCR5 and CXCR3 are predominantly 
expressed on TH1 cells in peripheral blood (148). Of note, higher levels of CXCL10, 
one of the ligands of CXCR3, were found in peritonitis samples (514.1 ± 82.7 pg/ml) 
compared to stable PD effluents (43.2 ± 22.5 pg/ml), suggesting a possible down-
regulation of CXCR3 on peritoneal T cells as a result of chemokine-mediated 
receptor internalization (149, 150). 
 
Sine CD4
+
 helper T cells can differentiate into TH1, TH2, TH17 or Treg cells in 
response to various stimuli and the different cytokines secreted by these cells 
mediate distinct effector functions (151), we evaluated different subsets of T cells 
and observed the predominant CD4
+
 T cells subsets in stable PD effluents to be TH1 
cells. This pattern of cytokine production was the same in CD8
+
 T cells and γδ T 
cells in stable PD patients. T lymphocytes in the peritoneal cavity of peritonitis 
patients on day1 were characterized by an increase in the percentage of TH2 cells, as 
well as TH2-type CD8
+
 T cells and IL-4 producing γδ T cells, without a significantly 
different percentage of TH1 cells in comparison with these cells in stable PD 
effluents. High numbers of TH2-type CD8
+
 T cell clones have been generated from 
HIV-infected patients (152). In the normal human peritoneum, TH2-type CD8
+
 T 
cells exhibited reduced cytolytic activity and provide B cell helper function (84). By 
measuring the expression patterns of cytokine mRNAs, Wang et al. demonstrated 
that peritoneal CD8
+
 T cells cloned from the PD effluents of new patients and during 
peritonitis on day 2 were associated with a TH2-type pattern (85). The role of 
peritoneal TH2-type CD8
+
 T cell in acute peritonitis still needs further evaluation. 
 
In this study, our data demonstrate that culture-positive peritonitis carries a worse 
prognosis in terms of technique and patient survival, in keeping with previous 
studies (20, 153-156). As compared to culture-negative infections, these episodes 
have a different inflammatory signature characterized by higher numbers (and 
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proportions) of infiltrating neutrophils and more severe peritoneal inflammation. 
Moreover, culture-positive peritonitis is skewed toward higher frequencies of TH1 
cells and lower frequencies of TH2 and Treg cells, according to the expressions of 
cytokine and transcription factor profiles. We then extended these observations by 
identifying that the capacity of the causative pathogen to produce HMB-PP, together 
with the infiltration of activated γδ T cells are important risk factors and possible 
predictors of patient outcomes from infection.  
Re-analysis of peritonitis data from validated registry data confirms that HMB-PP
+
 
bacteria (such as E. coli, Corynebacterium spp., and Pseudomonas spp.) caused 
clinically more severe infection, with higher rates of non-resolving infection, 
peritoneal catheter removal, and patient mortality (15, 18, 119, 133-137).  These 
findings emphasize the importance of shifting the focus away from a simple 
classification into Gram-negative and Gram-positive species, and the need to pay 
more attention to detailed host-pathogen interactions.  These interactions are clearly 
dependent on the nature of the causative pathogens and might impact on treatment 
outcomes. In this respect, the correct identification of the causative pathogen is of 
pivotal relevance for our understanding of the underlying inflammatory response and 
possible ways of improving patient management and refining/targeting treatment. 
Further improvements in culture techniques and the introduction of rapid molecular 
diagnostic methods such as 16S and 23S rDNA sequencing are therefore urgently 
needed (22, 23, 157, 158). 
There is a necessity for more research into the role of different leukocyte populations 
and soluble mediators during acute inflammatory responses, in order to dissect the 
interplay between neutrophils, monocytes/macrophages, and T cells, and the 
potentially detrimental consequences for clinical outcome (57, 112, 125, 126). One 
such interaction may lead to aberrant activation and expansion of γδ T cells and the 
perpetuation of inflammatory responses during acute peritonitis. γδ T cells clearly 
play a beneficial role in bridging innate and adaptive immune responses in infection 
and inflammation (87, 89, 94). However, their excessive activation in the peritoneal 
cavity of a vulnerable patient group, where the continuous exchange of PD effluent 
and thus the repeated removal of all infiltrating leukocytes and soluble mediators 
does not allow the natural progression and resolution of an anti-microbial immune 
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response, may ultimately contribute both to irreversible damage on the peritoneal 
membrane and to detrimental outcomes.   
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4.1. Introduction 
Infection-related morbidity and mortality remains unacceptably high, indicating that 
conventional research solutions have not made sufficient impact (159). Effective 
infection control is hampered by the poor performance of standard diagnostics and 
hence inadequate choice of treatments, and a deep lack of appreciation how the body 
senses and fights bacterial pathogens.   
Antimicrobial treatment is largely empirical as therapeutic intervention usually 
commences before the nature of the causative pathogen is known. Microbiological 
identification is often delayed and in many cases no organism can be identified. 
Rates of culture-negative infections in PD peritonitis may vary from 0-50 % (20), in 
sepsis they typically exceed >50% (160). Molecular tests that identify 
microorganisms in biological fluids often suffer from lack of specificity and 
unacceptably high rates of false positivity. Point-of-care methods that direct therapy 
especially in cases where the virulence of an organism is a determinant of outcome 
are urgently required (161-164). The failure in improving outcomes across diverse 
patient groups demonstrates that the physiological and pathophysiological events 
driving early inflammatory responses and pathogen clearance remain poorly 
understood.  It is becoming increasingly clear that the nature of the infection is a 
major determinant of outcome (124), and detailed knowledge about the intricate 
relationships between immunological, microbiological and clinical parameters in 
disease is needed. This is especially the case in particularly vulnerable individuals 
such as patients with sepsis or PD associated peritonitis, where overshooting host 
responses have detrimental consequences (57, 165). Positive identification of the 
causative pathogen is not only crucial in order to guide and refine patient 
management with respect to the choice of antibiotic treatment, it also provides 
important clues as to the underlying inflammatory mechanisms and how to 
manipulate them to resolve infection.   
Different types of pathogens carry different types of pathogen-associated molecular 
patterns, and hence interact with different components of the immune system. Each 
infection is therefore likely to leave a distinct immunological signature that can be 
assessed quantitatively and qualitatively (166-168). However, aside from theoretical 
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considerations, to our knowledge no experimental attempt has been made so far to 
translate the notion of pathogen-specific immune responses into the clinic and use it 
for diagnostic purposes. 
In the present study we performed a detailed immunological and microbiological 
analysis in PD patients on the first day of presentation with acute peritonitis. Our 
findings provide proof of concept that acute bacterial infections indeed leave 
characteristic disease-specific ‘immune fingerprints’ of diagnostic and prognostic 
value. Local fingerprints not only discriminated between episodes of culture-
negative and culture-positive PD associated peritonitis but also predicted infections 
caused by Gram
−
 or Gram
+
 bacteria. As such, our results have far-reaching 
implications for differential diagnosis of patients with suspected infections and may 
help guide patient management through faster biomarker-based diagnostics, better 
predictive risk modeling and improved targeting of therapy. 
 
4.2 Aims 
The aims of this Chapter were: 
1) To identify local ‘immune fingerprints’ of culture-negative, Gram− and 
Gram
+
 PD-associated peritonitis.  
2) To demonstrate the discrimination power and cut-off values of biomarkers 
with diagnostic potential.  
3) To demonstrate potential biomarkers for the immune signature of individual 
bacteria.  
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4.3 Results 
 
4.3.1 Acute episodes of peritonitis are associated with severe peritoneal 
inflammation.   
Following the analysis of Chapter 3, we tried to identify potential biomarkers with 
characteristic disease-specific ‘immune fingerprints’ of diagnostic value using the 
data collected from the 52 episodes of acute peritonitis on day1.   
As mentioned in Section 3.3.1, patients presenting with acute peritonitis were 
characterized by a significant peritoneal influx of immune cells, predominantly 
CD15
+
 neutrophils, CD14
+
 monocytes/macrophages and CD3
+
 T cells. While 
peritoneal leukocytes in stable patients comprised mainly of monocytes/macrophages 
and T cells, acute peritonitis was dominated by a massive recruitment of neutrophils, 
at times reaching >95% of all peritoneal cells and >10
11
 cells in total per PD bag. 
Within the peritoneal T cell population, there was a preferential increase in the 
frequency of V2+ T cells within the T cell population in acute peritonitis, while the 
percentages of CD4
+
 and CD8
+
 T cells remained virtually unchanged (Table 4.1).   
Soluble mediators significantly increased in acute peritonitis included IL-1b, IL-6, 
sIL-6R, IL-10, IL-22, CXCL8, CXCL10, TNF-a, TGF-b and MMP-3; at the same 
time levels of cytokines such as IL-2, IL-12p70, IL-17 and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) were not elevated above baseline or, in the case 
of IFN-γ, not significantly (Table 4.1). Taken together, these measurements 
identified a broad range of cellular and soluble biomarkers that indicate acute 
inflammatory responses in PD patients, some of which might be of diagnostic value.   
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Table 4.1 Immunological biomarkers in stable patients and patients presenting with a ‘cloudy 
bag’ on day 1 (mean ± SEM).  n.s., not significant. 
 
 Stable PD Cloudy bag p 
Gender (male/female) 9/6 32/20 n.s. 
Age (years) 60.4 ±
 
4.9 65.5 ±
 
2.0 n.s. 
Days on PD (days) 1,058 ±
 
219.2 1,142 ±
 
131.1 n.s. 
Neutrophils (∙106) 0.6 ± 0.3 7,048 ± 1,384 *** 
Monocytes (∙106) 2.8 ± 1.5 753.9 ± 166.0 *** 
CD4
+
 T cells (∙106) 0.3 ± 0.2 32.3 ± 15.7 *** 
CD8
+
 T cells (∙106) 0.3 ± 0.2 24.5 ± 12.0 *** 
V2+ T cells (∙106) 0.01 ± 0.003 1.1 ± 0.4 *** 
Neutrophils (% of total) 9.0 ± 4.2 80.3 ± 2.2 *** 
Monocytes (% of total) 28.9 ± 9.4 12.9 ± 1.9 n.s. 
T cells (% of total) 17.5 ± 6.8 1.0 ± 0.3 *** 
CD4
+
 (% of T cells) 52.2 ± 3.3 50.6 ± 2.1 n.s. 
CD8
+
 (% of T cells) 40.0 ± 3.8 37.6 ± 2.1 n.s. 
V2+ (% of T cells) 1.3 ± 0.3 2.9 ± 0.4 * 
IL-1b (pg/ml) 3.7 ±
 
1.6 45.1 ±
 
12.6 *** 
IL-2 (pg/ml) 6.2 ± 2.2 11.4 ± 2.1 n.s. 
IL-6 (pg/ml) 37.1 ±
 
7.3 3,249 ±
 
623.6 *** 
sIL-6R (pg/ml) 360.1 ± 50.8 639.6 ± 50.3 ** 
IL-10 (pg/ml) 10.9 ± 3.8 85.6 ± 19.4 *** 
IL-12p70 (pg/ml) 4.2 ±
 
1.5 4.5 ±
 
1.0 n.s. 
IL-17 (pg/ml) 1.5 ± 1.0 6.7 ± 2.7 n.s. 
IL-22 (pg/ml) 13.9 ±
 
7.7 121.8 ±
 
36.5 ** 
CXCL8 (pg/ml) 18.1 ± 3.2 699.3 ± 191.7 *** 
CXCL10 (pg/ml) 43.2 ± 22.5 514.1 ± 82.7 *** 
IFN- (pg/ml) 52.7 ±
 
16.6 123.0 ±
 
39.7 n.s. 
TNF-a (pg/ml) 21.8 ± 8.4 86.8 ± 18.8 * 
GM-CSF (pg/ml) 11.3 ±
 
4.4 15.5 ±
 
3.8 n.s. 
TGF-b (pg/ml) 78.4 ±
 
10.8 151.4 ±
 
15.0 ** 
MMP-3 (pg/ml) 1,540 ± 184.9 3,029 ± 427.3 ** 
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4.3.2 Culture-negative and culture-positive episodes of peritonitis display 
distinct immune signatures.   
We next stratified patients presenting with a ‘cloudy bag’ into distinct subgroups, 
according to the microbiological culture results. Together with Section 3.3.9, these 
analyses revealed that immune signatures were markedly different between patients 
with confirmed culture-positive infection and those with culture-negative infection. 
Patients with culture-positive peritonitis had significantly higher numbers of 
neutrophils and monocytes/macrophages as well as CD4
+
, CD8
+
 and V2+ T cells 
(Figure 3.11 and Table 4.2). However, besides these quantitative differences we also 
noted pronounced qualitative differences. In culture-positive patients, a larger 
proportion of the infiltrating immune cells were neutrophils whereas a smaller 
proportion were monocytes/macrophages, suggesting that the neutrophil:monocyte 
ratio might be of relevance for diagnostic purposes (Table 4.2). In contrast, the 
proportion of T cells in the infiltrate and the relative composition of CD4
+
, CD8
+
 and 
V2+ T cells within the T cell population did not show any difference between 
culture-positive and culture-negative infection. In line with differences on the 
cellular level, the two patient groups could also be distinguished based on the 
peritoneal levels of inflammatory markers, with higher levels of IL-1b, IL-2, IL-6, 
IL-10, IL-22 and TNF-α (as well as sIL-6R and MMP-3 with borderline significance) 
in culture-positive patients, whereas IL-12p70, IL-17, CXCL8, CXCL10, IFN-, 
GM-CSF and TGF-b showed no such differences (Figure 3.10 and Table 4.2). Taken 
together, these findings confirm earlier reports that patients with culture-positive 
peritonitis experience a more severe peritoneal inflammatory response than those 
with culture-negative peritonitis, and identify immune signatures that might have 
discriminatory power between the two groups. 
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Table 4.2 Immunological biomarkers in patients presenting with a ‘cloudy bag’ on day 1, 
depending on the microbiological culture results (mean ± SEM).  n.s., not significant. 
 
 Culture-negative Culture-positive p 
Gender (male/female) 10/5 22/15 n.s. 
Age (years) 66.7 ± 3.7 65.0 ± 2.3 n.s. 
Days on PD (days) 1,185 ±
 
230.0 1,140 ±
 
164.9 n.s. 
Neutrophils (∙106) 1,225 ± 772.9 9,342 ± 1,756 *** 
Monocytes (∙106) 245.5 ± 81.4 954.1 ± 220.4 * 
CD4
+
 T cells (∙106) 4.3 ± 1.9 43.5 ± 21.7 ** 
CD8
+
 T cells (∙106) 1.8 ± 0.5 33.6 ± 16.5 ** 
V2+ T cells (∙106) 0.1 ± 0.04 1.4 ± 0.5 ** 
Neutrophils (% of total) 68.2 ± 5.6 85.0 ± 1.6 ** 
Monocytes (% of total) 23.6 ± 5.1 8.8 ± 1.1 ** 
T cells (% of total) 1.4 ± 0.7 0.8 ± 0.2 n.s. 
CD4
+
 (% of T cells) 54.0 ± 4.2 49.3 ± 2.5 n.s. 
CD8
+
 (% of T cells) 36.6 ± 3.8 37.9 ± 2.6 n.s. 
V2+ (% of T cells) 2.4 ± 0.4 2.9 ± 0.6 n.s. 
IL-1b (pg/ml) 7.2 ±
 
3.1 62.9 ±
 
17.5 *** 
IL-2 (pg/ml) 6.7 ± 2.0 13.6 ± 2.8 * 
IL-6 (pg/ml) 1,502 ±
 
677.8 4,064 ±
 
823.2 ** 
sIL-6R (pg/ml) 493.9 ± 58.9 699.6 ± 64.5 0.063 
IL-10 (pg/ml) 16.4 ± 4.5 117.9 ± 26.4 *** 
IL-12p70 (pg/ml) 2.4 ±
 
0.7 5.5 ±
 
1.4 n.s. 
IL-17 (pg/ml) 4.7 ± 3.4 7.8 ± 3.7 n.s. 
IL-22 (pg/ml) 55.1 ±
 
24.5 151.0 ±
 
50.7 * 
CXCL8 (pg/ml) 470.0 ± 296.9 806.3 ± 245.5 n.s. 
CXCL10 (pg/ml) 323.1 ± 123.6 603.6 ± 104.3 n.s. 
IFN- (pg/ml) 59.4 ±
 
20.6 152.6 ±
 
57.0 n.s. 
TNF-a (pg/ml) 16.3 ± 5.3 119.7 ± 25.5 ** 
GM-CSF (pg/ml) 8.7 ±
 
2.9 18.7 ±
 
5.4 n.s. 
TGF-b (pg/ml) 115.2 ±
 
16.8 166.1 ±
 
19.6 n.s. 
MMP-3 (pg/ml) 1,969 ± 291.8 3,479 ± 581.4 0.056 
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4.3.3 A combination of immunological biomarkers accurately predicts culture-
negative episodes of peritonitis on day 1.   
Given the distinct immune signatures observed in the different patient groups, we 
tested whether specific immunological biomarkers on day 1 could predict the 
microbiological culture results. AUROC calculations identified a number of 
parameters with discriminatory power, such as the proportion of neutrophils amongst 
peritoneal cells as well as the levels of IL-1b, IL-10, TNF-a and IL-6 (Table 4.3). A 
simple model for the discriminatory potential between culture-negative and culture 
positive peritonitis was developed by combination of biomarkers according to the 
cut-off values determined by Youden index (Table 4.4). For culture-positive 
prediction, IL-10 ( 23.3 pg/ml) (one point), IL-1β ( 4.1 pg/ml) (one point), TNF-α 
( 19.5 pg/ml) (one point), and IL-6 ( 1,035 pg/ml) (one point) were used to 
calculate AUROC values. Conversely, IL-10 (< 23.3 pg/ml) (one point) and IL-1β (< 
4.1 pg/ml) (one point) and proportion of peritoneal monocytes/macrophages 
(19.1%) (one point) were used for culture-negative prediction. Combination of the 
parameters with the highest AUROC values yielded an excellent discriminatory 
potential for IL-1b and IL-10 levels to predict cases of culture-positive infection. 
Similarly, combination of the proportion of peritoneal monocytes/macrophages with 
IL-1b and IL-10 levels resulted in an excellent discriminatory potential to predict 
cases of culture-negative infection (Table 4.3), as illustrated in Figure 4.1A. 
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Table 4.3 Ability of immunological biomarkers to discriminate between culture-negative and 
culture-positive episodes of peritonitis on day 1. 
 
 AUROC ± SEM 95% CI p 
For culture-positive prediction 
Neutrophils (% of total) 0.805 ± 0.073 0.663 - 0.948 ** 
IL-1b (pg/ml) 0.886 ± 0.059 0.770 - 1.000 *** 
IL-10 (pg/ml) 0.857 ± 0.057 0.745 - 0.970 *** 
TNF-a (pg/ml) 0.814 ± 0.065 0.687 - 0.941 ** 
IL-6 (pg/ml) 0.755 ± 0.082 0.594 - 0.916 ** 
IL-1b + IL-10a 0.924 ± 0.050 0.825 - 1.000 *** 
IL-1b + IL-10 + TNF-aa 0.908 ± 0.054 0.802 - 1.000 *** 
IL-1b + IL-10 + TNF-a + IL-6 a 0.888 ± 0.059 0.773 - 1.000 *** 
      
For culture-negative prediction 
Monocytes (% of total)
 a
 0.787 ±
 
0.078 0.634 - 0.941 ** 
Monocytes + IL-1b + IL-10 a 0.927 ± 0.052 0.825 - 1.000 *** 
Monocytes + IL-1ba 0.857 ± 0.076 0.708 - 1.000 *** 
a
, The unit is point(s). 
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Figure 4.1 Examples of immunological biomarkers in patients presenting with a ‘cloudy bag’ on 
day 1, depending on the microbiological culture results.  
(A) Discrimination between culture-negative and culture-positive infections.  (B) Discrimination 
between Gram
−
 and non-Gram
−
 infections. (C) Discrimination between Gram
+
 and non-Gram
+
 
infections.  Data points represent individual episodes (white, culture-negative; blue, confirmed Gram
+
 
infection; red, confirmed Gram
−
 infection. Dashed lines indicate calculated cut-off values for positive 
or negative discrimination. 
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Levels of IL-1β and IL-10 gave the best Youden Index and highest overall 
correctness as individual parameters, for prediction of either culture-positive or 
culture-negative peritonitis (Table 4.4).  When combined together, IL-1β ( 4.1 
pg/ml) and IL-10 ( 23.3 pg/ml) resulted in a 79% sensitivity and 97% specificity for 
the correct prediction of culture-negative peritonitis. Univariate analyses indicated 
that the proportion of neutrophils and monocytes/macrophages amongst total 
peritoneal cells as well as the levels of IL-1β and IL-10 had prognostic value on day 
1. Further multivariate analyses of these four parameters and combinations of 
parameters listed in Table 4.4 confirmed that combination of IL-1β and IL-10 had 
independent prognostic significance for the correct prediction of culture-negative 
peritonitis on day 1 (Table 4.5). 
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Table 4.4 Prediction of culture-negative and culture-positive infection on the first day of 
presentation with acute peritonitis. 
 
 
Cut-off 
Point 
 
Youden 
Index 
 
Sensitivity 
(%) 
 
Specificity 
(%) 
Overall 
Correctness 
(%) 
For culture-positive prediction 
Neutrophils (% of total) 79.0 0.59 82 77 79.5 
IL-1β (pg/ml) 4.1 0.72 93 79 86 
IL-10 (pg/ml) 23.3 0.73 80 93 86.5 
TNF-a (pg/ml) 19.5 0.48 77 71 74 
IL-6 (pg/ml) 1,035 0.45 73 71 72 
IL-1β + IL-10a 0.5 0.75 97 79 88 
IL-1β + IL-10 + TNF-aa 1.5 0.69 83 86 84.5 
IL-1β + IL-10 + TNF-a 
+ IL-6
 a
 
0.5 0.68 97 71 84 
      
For culture-negative prediction 
Monocytes (% of total) 19.1 0.53 62 91 76.5 
IL-1β + IL-10 a 1.5 0.75 79 97 88 
Monocytes + IL-1b  
+ IL-10
 a
 
1.5 0.73 77 96 86.5 
IL-1β + IL-10 + TNF-aa 1.5 0.69 86 83 84.5 
Monocytes + IL-1βa 0.5 0.63 77 86 81.5 
a
, The unit is point(s). 
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Table 4.5 Immunological biomarkers showing diagnostic significance for discrimination 
between culture-negative and culture-positive episodes of peritonitis on day 1. 
 
 
b
Coefficient 
Standard 
error 
Odds ratio 
(95%CI) 
 
p 
Univariate logistic regression 
Monocytes (% of total) -0.121 0.042 0.886 (0.816 - 0.963) ** 
Neutrophils (% of total) 0.096 0.034 1.101 (1.030 - 1.177) ** 
IL-1b  0.079 0.038 1.082 (1.006 - 1.165) * 
IL-10 0.052 0.023 1.053 (1.007 - 1.101) * 
     
Multivariate logistic regression (backward) 
IL-1b + IL-10 a 3.404 1.019 30.086 (4.082 - 221.765) ** 
Constant -3.057 1.225 – – 
a
, The unit is point(s). 
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4.3.4 Distinct immune fingerprints in patients with Gram
−
 infections have 
diagnostic potential on day 1.   
We next tested whether pathogen-specific immune fingerprints exist that could 
predict infections by certain groups of bacteria. Given the importance of Gram
−
 
bacteria in the clinic and their association with worse outcomes we initially 
concentrated on the prediction of Gram
−
 infections. Amongst all patients presenting 
with a cloudy bag on day 1, patients with confirmed Gram
−
 infections displayed 
larger numbers of infiltrating neutrophils and consequently lower proportions of 
monocytes/macrophages and T cells than the rest of the patients, i.e. individuals with 
culture-negative or Gram
+
 infections (Table 4.6). Within the T cell population, V2+ 
T cells were significantly increased and expressed higher levels of the activation 
marker HLA-DR in Gram
−
 infections. In return, peritoneal monocytes/macrophages 
expressed lower levels of CD86 in Gram
−
 infections, compared to the rest of the 
patients. Inflammatory markers significantly increased in Gram
−
 infections included 
IL-1b, IL-10 and TNF-a (Figure 4.1B; Table 4.6). AUROC calculations identified 
the combination of V2+ T cell frequencies and peritoneal levels of IL-10 as 
excellent discriminator to predict Gram
−
 infections (Table 4.7).  This combination 
also had the highest overall correctness, with a 100% sensitivity and 93% specificity 
for the correct prediction of Gram
−
 peritonitis (Table 4.8). The prognostic value of 
the proportion of monocytes/macrophages amongst all cells ( 10.7%) and their 
expression of CD86 ( 67.9%), the frequency of V2+ T cells with the T cell 
population ( 6.3%) and their expression of HLA-DR ( 16.1%), and peritoneal IL-
10 levels ( 110.1 pg/ml) were all confirmed by univariate analyses. Multivariate 
analysis of these parameters identified the V2+ T cell frequency as independent 
prognostic biomarker for the prediction of Gram
−
 peritonitis in all patients presenting 
with a cloudy bag on day 1 (Table 4.9). 
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Table 4.6 Immunological biomarkers in patients presenting with a ‘cloudy bag’ on day 1, 
depending on the absence or presence of a confirmed Gram
−
 infection (mean ± SEM).  n.s., not 
significant. 
 Other Gram
−
 p 
Gender (male/female) 25/15 7/5 n.s. 
Age (years) 64.1 ±
 
2.4 70.1 ±
 
2.9 n.s. 
Days on PD (days) 1,234 ±
 
156.2 899.3 ±
 
248.3 n.s. 
Neutrophils (∙106) 5,875 ± 1,580 10,779 ± 2,686 * 
Monocytes (∙106) 754.7 ± 206.1 751.1 ± 242.9 n.s. 
CD4
+
 T cells (∙106) 39.3 ± 20.5 9.9 ± 3.4 n.s. 
CD8
+
 T cells (∙106) 29.5 ± 15.6 8.6 ± 2.8 n.s. 
V2+ T cells (∙106) 1.1 ± 0.4 1.1 ± 0.4 n.s. 
Neutrophils (% of total) 78.1 ± 2.7 87.7 ± 2.3 n.s. 
Monocytes (% of total) 15.1 ± 2.3 5.8 ± 1.0 * 
T cells (% of total) 1.3 ± 0.3 0.2 ± 0.03 * 
CD4
+
 (% of T cells) 52.7 ± 2.3 43.7 ± 4.6 n.s. 
CD8
+
 (% of T cells) 37.8 ± 2.4 36.6 ± 5.0 n.s. 
V2+ (% of T cells) 2.0 ± 0.2 5.0 ± 1.4 * 
HLA-DR
+
 (% of  T 
cells) 
10.8 ± 1.8 22.5 ± 4.7 * 
CD86
+
 (% of monocytes) 72.6 ± 3.6 53.1 ± 7.2 * 
IL-1b (pg/ml) 35.0 ±
 
12.5 79.5 ±
 
34.7 * 
IL-2 (pg/ml) 12.2 ± 2.6 8.8 ± 1.9 n.s. 
IL-6 (pg/ml) 2,561 ±
 
538.8 5,586 ±
 
1,942 n.s. 
sIL-6R (pg/ml) 606.3 ± 57.6 751.4 ± 100.9 n.s. 
IL-10 (pg/ml) 49.4 ± 10.6 208.6 ± 65.5 ** 
IL-12p70 (pg/ml) 4.6 ±
 
1.3 4.1 ±
 
1.4 n.s. 
IL-17 (pg/ml) 8.4 ± 3.7 2.4 ± 1.3 n.s. 
IL-22 (pg/ml) 139.8 ±
 
45.9 56.8 ±
 
22.9 n.s. 
CXCL8 (pg/ml) 742.6 ± 237.5 552.3 ± 257.8 n.s. 
CXCL10 (pg/ml) 570.1 ± 97.7 306.9 ± 130.2 n.s. 
IFN- (pg/ml) 144.5 ±
 
50.9 50.0 ±
 
11.6 n.s. 
TNF-a (pg/ml) 65.3 ± 17.9 159.7 ± 51.8 * 
GM-CSF (pg/ml) 16.6 ±
 
4.8 12.1 ±
 
3.6 n.s. 
TGF-b (pg/ml) 143.0 ±
 
15.0 179.3 ±
 
42.6 n.s. 
MMP-3 (pg/ml) 2,804 ± 359.2 3,765 ± 1,429 n.s. 
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Table 4.7 Ability of immunological biomarkers to discriminate between Gram
−
 and non-Gram
−
 
episodes of peritonitis on day 1. 
 
 AUROC ± SEM 95% CI p 
For Gram
−
 prediction 
Monocytes (% of total) 0.745 ± 0.075 0.597 - 0.893 * 
V2+ (% of T cells) 0.710 ± 0.106 0.501 - 0.918 * 
HLA-DR
+
 (% of  T cells) 0.720 ±
 
0.097 0.530 - 0.911 * 
CD86
+
 (% of monocytes) 0.740 ± 0.083 0.578 - 0.903 * 
IL-10 (pg/ml) 0.803 ± 0.092 0.622 - 0.984 ** 
IL-1b (pg/ml) 0.738 ± 0.086 0.569 - 0.907 * 
TNF-a (pg/ml) 0.735 ± 0.091 0.557 - 0.914 * 
IL-10 + V2+ a 0.976 ± 0.022 0.934 - 1.000 *** 
IL-10 + V2+ + HLA-DR+ a 0.959 ± 0.031 0.899 - 1.000 *** 
IL-1b + IL-10 + TNF-aa 0.844 ± 0.077 0.693 - 0.995 ** 
a
, The unit is point(s). 
 
Table 4.8 Prediction of Gram
−
 infection on the first day of presentation with acute peritonitis. 
 
 
 
Cut-off 
Point 
 
Youden 
Index 
 
Sensitivity 
(%) 
 
Specificity 
(%) 
Overall 
Correctness 
(%) 
For Gram
−
 prediction 
Monocytes (% of total) 10.7 0.50 50 100 75 
V2+ (% of T cells) 6.3 0.46 46 100 73 
HLA-DR
+
 (% of  T 
cells) 
16.1 0.48 64 84 74 
CD86
+
 (% of monocytes) 67.9 0.47 74 73 73.5 
IL-10 (pg/ml) 110.1 0.61 70 91 80.5 
IL-1b (pg/ml) 14.0 0.55 90 65 77.5 
TNF-a (pg/ml) 32.8 0.45 80 65 72.5 
IL-10 + V2+ a 0.5 0.93 100 93 96.5 
IL-10 + V2+ + HLA-
DR
+ a
 
0.5 0.78 100 78 89 
IL-1b + IL-10 + TNF-aa 2.5 0.61 70 91 80.5 
a
, The unit is point(s). 
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Table 4.9 Immunological biomarkers showing diagnostic significance for prediction of Gram
−
 
episodes of peritonitis on day 1. 
 
 
b
Coefficient 
Standard 
error 
Odds ratio 
(95%CI) 
 
p 
Univariate logistic regression 
Monocytes (% of total) -0.189 0.093 0.828 (0.690 - 0.994) * 
V2+ (% of T cells) 0.385 0.159 1.469 (1.075 - 2.008) * 
HLA-DR
+
 (% of  T cells) 0.072 0.029 1.075 (1.014 - 1.139) * 
CD86
+
 (% of monocytes) -0.037 0.016 0.964 (0.934 - 0.995) * 
IL-10 0.012 0.005 1.012 (1.003 - 1.022) * 
     
Multivariate logistic regression (backward) 
V2+ (% of T cells) 0.571 0.246 1.770 (1.093 - 2.866) * 
Constant -4.591 1.376 – – 
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4.3.5 Distinct immune fingerprints in patients with Gram
+
 infections have 
diagnostic potential on day 1.   
In an analogous way to the prediction of Gram
−
 infections, we next attempted to 
identify predictors of Gram
+
 infections. Amongst all patients presenting with a 
cloudy bag on day 1, patients with confirmed Gram
+
 infections displayed larger 
numbers of infiltrating CD4
+
 and CD8
+
 T cells than the rest of the patients, i.e. 
individuals with culture-negative or Gram
−
 infections (Table 4.10), while the 
proportion of V2+ T cells within the T cell population was significantly lower in 
Gram
+
 infections. Inflammatory markers significantly increased in Gram
+
 infections 
included IL-22 and CXCL10 (Figure 4.1C; Table 4.10). AUROC calculations 
identified the combination of CXCL10 ( 301.2 pg/ml) and IL-22 levels ( 54.3 
pg/ml) and V2+ T cell frequencies ( 2.7%) as excellent discriminator to predict 
Gram
+
 infections (Table 4.11). This combination also had the highest overall 
correctness, with a 89% sensitivity and 67% specificity for the correct prediction of 
Gram
+
 peritonitis. In return, CXCL10 levels ( 301.2 pg/ml) combined with total 
CD4
+
 T cell counts ( 15.2·106) had a sensitivity of only 53% yet at a specificity of 
95% for the prediction of Gram
+
 peritonitis (Table 4.12). CD4
+
 T cell counts as well 
as V2+ T cell frequencies and CXCL10 levels had prognostic value as confirmed by 
univariate analyses. Multivariate analysis of these parameters and combinations of 
parameters listed in Table 4.11 identified combination of CD4
+
 T cell counts and 
CXCL10 levels as independent biomarkers for the prediction of Gram
+
 peritonitis in 
all patients presenting with a cloudy bag on day 1 (Table 4.13). 
Chapter 4: Local immune fingerprints 
 
95 
 
Table 4.10 Immunological biomarkers in patients presenting with a ‘cloudy bag’ on day 1, 
depending on the absence or presence of a confirmed Gram
+
 infection (mean ± SEM).  n.s., not 
significant. 
 
 Other Gram
+
 p 
Gender (male/female) 17/10 15/10 n.s. 
Age (years) 68.2 ±
 
2.4 62.4 ± 3.1 n.s. 
Days on PD (days) 1,058 ±
 
167.9 1,266 ± 213.9 n.s. 
Neutrophils (∙106) 5,604 ± 1,610 8,623 ± 2,293 n.s. 
Monocytes (∙106) 477.2 ± 128.0 1,056 ± 309.1 n.s. 
CD4
+
 T cells (∙106) 6.8 ± 1.9 60.2 ± 32.2 ** 
CD8
+
 T cells (∙106) 4.9 ± 1.5 46.1 ± 24.5 * 
V2+ T cells (∙106) 0.6 ± 0.2 1.6 ± 0.7 n.s. 
Neutrophils (% of total) 77.2 ± 3.8 83.7 ± 2.1 n.s. 
Monocytes (% of total) 15.4 ± 3.3 10.3 ± 1.5 n.s. 
T cells (% of total) 0.9 ± 0.4 1.1 ± 0.3 n.s. 
CD4
+
 (% of T cells) 49.3 ± 3.2 51.9 ± 2.9 n.s. 
CD8
+
 (% of T cells) 36.6 ± 3.0 38.6 ± 3.1 n.s. 
V2+ (% of T cells) 3.6 ± 0.7 1.8 ± 0.3 * 
HLA-DR
+
 (% of  T 
cells) 
17.2 ± 3.0 10.3 ± 2.1 n.s. 
CD86
+
 (% of monocytes) 62.9 ± 5.3 73.0 ± 4.1 n.s. 
IL-1b (pg/ml) 37.3 ± 16.0 54.5 ± 20.1 n.s. 
IL-2 (pg/ml) 7.6 ± 1.4 16.0 ± 4.0 n.s. 
IL-6 (pg/ml) 3,204 ± 970.8 3,303 ± 753.0 n.s. 
sIL-6R (pg/ml) 607.2 ± 60.0 674.8 ± 83.2 n.s. 
IL-10 (pg/ml) 96.5 ± 33.1 72.5 ± 16.0 n.s. 
IL-12p70 (pg/ml) 3.1 ± 0.7 6.2 ± 2.0 n.s. 
IL-17 (pg/ml) 3.7 ± 1.9 12.1 ± 6.5 n.s. 
IL-22 (pg/ml) 55.8 ± 16.8 193.8 ± 71.8 ** 
CXCL8 (pg/ml) 504.3 ± 199.9 933.3 ± 346.0 n.s. 
CXCL10 (pg/ml) 316.6 ± 88.8 738.4 ± 131.4 ** 
IFN- (pg/ml) 55.5 ± 12.7 204.0 ± 83.6 n.s. 
TNF-a (pg/ml) 76.0 ± 25.8 99.7 ± 28.0 n.s. 
GM-CSF (pg/ml) 10.1 ± 2.2 22.0 ± 7.8 n.s. 
TGF-b (pg/ml) 143.7 ±
 
21.6 159.8 ±
 
21.3 n.s. 
MMP-3 (pg/ml) 2,760 ± 658.1 3,336 ± 532.7 n.s. 
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Table 4.11 Ability of immunological biomarkers to discriminate between Gram
+
 and non-
Gram
+
 episodes of peritonitis on day 1. 
 
 AUROC ± SEM 95% CI p 
For Gram
+
 prediction 
CD4
+
 T cells (∙106) 0.741 ± 0.079 0.587 - 0.895 ** 
CD8
+
 T cells (∙106) 0.723 ± 0.083 0.561 - 0.885 * 
V2+ (% of T cells) 0.699 ±
 
0.079 0.543 - 0.854 * 
CXCL10 (pg/ml) 0.744 ± 0.075 0.596 - 0.891 ** 
IL-22 (pg/ml) 0.736 ± 0.074 0.591 - 0.881 ** 
CXCL10 + V2+ a 0.821 ± 0.066 0.691- 0.951 *** 
CXCL10 + IL-22 + V2+ a 0.816 ± 0.069 0.681- 0.951 ** 
CXCL10 + CD4
+ a
 0.797 ± 0.073 0.653 - 0.941 ** 
CXCL10 + IL-22 
a
 0.794 ± 0.068 0.661 - 0.926 ** 
a
, The unit is point(s). 
 
Table 4.12 Prediction of Gram
+
 infection on the first day of presentation with acute peritonitis. 
 
 
 
Cut-off 
Point 
 
Youden 
Index 
 
Sensitivity 
(%) 
 
Specificity 
(%) 
Overall 
Correctness 
(%) 
For Gram
+
 prediction 
CD4
+
 T cells (∙106) 15.2 0.46 55 91 73 
CD8
+
 T cells (∙106) 7.8 0.46 60 86 73 
CXCL10 (pg/ml) 301.2 0.49 77 72 74.5 
IL-22 (pg/ml) 54.3 0.39 73 67 70 
CXCL10 + IL-22 + V2+ a 1.5 0.561 89 67 78 
CXCL10 + V2+ a 0.5 0.524 100 52 76 
CXCL10 + CD4
+ a
 1.5 0.48 53 95 74 
CXCL10 + IL-22 
a
 0.5 0.49 91 55 73 
a
, The unit is point(s). 
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Table 4.13 Immunological biomarkers showing diagnostic significance for prediction of Gram
+
 
episodes of peritonitis on day 1. 
 
 
b
Coefficient 
Standard 
error 
Odds ratio 
(95%CI) 
 
p 
Univariate logistic regression 
CD4
+
 T cells (∙106) 0.062 0.026 1.064 (1.011 - 1.119) * 
CD8
+
 T cells (∙106) 0.077 0.035 1.080 (1.008 - 1.156) * 
V2+ (% of T cells) -0.388 0.185 0.679 (0.472 - 0.976) * 
CXCL10 (pg/ml) 0.002 0.001 1.002 (1.000 - 1.003) * 
     
Multivariate logistic regression (backward) 
CXCL10 + CD4
+
 (points) 1.932 0.603 6.901 (2.117 – 22.492) ** 
Constant -1.530 0.579 – – 
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4.3.6 Pathogen-specific immune fingerprints in acute peritonitis reveal 
fundamentally different immune responses to distinct bacterial infections.   
The above immune fingerprint analyses of patients presenting with a ‘cloudy bag’ 
identified a number of immunological biomarkers that could predict culture-negative, 
culture-positive, Gram
+
 and/or Gram
−
 infections (Table 4.14). However, being 
preliminary in nature and so far limited to a single hospital, these findings will have 
to be confirmed in independent centres.  The performance of diagnostic laboratories 
and their ability to positively identify bacteria by microbiological culture varies 
greatly between different centres, as well as the spectrum of micro-organisms 
patients become infected with (20, 169-171). In this respect we noted pronounced 
pathogen-specific differences in certain immunological parameters that may bias the 
sensitivity/specificity of future biomarker-based diagnostic methods. Our data imply 
that the fingerprints outlined so far only represent only the first level of an in-depth 
analysis of the immune response in acute infection. In fact, the immune responses to 
different bacteria differed greatly, suggesting that the identification of pathogen-
specific fingerprints is feasible.   
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Table 4.14 Biomarkers of potential diagnostic value in patients presenting with a ‘cloudy bag’ 
on day 1, depending on the microbiological culture results. 
 
 
Culture-
negative 
Culture-
positive 
Gram
+ 
Gram
− 
Monocytes (% of total)  19.1 < 19.1  < 10.7 
CD4
+
 T cells (∙106)    15.2  
V2+ (% of T cells)    2.7  6.3 
HLA-DR
+
 (% of  T cells)     16.1 
CD86
+
 (% of monocytes)    < 67.9 
IL-1b (pg/ml) < 4.1  4.1   14.0 
IL-10 (pg/ml) < 23.3  23.3   110.1 
IL-22 (pg/ml)    54.3  
CXCL10 (pg/ml)    301.2  
TNF-a (pg/ml) < 19.5  19.5   32.8 
 
Within the Gram
+
 group, patients with streptococcal infections were characterized by 
a higher proportion of infiltrating neutrophils (not shown) than patients with 
confirmed Staphylococcus aureus infections (Figure 4.2).  The dominant role of 
neutrophils in the immune responses was mirrored by high levels of IL-1β and 
CXCL8 during streptococcal infections while levels of IFN-γ, IL-22 and CXCL10 
were very low.  In striking contrast, S. aureus infections showed a higher proportion 
of monocytes/macrophages and T cells and higher levels of IFN-γ, IL-22 and 
CXCL10, compared to streptococcal infections, while IL-1β and CXCL8 were 
virtually absent.  Within the Gram
−
 group, patients with infections caused by E. coli 
or other coliform bacteria (Enterobacter, Klebsiella, Proteus, Morganella) were 
characterized by higher levels of sIL-6R, IL-10 and TNF-α, compared to infections 
caused by pseudomonad species (Figure 4.2 and Table 4.15).   
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Figure 4.2 Pathogen-specific immune fingerprints in acute peritonitis. 
(A) Relative frequency of peritoneal monocytes/macrophages (CD14
+
) and T cells (CD3
+
) and 
proportion of Vδ2+ T cells within the peritoneal CD3+ T cell population in stable and infected PD 
patients on day 1 of acute peritonitis. (B) Peritoneal levels (in ng/ml) of IL-1β, IL-6, sIL-6R, IL-10, 
IL-22, CXCL8, CXCL10, IFN-γ and TNF-α in stable and infected PD patients on day 1 of acute 
peritonitis. Causative pathogens identified by microbiological culture results were grouped into 
Gram
+
 organisms shown in blue (circles, Staphylococcus aureus; downward triangles, coagulase-
negative Staphylococcus spp.; squares, Streptococcus spp.; upward triangles, coryneform bacteria) 
and Gram
−
 organisms in red (circles, E. coli; downward triangles, other coliform bacteria; squares, 
Pseudomonas spp.). Data points represent individual episode, horizontal lines mean values per group. 
Chapter 4: Local immune fingerprints 
 
101 
 
Table 4.15 Pathogen-specific immune fingerprints in patients with confirmed culture-positive 
infection, depending on the microbiological culture results. −, absent or low levels; +, present; 
++, elevated; +++, highly elevated. 
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IF
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Gram
+
 bacteria 
Staphylococcus aureus − + ++ + ++ − +++ ++ + 
Coag.-neg. staphylococci + + ++ + + ++ ++ + + 
Streptococcus spp. ++ ++ + + − +++ + − + 
Corynebacterium spp. − +++ ++ + − + + + − 
Gram
−
 bacteria 
E. coli ++ +++ ++ ++ − +++ − + +++ 
Other Enterobacteriaceae + ++ +++ +++ + ++ + + +++ 
Pseudomonas spp. + + + + − + + − − 
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4.4 Discussion 
Biomarkers can assist in the care of patients for diagnostic, prognostic and predictive 
purposes.  Fundamental for the use of biomarkers in these situations is their accuracy 
and their ability to discriminate correctly one condition from another (172). However, 
given the huge biological variability between individual patients and the underlying 
causes of disease no biomarker offers 100% performance with optimum specificity 
and sensitivity. Sensitivity defines how good a test is at identifying patients with a 
certain condition, with a high sensitivity indicating a low false-negative rate. 
Specificity on the other hand defines how good a test is at correctly identifying 
patients without this condition, with a high specificity required for diagnostic tests 
with a low false-positive rate (172, 173). The utility of biomarkers therefore depends 
heavily on the clinical needs, for instance in the context of PD, whether correct 
identification of truly culture-negative (i.e. non-infectious) episodes of peritonitis or 
rather accurate prediction of the causative pathogen is sought. It is worth noting that 
at present even the two most widely used pro-inflammatory biomarkers remain of 
limited use in the clinic. Both C-reactive protein and procalcitonin are associated 
with early inflammatory responses, however they do not reach satisfying 
discriminatory power to distinguish infectious from non-infectious inflammation due 
to relatively poor sensitivity and specificity (174, 175). Moreover, both proteins have 
questionable relevance as diagnostic and prognostic biomarkers in patients with PD-
associated peritonitis (176). Our research highlights the importance of combining 
humoral and cellular parameters to establish accurate ‘immune fingerprints’ in 
patients with a suspected infection. Our results reveal striking differences in the 
quality of local immune responses in culture-negative infections and to Gram
−
 and 
Gram
+
 bacteria. We are aware that in order to establish robust pathogen-specific 
immune fingerprints, accurate microbiological identification of the causative agents 
is absolutely critical. The fact that the majority of culture-negative and culture-
positive episodes in the present study could easily be distinguished based on a range 
of immune parameters may indicate that the microbiological analysis at the 
University Hospital of Wales only yielded few false-positive and/or false-negative 
culture results. However, for optimum stratification in future studies and to 
circumvent the grave limitations of conventional culture techniques at a point in time 
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when the sequence information of >1,000 bacterial genomes is readily available, 
state-of-the-art molecular diagnostic methods such as 16S and 23S rDNA 
amplification, MALDI-ToF (Matrix-assisted laser desorption/ionization-time-of-
flight mass spectrometer) analysis and/or whole-sample sequencing and 
metagenomics should be employed as ‘gold standard’ (158, 160-163, 177).   
Our data (as shown in Chapter 3) and other studies showed that culture-negative 
peritonitis in PD patients is associated with a fairly benign course with low rates of 
technique failure (20, 153-156). Our results demonstrate that episodes of culture-
negative peritonitis have significantly different immune fingerprints characterized by 
lower numbers (and proportions) of infiltrating neutrophils and less severe peritoneal 
inflammation as indicated by lower cytokine levels, compared to culture-positive 
infections. In this respect, the cytokines IL-1β, IL-10, TNF-α, and the ratio of 
neutrophils to monocytes/macrophages are particularly promising candidates for a 
future biomarker-based diagnosis of culture-negative peritonitis. Such a prediction of 
culture-negative episodes would have important clinical implications as it would 
allow the identification of low-risk patients and patients which may not require 
antimicrobial therapy, thereby reducing unnecessary exposure to antibiotics (19, 119, 
178). In return, accurate prediction of culture-positive episodes with higher risk of 
treatment failure or even mortality would allow closer monitoring and refined 
management of affected patients. 
The present study identified distinct immune fingerprints characteristic of Gram
−
 and 
Gram
+
 infections. While it is well-established that patients with Gram
−
 and Gram
+
 
infections present with different clinical signs and outcomes (15, 18, 119, 123, 133, 
136, 137), a differential diagnosis is missing that would guide treatment and allow 
predictive risk modelling at the time of presentation with a ‘cloudy bag’.  Here, on 
day 1 of acute peritonitis, Gram
−
 infections (particularly those caused by coliform 
bacteria) were dominated by large numbers of infiltrating neutrophils and elevated 
levels of cytokines like IL-1β, IL-10 and TNF-α. It is likely that a large proportion of 
the immune fingerprints in Gram
−
 infections were due to pronounced responses to 
bacterial LPS which is present in the outer cell wall of Gram
−
 organisms but absent 
from Gram
+
 organisms.  LPS is a powerful inducer of pro-inflammatory cytokines 
and chemokines by monocytes/macrophages and neutrophils including IL-1β, TNF-α 
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and CXCL8. At the same time, LPS stimulation also leads to secretion or large 
amounts of IL-6 and IL-10 by monocytes/macrophages (but not human neutrophils) 
(179, 180). Another powerful microbial factor present in the vast majority of Gram
−
 
bacteria (including the causative pathogens identified in the present study) is HMB-
PP, the natural activator of human Vγ9/Vδ2 T cells. In contrast, most Gram+ bacteria 
do not produce HMB-PP and consequently do not activate Vγ9/Vδ2 T cells (94, 113). 
Despite the very low proportion of T cells in acute Gram
−
 infections, Vγ9/Vδ2 T 
cells were selectively enriched among peritoneal T cells in those patients, thereby 
singling out Vγ9/Vδ2 T cells as highly sensitive and selective responder cells of 
potential diagnostic and prognostic value in acute peritonitis.  
Immune fingerprints in Gram
+
 infections (especially those caused by staphylococci) 
were markedly different from those in Gram
−
 infections and were indicative of a 
relatively large underlying T cell component with higher numbers of CD4
+
 and 
CD8
+
 T cells and elevated levels of CXCL10, IFN-γ and IL-22. Of note, immune 
fingerprints in streptococcal infections were more biased toward innate, neutrophil-
driven responses with pronounced levels of IL-1b and CXCL8. This indicates 
fundamental differences in the immune response to distinct groups of bacteria, which 
merit further investigation. Previous study demonstrated the presence of functional 
effector memory CD4
+
 T cells in the peritoneal cavity of PD patients, which 
mounted more substantial TH1 responses to recall antigens than their counterparts 
from peripheral blood (126). Why such recall T cell responses should play a larger 
role in staphylococcal infections compared to infections caused by other bacteria 
such as streptococci or E. coli is not clear. In more general terms, our results 
emphasize the importance of shifting the focus away from a simple classification 
into Gram
−
 and Gram
+
 (i.e. LPS containing and LPS deficient) species, and the need 
to pay more attention to detailed host-pathogen interactions that are dependent on the 
nature of the causative organism and might impinge on treatment outcomes. 
The notion of diagnostic and/or prognostic immune fingerprints has far-reaching 
basic as well as clinical implications for our view of acute inflammatory responses in 
infection. First, because this pilot study provides for the first time proof-of-concept 
for disease-specific immune responses which are triggered by unique combinations 
of pathogen-associated molecular patterns interacting with distinct aspects of the 
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human immune system. Second, because it suggests that differential biomarker-
based diagnosis of non-infectious and infectious syndromes is feasible and may 
extend to the discrimination of bacterial, viral and fungal causes of disease. Third, 
because our findings lay the foundations for targeted therapies that modulate disease-
specific pathways to fight infection and reduce inflammation-related tissue damage.  
Besides episodes of acute peritonitis in PD patients, similar local and/or systemic 
immune fingerprints are likely to be found in other infectious scenarios such as 
urinary tract infections (181), lower respiratory tract infection including pneumonia 
and cystic fibrosis (182, 183), complicated skin and soft tissue infections (184), and 
sepsis (164, 185-187), where early diagnostic and prognostic biomarkers are urgently 
needed. 
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5.1 Introduction 
 
Human γδ T cells reactive to HMB-PP contribute to the development of microbe-
specific immunity in the peritoneal cavity (113). The majority of circulating 
Vγ9/Vδ2 T cells shows migration properties similar to monocytes (188), suggesting 
that these two cell types are co-recruited to the site of inflammation and interact with 
each other at early stages of infection (94). Vγ9/Vδ2 T cell responses in vitro are 
greatly facilitated by contact with monocytes as ‘feeder cells’, which most likely act 
by ‘presenting’ HMB-PP to Vγ9/Vδ2 T cells and by providing contact-dependent 
signals (94). We have shown that peritoneal infections with HMB-PP producing 
bacteria are associated with higher frequencies of peritoneal γδ T cells and 
morbidity/mortality compared to HMB-PP negative infections, implying that γδ T 
cells may be of diagnostic, prognostic and therapeutic value in peritoneal dialysis 
(PD) associated peritonitis (as shown in Chapter 3).  
 
The peritoneal membrane is lined with a monolayer of mesothelial cells, which are 
an integral part of the peritoneal immune response. By secreting numerous 
cytokines/chemokines, growth factors, matrix proteins, and intracellular adhesion 
molecules, and their ability to present antigens to lymphocytes, HPMC play a critical 
role in peritoneal homeostasis (26). HPMC isolated from omental specimens possess 
morphologic and biochemical properties identical to the properties identified in 
peritoneal mesothelial stem cells. Therefore, cultured HPMC provide a suitable tool 
for the study of methothelial cells (26, 117, 189). 
 
The regulation of γδ T cells by HPMC has not been investigated so far. By co-
culturing freshly isolated Vγ9/Vδ2 T cells and HPMC from primary culture, we 
demonstrate in this Chapter that resting HPMC are potent suppressors of γδ T cell 
cytokine production and proliferation in the presence of HMB-PP, suggesting an 
important homeostatic function of HPMC in the peritoneal cavity. 
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5.2 Aims  
The aims of this Chapter were: 
1) To examine the responses of γδ T cells from peripheral blood, omental tissue and 
peritoneal cavity to HMB-PP. 
2) To investigate γδ T-cell responses to HMB-PP when co-cultured with mesothelial 
cells or in the presence of culture supernatants of mesothelial cells. 
3) To explore possible mechanisms involved in the regulation of human γδ T cells by 
mesothelial cells.  
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5.3 Results 
 
5.3.1 Impaired responses to HMB-PP in peritoneal γδ T cells 
To examine the responses of human γδ T cells to HMB-PP, we collected PBMC 
from healthy donors, leukocytes from omental specimens of patients undergoing 
elective abdominal surgery and leukocytes from stable PD effluents. Cells were 
cultured (0.5 × 10
6
 cells/well) in the presence of 100 nM HMB-PP for 20 hours. 
Thereafter, cells were stimulated with PMA (50 ng/ml) and Ionomycin (1μg/ml) in 
the presence of brefeldin-A (10μg/ml) for 4 hours before intracellular cytokine 
staining. γδ T cells from these three compartments could response to HMB-PP, as 
demonstrated by the percentage of γδ T cells expressing surface CD25 and CD69, 
and intracellular IFN-γ and TNF-α. Of note, the responses of peritoneal γδ T cells 
were significantly lower than their counterparts in peripheral blood or omental 
specimens (Figure 5.1). 
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Figure 5.1 Peritoneal γδ T cells respond to HMB-PP with impaired activation.  
Leukocytes were collected from peripheral blood of health donors (PBMC), omental specimens (Om) 
and stable PD effluents (PD) and cultured in the presence of 100 nM HMB-PP for 20 hours. 
Leukocytes were also cultured in the absence of HMB-PP for 20 hours as negative control. γδ T cell 
responses are shown as % of Vγ9+ (PBMC) or Vδ2+ T cells (Om and PD) expressing surface CD25 
and CD69, and intracellular IFN-γ and TNF-α. Statistical differences between different groups were 
analyzed using the Mann-Whitney U test for unpaired samples and the paired t test for paired samples. 
Error bars indicate SEM. 
＊
, P<0.05; 
＊＊
, P<0.01. 
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5.3.2 Mesothelial cells inhibit the HMB-PP-induced responses and proliferation 
of γδ T cells 
Previous studies pointed out that although peritoneal lymphocytes display an 
activated phenotype, they appear to be functionally impaired, with a significantly 
lower IL-2 production in comparison with circulating lymphocytes (35, 61, 62). 
Continuous exposure to  non-physiologic peritoneal dialysis fluid may result in an 
impairment of the local peritoneal host defense mechanisms (190). Apart from 
immune cells, HPMC, the largest resident cell population, take part in peritoneal host 
defense and can be harvested from PD effluents with cell number around 25,000 per 
PD bag (29). These detached HPMC are still viable (191) and might contribute to the 
impaired γδ T-cell responses to HMB-PP in the above experiments. Yet, the 
interplay between γδ T cell and HPMC has not been addressed. We therefore 
examined the interaction between these two cell types in co-cultures. 
Vγ9+ T cells were purified from PBMC of healthy donors using positive selection 
and monocytes were purified using anti-CD14 microbeads (Miltenyi Biotec). Freshly 
purified γδ T cells were cultured alone or co-cultured with autologous monocytes as 
accessory cells or co-cultured with mesothelial cells for 20 hours at different ratios 
and in the absence or presence of HMB-PP. In the co-cultures, monocytes provided 
potent stimulation for production of IFN-γ and TNF-α as shown by intracellular 
staining of Vγ9+ T cells. In contrast, HPMC strongly inhibited the production of IFN-
γ and TNF-α (Figure 5.2). After 4 days of co-culture in a CFSE dilution assay, γδ T 
cells alone did not proliferate even in the presence of 100 nM HMB-PP. The 
presence of HPMC resulted in decreased frequencies of divided Vγ9+ T cells in the 
co-cultures of γδ T cells and monocytes  (Figure 5.3).  
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Figure 5.2 HPMC inhibit the HMB-PP-induced cytokine secretion by γδ T cells.  
γδ T cells (Vγ9+) were cultured alone (top) or co-cultured with monocytes (middle) or co-cultured 
with mesothelial cells (bottom) for 20 hours at the indicated ratios, in the absence (medium) or 
presence of HMB-PP at different concentrations. γδ T cell responses are shown as frequencies of 
intracellular IFN-γ and TNF-α in Vγ9+ T cells. Data shown are representative from experiments using 
one blood donor and two different omental specimens. 
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Figure 5.3 HPMC inhibit the HMB-PP-induced proliferation of γδ T cell.  
γδ T cells (Vγ9+) were cultured alone or co-cultured with monocytes or mesothelial cells or co-
cultured with both monocytes and HPMC at the indicated ratios for 4 days, in the absence (medium) 
or presence of HMB-PP at different concentrations. Data shown are frequencies of divided CFSE-
labelled γδ T cells. Data shown are representative from experiments using one blood donor and two 
different omental specimens. 
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5.3.3 The inhibition of γδ T cell responses is mediated by soluble factors 
released by primary HPMC.  
 
To determine whether the inhibition of γδ T cell response was mediated by soluble 
factors, we repeated the above experiments using culture supernatants of HPMC. 
Under these conditions, supernatants of HPMC inhibited the HMB-PP stimulated 
expression of surface CD25 and CD69 and cytokine production of γδ T cells (Figure 
5.4). A CFSE dilution assay showed a dose-dependent inhibition of γδ T-cell 
proliferation by supernatants of HPMC (Figure 5.5). A similar inhibition of cytokine 
production was also noted in anti-CD3/CD28-stimulated CD4
+
 and CD8
+
 T cells 
(Figure 5.6). 
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Figure 5.4 Culture supernatants of mesothelial cells inhibit γδ T cell responses.  
γδ T cells (Vγ9+) were cultured alone (left) or co-cultured with monocytes (right) at a ratio of 1:1 for 
20 hours, in the presence of 100 nM HMB-PP and in the absence (medium) or presence of 50% 
HPMC supernatants (Sn). Data shown are frequencies of Vγ9+ T cells expressing surface CD25 and 
CD69, and intracellular IFN-γ and TNF-α, as determined in three independent experiments using one 
blood donor and seven different omental specimens. Statistical differences between groups were 
analyzed using the Wilcoxon signed-rank test. Error bars indicate SEM. 
＊
, P<0.05; 
＊＊
, P<0.01. 
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Figure 5.5 Culture supernatants of mesothelial cells inhibit γδ T cell proliferation.  
(A) γδ T cells (Vγ9+) were co-cultured with monocytes at a ratio of 1:1 for 4 days, in the presence of 
100 nM HMB-PP and in the absence (medium) or presence of the indicated proportions of HPMC 
supernatants (Sn). Data shown are proliferation and CD25 expression of CFSE-labelled γδ T cells 
(representative of three experiments). (B) Data shown are proportions of divided Vγ9+ T cells, as 
determined in two independent experiments using one blood donor and three different omental 
specimens. Statistical differences between groups were analyzed using the paired t test. Error bars 
indicate SEM. 
＊
, P<0.05. 
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Figure 5.6 Culture supernatants of mesothelial cells inhibit CD4
+
 and CD8
+
 T cell responses.  
CD3
+
 T cells were cultured in the absence (medium) or presence of anti-CD3/CD28 beads, or 50% 
HPMC supernatants (Sn). Data shown are frequencies of CD3
+
CD4
+
 (left) or CD3
+
CD8
+
 (right)
 
T 
cells expressing surface CD25 and CD69, and intracellular IFN-γ and TNF-α using one blood donor 
and three different omental specimens. Statistical differences between groups were analyzed using the 
paired t test. Error bars indicate SEM. 
＊
, P<0.05. 
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5.3.4 The inhibition of γδ T-cell responses by supernatants of HPMC can be 
abrogated by SB-431542 
 
To identify the soluble mediator(s) responsible for HPMC suppression of γδ T-cell 
responses, we first tested SB-431542, which is a selective inhibitor of TGF-β and/or 
activin signalling via activin receptor-like kinase (ALK)-4, ALK-5 and ALK-7 (192). 
In the presence of 10 μM SB-431542, inhibition of γδ T-cell cytokine production by 
HPMC could be rescued, but not the expression of surface CD25 and CD69 (Figure 
5.7). A CFSE dilution assay in the presence of monocytes also demonstrated that 
SB431542 significantly rescued the suppressive activity of HPMC supernatants on 
γδ T-cells (Figure 5.8). We also tried similar blocking experiments with CD4+ and 
CD8
+
 T cells but did not manage to get consistent results (data not shown). 
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Figure 5.7 Inhibition of γδ T-cell cytokine production can be rescued by SB-431542. 
 γδ T cells (Vγ9+) were cultured alone (left) or co-cultured with monocytes (right) at a ratio of 1:1 for 
20 hours, in the presence of 100 nM HMB-PP and in the absence (M) or presence of 50% HPMC 
supernatants (Sn), or in the absence or presence of 10 μM SB431542 (SB). Data shown are 
frequencies of Vγ9+ T cells expressing surface CD25 and CD69, and intracellular IFN-γ and TNF-α, 
as determined in two independent experiments using one blood donor and three different omental 
tissues. Statistical differences between groups were analyzed using the paired t test. Error bars 
indicate SEM. 
＊
, P<0.05; 
＊＊
, P<0.01. 
Chapter 5: Regulation of γδ T-cell responses by HPMC 
 
120 
 
B Divided Vγ9+ (% )
*
M Sn Sn+ SB
*
A Medium Sn Sn+SB431542
97.5 1.6
0.2
46.2 15.3
3.6
69.1 18.6
1.8
96.4 52.5 72.7
CFSE
C
D
25
 
 
Figure 5.8 Inhibition of γδ T cell proliferation can be rescued by SB-431542.  
(A) γδ T cells (Vγ9+) were co-cultured with monocytes at a ratio of 1:1 for 4 days, in the presence of 
100 nM HMB-PP and the absence (medium) or presence of 50% HPMC supernatants (Sn), or in the 
presence of 10 μM SB-431542 (SB). Data shown are proliferation and CD25 expression of CFSE-
labeled γδ T cells (representative of three experiments). (B) Data shown are proportions of divided 
Vγ9+ T cells, as determined in three experiments using one blood donor and three different omental 
specimens. Statistical differences between groups were analyzed using the paired t test. Error bars 
indicate SEM. 
＊
, P<0.05. 
 
Chapter 5: Regulation of γδ T-cell responses by HPMC 
 
121 
 
5.3.5 TGF-β1 but not activin-A mimics the HPMC-mediated inhibition of γδ T 
cell responses to HMB-PP 
The above data suggested that TGF-β and/or activin A could play a role in the 
suppressive activity of HPMC. Therefore, we tested the effects of recombinant TGF-
β1 and activin-A addition in γδ T-cell activation and proliferation experiments. We 
also tested the effects of monoclonal anti-TGF-β1 antibody and follistatin, an 
antagonist of activin A, in experiments using supernatants of HPMC. Figures 5.9 and 
5.10 show that recombinant TGF-β1 inhibited γδ T cell responses and proliferation. 
The effect of neutralizing antibodies against TGF-β1 was inconsistent (Figure 5.11). 
In contrast, recombinant activin A did not inhibit γδ T cell responses and 
proliferation (Figure 5.10 and 5.12), nor did follistatin rescue the suppressive activity 
of HPMC supernatants. Altogether, recombinant TGF-β1 but not activin A 
mimicked the HPMC-mediated inhibition of γδ T cell responses to HMB-PP. 
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Figure 5.9 Recombinant TGF-β1 mimics the HPMC-mediated inhibition of γδ T cell responses.  
γδ T cells (Vγ9+) were cultured alone (left) or co-cultured with monocytes (right) at a ratio of 1:1 for 
20 hours, in the presence of 100 nM HMB-PP and different concentrations of recombinant TGF-β1 
(ng/ml). Data shown are frequencies of Vγ9+ T cells expressing surface CD25 and CD69, and 
intracellular IFN-γ and TNF-α, as determined in three independent experiments using three blood 
donors. Statistical differences between groups were analyzed using the paired t test. Error bars 
indicate SEM. 
＊
, P<0.05. 
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Figure 5.10 Recombinant TGF-β1 mimics the HPMC-mediated inhibition of γδ T cell 
proliferation.  
γδ T cells (Vγ9+) were co-cultured with monocytes at a ratio of 1:1 for 4 days, in the presence of 100 
nM HMB-PP and different concentrations of (A) recombinant TGF-β1 (ng/ml) or (B) activin A 
(ng/ml). Data shown are proportions of divided CFSE-labeled Vγ9+ T cells, as determined in three 
experiments using three blood donors. Statistical differences between groups were analyzed using the 
paired t test. Error bars indicate SEM. 
＊
, P<0.05. 
Chapter 5: Regulation of γδ T-cell responses by HPMC 
 
124 
 
%CD25+ %CD69+
%IFN- γ + %TNF- α +
0
20
60
40
0
10
30
20
40
50
0
10
30
20
40
50
0
20
60
40
80
100
%CD25+ %CD69+
%IFN- γ + %TNF- α +
0
20
60
40
80
100
0
20
60
40
80
100
0
20
60
40
80
100
0
20
60
40
80
100 120
γδ : monocytes = 1: 1γδ T  cells 
*
P=0.05
*
80 120
 
 
Figure 5.11 Inhibition of γδ T cell responses could not be reversed by anti-TGF-β1 antibody.  
γδ T cells (Vγ9+) were cultured alone (left) or co-cultured with monocytes (right) at a ratio of 1:1 for 
20 hours, in the presence of 100 nM HMB-PP and in the absence (Medium) or presence of 50% 
HPMC supernatants (Sn), or in the presence of 10 ng/ml anti-TGF-β1 antibody. Data shown are 
frequencies of Vγ9+ T cells expressing surface CD25 and CD69, and intracellular IFN-γ and TNF-α, 
as determined using one blood donor and three different omental specimens. Statistical differences 
between groups were analyzed using the paired t test. Error bars indicate SEM. 
＊
, P<0.05. 
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Figure 5.12 Recombinant activin-A could not inhibit γδ T cell responses.  
γδ T cells (Vγ9+) were cultured alone (left) or co-cultured with monocytes (right) at a ratio of 1:1 for 
20 hours, in the presence of 100 nM HMB-PP and different concentrations of recombinant activin A 
(ng/ml). Data shown are frequencies of Vγ9+ T cells expressing surface CD25 and CD69, and 
intracellular IFN-γ and TNF-α, as determined in three independent experiments using three blood 
donors. Statistical differences between groups were analyzed using the paired t test. Error bars 
indicate SEM. 
＊
, P<0.05. 
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Figure 5.13 The effects of blocking suppression of HPMC supernatants on γδ T cell responses 
with follistatin.  
(A) γδ T cells (Vγ9+) were cultured alone (left) or co-cultured with monocytes (right) at a ratio of 1:1 
for 20 hours, in the presence of 100 nM HMB-PP and in the absence (M) or presence of 50% HPMC 
supernatants, which were pre-treated with different concentrations of follistatin (ng/ml) for 30 
minutes. Data shown are frequencies of Vγ9+ T cells expressing surface CD25 and CD69, and 
intracellular IFN-γ and TNF-α, as determined using one blood donor and three omental specimens. (B) 
γδ T cells (Vγ9+) were co-cultured with monocytes at a ratio of 1:1 for 4 days, in the presence of 100 
nM HMB-PP and in the absence (M) or presence of 50% HPMC supernatants, which were pre-treated 
with different concentrations of follistatin (ng/ml) for 30 minutes. Data shown are proportions of 
divided CFSE-labeled Vγ9+ T cells, as determined using one blood donor and three omental 
specimens. Statistical differences between groups were analyzed using the paired t test. Error bars 
indicate SEM. 
＊
, P<0.05. 
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5.3.6 IL-10 might not be involved in the HPMC-mediated inhibition of γδ T cell 
responses to HMB-PP. 
Since it was shown that IL-10 could regulate γδ T-cell response to M. tuberculosis 
(193), we investigated whether IL-10 influenced the γδ T-cell response and 
proliferation in our in vitro model. Recombinant IL-10 did not inhibit γδ T-cell 
responses in the experiments without monocytes. In the presence of monocytes, the 
data about inhibition of the γδ T-cell responses and proliferation by IL-10 were 
inconsistent (Figure 5.14). The rescue effect of IL-10 receptor inhibitor is 
undetermined (Figure 5.15) due to inconsistent data. 
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Figure 5.14 IL-10 could not inhibit γδ T cell responses and proliferation.  
(A) γδ T cells (Vγ9+) were cultured alone (left) or co-cultured with monocytes (right) at a ratio of 1:1 
for 20 hours, in the presence of 100 nM HMB-PP and different concentrations of recombinant IL-10 
(ng/ml). Data shown are frequencies of Vγ9+ T cells expressing surface CD25 and CD69, and 
intracellular IFN-γ and TNF-α, as determined in three independent experiments using two blood 
donors. (B) γδ T cells (Vγ9+) were co-cultured with monocytes at a ratio of 1:1 for 4 days, in the 
presence of 100 nM HMB-PP and different concentrations of recombinant IL-10 (ng/ml). Data shown 
are proportions of divided CFSE-labeled Vγ9+ T cells, as determined in two experiments using two 
blood donors. Error bars indicate SEM.  
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Figure 5.15 No consistent rescue effect of IL-10 receptor inhibitor.  
γδ T cells (Vγ9+) were cultured alone (left) or co-cultured with monocytes (right) at a ratio of 1:1 for 
20 hours, in the presence of 100 nM HMB-PP and in the absence (M) or presence of 50% HPMC 
supernatants (Sn) or presence of 10 ng/ml anti-IL-10 receptor antibody (αIL-10R). Data shown are 
frequencies of Vγ9+ T cells expressing surface CD25 and CD69, and intracellular IFN-γ and TNF-α, 
as determined using one blood donor and three different omental tissues. Statistical differences 
between groups were analyzed using the paired t test. Error bars indicate SEM. 
＊
, P<0.05. 
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5.3.6 The rescue effect of exosome-depletion for HPMC-mediated inhibition of 
γδ T-cell responses is undetermined. 
Exosomes are nanometer-sized vesicles secreted by diverse cell types that play 
different roles according to their origin (194). For example, tumour exosomes 
express membrane-associated TGF-β1, which contributes to the anti-proliferative 
effects (195). 
 
To evaluate whether exosomes play a role in the suppressive activity of mesothelial 
cells, we tested HPMC supernatants, which were subjected to serial centrifugation 
(2,000 g, 20 min, to remove dead cells; 10,000 g, 20 min, to remove cell debris; 
100,000 g, 1 hour, to remove most exosomes (Optima-Max ultracentrifuge, 
Beckman Coulter); 200,000 g, 1 hour, to remove all exosomes (Optima-Max 
ultracentrifuge, Beckman Coulter). No consistent rescue of HPMC-mediated 
inhibition of γδ T-cell responses by exosome-depletion was achieved (Figure 5.16).  
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Figure 5.16 No consistent rescue by exosome depletion.  
γδ T cells (Vγ9+) were cultured alone (A) or co-cultured with monocytes (B) at a ratio of 1:1 for 20 
hours, in the presence of 100 nM HMB-PP and in the absence (Medium) or presence of 50% HPMC 
supernatants (Sn) or in the presence of 50% HPMC supernatants pre-processed with centrifugation at 
different speeds. Data shown are frequencies of Vγ9+ T cells expressing surface CD25 and CD69, and 
intracellular IFN-γ and TNF-α, as determined using one blood donor and three different omental 
tissues. Error bars indicate SEM. 
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5.4 Discussion 
 
This study uncovered an unexpected regulation of γδ T-cell responses to HMB-PP 
by HPMC. Resting HPMC were potent suppressors of γδ T cell cytokine production 
and proliferation in the presence of HMB-PP. This inhibition was mediated by 
soluble factors released by primary HPMC and could be counteracted by SB-431542. 
Of note, recombinant TGF-β1 but not activin-A mimicked the HPMC-mediated 
inhibition of γδ T cell responses to HMB-PP.  
 
HPMC actively participate in the control of inflammation in both the normal and 
inflamed peritoneal cavity (196). Unstimulated confluent HPMC were shown to 
constitutively release considerable amounts of TGF-β1 but only minimal amounts of 
TGF-β2 (197, 198). Most of TGF-β is released by HPMC in the latent form. The 
activation process may be the most important step for controlling TGF-β effects 
(198). It has been shown that HPMC produce dermatan sulfate proteoglycans, which 
may be involved in the control of the TGF-β activity in the peritoneum (199), 
suggesting that the mesothelium itself may play an important role in controlling 
bioavailability of secreted TGF-β. 
 
The TGF-β superfamily is a large family of structurally related regulatory proteins in 
humans. The TGF-β superfamily ligands can be divided into distinct subgroups: the 
TGF-β subfamily, including TGF-β1-3, the activins, the bone morphogenetic 
proteins (BMPs) and nodal. These ligands bind to the constitutively active type II 
receptors that subsequently activate type I receptors (Figure 5.17) (200). There are 
seven type I receptors have been identified so far (201, 202). SB-431542 acts as a 
competitive ATP binding site kinase inhibitor and is a selective inhibitor for ALK-4, 
5, and 7 (192). In this study, SB-431542 rescued the suppressive activity of HPMC, 
which suggested that TGF-β and/or activin A could play a role in the suppressive 
activity of HPMC. 
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Figure 5. 17 TGF-β superfamily signalling pathways.  
TGF-β superfamily ligands bind to the active type II receptors that subsequently phosphorylate type I 
receptors. Activation of type I receptors propagates the signal by phosphorylating intracellular 
receptor-regulated Smads. Smads associate with the common-mediated co-Smad 4 and translocate to 
the nucleus wherein they initiate gene transcription. Smad 7 is induced in response to TGF-β ligands 
and inhibits downstream signalling. ALK, activin-like kinase; BMP, bone morphogenetic protein. 
Taken from (200). 
 
TGF-β is a multifunctional cytokine exerting diverse effects including the 
suppression of immune responses, stimulation of extracellular matrix formation, and 
modulation of cellular proliferation and differentiation (203). It has been shown to 
suppress the proliferation of bromohydrin pyrophosphate-activated γδ T cells in the 
presence of IL-2 (204) and to inhibit γδ T cell proliferation induced by 
Mycobacterium tuberculosis-pulsed monocytes (193). We showed above that 
recombinant TGF-β1 also suppressed the proliferation and cytokine production of 
HMB-PP-activated γδ T cells in the presence of monocytes.  
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Activin A is a pleiotropic cytokine that plays an important role in fundamental 
biological processes, such as development and tissue repair. An increasing body of 
evidence proposes that activin A exerts a crucial role in immune-mediated responses 
and associated diseases, with both pro- (205, 206) and anti-inflammatory effects 
(207, 208) depending on the cell type and the cytokine milieu (200). Activin A and 
its receptors are expressed by a wide range of immune cells (207, 209) and tissue 
cells, such as epithelial cells (in the mouse lung and intestine) and fibroblasts (200, 
210, 211). The biological effects of activin A are controlled through interaction with 
its physiological antagonist, follistatin (212). Notably, follistatin can also inhibit 
certain functions of other TGF-β superfamily members, including TGF-β3 and the 
BMPs (213, 214). In this study, recombinant activin A did not inhibit γδ T cell 
response and proliferation nor did follistatin show any significant rescue effect. 
Previous studies have showed that stimulation of rat and mouse macrophages with 
recombinant activin A increased TNF-α, IL-1β and prostaglandin E2 release and 
enhanced their phagocytosis in vivo and in vitro, pointing to pro-inflammatory 
effects (205, 206). This might be the reason why γδ T-cell responses to HMB-PP 
were enhanced in experiments co-cultured with monocytes in the presence of activin 
A (Figure 5.12). 
 
HPMC can dynamically participate in peritoneal homeostasis through release of pro- 
and anti-inflammatory mediators. Previous studies have identified a role of 
mesothelial cells in orchestrating peritoneal response during inflammation and 
infection (56, 215). They have been shown to secrete numerous pro-inflammatory 
cytokines and chemokines such as IL-6, IL-8 and MCP-1 on exposure to bacterial 
products and inflammatory cytokines (42-44). On the other hand, un-stimulated 
HPMC were showed to release anti-inflammatory cytokines such as TGF-β (198) 
and prostaglandins (196) and the secretion was enhanced when stimulated by IL-1β. 
Increased intraperitoneal secretion of TGF-β in PD-associated peritonitis (as shown 
in Chapter 4) may serve as a negative feedback loop inhibiting inflammation.  
 
The data presented support the concept that HPMC are significantly incorporated in 
the cytokine network operating in peritoneal diseases. Resting HPMC are potent 
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suppressors of γδ T cell cytokine production and proliferation in the presence of 
HMB-PP. Additional studies are necessary to better define the precise functions of 
HPMC-derived TGF-β. Our results also propose that human CD4+ and CD8+ αβ T 
cells are similarly regulated by HPMC, suggesting a pivotal homeostatic function of 
HPMC in the regulation of peritoneal immunity. 
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6.1 General discussion 
 
Over the last thirty years, PD has become an alternative to HD for the treatment of 
ESRD that is widespread around the world. Despite advances in treatment, PD-
associated peritonitis and loss of peritoneal membrane function remain major causes 
for the transfer from PD to HD (13, 216). Continuing exposure of bio-incompatible 
PD solutions, glucose degradation products, and advanced glycation end-products 
cause peritoneal inflammation (30, 34), which leads to fibrosis, angiogenesis, 
progressive increased solute transport and ultimately ultrafiltration failure (56). In 
rare but serious cases, encapsulating peritoneal sclerosis may occur after chronic 
peritoneal inflammation (217). Peritoneal inflammation is characterized by increased 
vascular permeability, activation and expansion of peritoneal leukocytes, recruitment 
of infiltrating cells to the peritoneal cavity, release of pro- and anti-inflammatory 
mediators, and increased matrix protein synthesis and tissue remodelling (26). 
Chronic changes in the peritoneum with fibrosis develop after years of PD. The most 
noticeable changes are found in patients after severe and recurrent episodes of 
peritonitis (218). Peritonitis significantly contributes to peritoneal changes by 
inducing mesothelial damage, massive inflammatory response, and increased 
vascularisation of peritoneal tissue, leading to impaired membrane function (40). 
Given that peritonitis episodes may not only be the proximate cause of acute 
technique failure but also cause ultrafiltration failure and membrane-related 
problems at a later time, it is important to understand the peritoneal immune 
response, microbiology and clinical outcomes in these infections.  
 
In the present thesis, my data demonstrate that leukocytes are recruited to the 
peritoneal cavity, starting with a rapid accumulation of CD15
+
 neutrophils, which are 
later replaced by a population of mononuclear cells, including CD14
+
 
monocytes/macrophages and CD3
+
 T cells. Of note, γδ T cells are also recruited to 
the peritoneal cavity in the early stage. I next examined the phenotypes and 
functional characteristics of T cell subsets, especially γδ T cells, and their correlation 
with clinical outcomes in PD-associated peritonitis patients. In comparison with 
circulating γδ T cells from healthy donors, peritoneal γδ T cells from acute 
peritonitis on day 1 are activated with higher expression of CD25 and CD69. In 
terms of memory subsets of γδ T cells, the frequencies of peritoneal 
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CD45RA
+
CD27
+ γδ T cells are decreased and CD45RA
－
CD27
－  γδ T cells are 
increased in peritonitis patients, compared with circulating γδ T cells from healthy 
donors. Expression of HLA-DR on peritoneal γδ T cells from peritonitis patients is 
also higher in comparison with circulating γδ T cells. In summary, peritoneal γδ T 
cells are activated and contribute to the inflammatory response on PD-associated 
peritonitis day 1. All together these data imply a significant role of Vγ9/Vδ2 T cells 
as early responders during acute peritonitis.  
 
Vγ9/Vδ2 T cells are believed to play a beneficial role in bridging innate and adaptive 
immune responses in infection and inflammation (87, 89, 94). Stimulation of 
Vγ9/Vδ2 T cells at the site of infection is likely to amplify the local inflammatory 
response with important consequences for pathogen clearance and the development 
of microbe-specific immunity (113). However, their excessive activation in the 
peritoneal cavity of a vulnerable patient group may ultimately contribute both to 
irreversible damage on the peritoneal membrane and to detrimental outcomes. This 
conclusion is supported by my findings in patients with PD-associated peritonitis 
demonstrating that the capacity of the causative pathogen to produce HMB-PP and 
frequencies of peritoneal Vγ9/Vδ2 T cells on day 1 may predict the subsequent 
clinical outcome from infection. 
My findings also highlight possible new avenues of therapeutic intervention in 
bacterial peritonitis. The antibiotic fosmidomycin and related compounds might be 
of particular interest in this respect. Fosmidomycin inhibits 1-deoxy-D-xylulose-5-
phosphate reductoisomerase (Dxr), the first enzyme in the non-mevalonate pathway 
of isoprenoid biosynthesis, in which HMB-PP is a key intermediate (87, 219). Thus, 
fosmidomycin might serve two purposes in treating infections: by directly inhibiting 
an essential pathway in a broad range of pathogenic bacteria (220), and by 
abrogating HMB-PP driven hyper-inflammatory responses. Other ways of 
specifically manipulating excessive γδ T cell mediated responses may include the 
use of anti-γδ TCR antibodies or antagonistic compounds such as bromohydrin 
pyrophosphonate (221).  
 
Given that each microorganism displays a distinct set of pathogen-associated 
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patterns and interacts with the human immune system in a unique and specific 
manner, my data provide evidence that the ensuing immunological signatures in 
acute PD-associated peritonitis can predict the nature of the causative pathogen and 
discriminate between culture-negative, Gram
+
 and Gram
−
 episodes. This research 
highlights the importance of combining humoral and cellular parameters to establish 
accurate ‘immune fingerprints’ in patients with a suspected infection. Particularly 
promising humoral and cellular parameters in the definition of disease-specific 
immune fingerprints include local levels of IL-1β, IL-10, IL-22, TNF-α and 
CXCL10, as well as the relative proportion of neutrophils and 
monocytes/macrophages among total peritoneal cells and the frequency of γδ T cells 
within the peritoneal T cell population. 
 
Inflammation is essential to survival during infection and maintains tissue 
homeostasis under various noxious conditions (222). The effector mechanisms used 
to control infection include production of pro-inflammatory cytokines, chemokines 
and recruitment of inflammatory cells to the site of infection. Although these 
responses help to eliminate or slow the spread of the pathogen, if they are not tightly 
controlled, they can easily become detrimental when excessive and result in severe 
inflammation and collateral tissue damage. Inflammation and the immune response 
to pathogens are regulated by various host suppressor mechanisms, but the 
regulatory principles are still incompletely understood, in part due to the complexity 
of the inflammatory response and the multitude of components involved. One key 
mechanism is regulated by the production of anti-inflammatory cytokines by cells of 
the immune system in response to pathogen-derived products (222, 223).  
 
HPMC play an important role in regulating the inflammatory response in the 
peritoneal cavity. During PD-associated peritonitis, they produce pro-inflammatory 
cytokines/chemokines, which contributing to the recruitment of leukocytes toward 
the site of infection. On the other hand, HPMC can release anti-inflammatory 
cytokines such as TGF-β (198) and prostaglandins (196) and the secretion was 
enhanced when stimulated by IL-1β. Increased intraperitoneal secretion of TGF-β in 
PD-associated peritonitis may serve as a negative feedback loop inhibiting 
inflammation. In the present study, I revealed a novel regulation of Vγ9/Vδ2 T cells 
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by HPMC and demonstrated that resting HPMC are potent suppressors of γδ T cell 
cytokine production and proliferation in the presence of HMB-PP, suggesting a 
pivotal homeostatic function of HPMC in the regulation of peritoneal immunity.  
 
In conclusion, these findings improve our insight into the complex cellular 
interactions in acute PD peritonitis and peritoneal homeostasis, identify novel 
biomarkers of possible diagnostic and predictive value and highlight new avenues 
for therapeutic intervention. 
 
6.2 Future work 
 
The aim of my research was to understand the peritoneal immune response, 
microbiology and outcomes in PD-associated peritonitis. Despite the promising 
results obtained in this study, some of them are limited by the small sample size. 
Furthermore, the study of peritoneal immune responses was conducted in a single 
institution, the University Hospital of Wales, Cardiff, UK. Consequently, the results 
may not be directly extrapolated to other patient populations. In spite of these 
limitations, our findings have provided us with novel insights into the role of human 
peritoneal leukocytes, especially Vγ9/Vδ2 T cells, in PD-associated peritonitis. Our 
future aims are to investigate the following:  
 
6.2.1 Predictive markers for clinical outcome in PD-associated peritonitis 
In Chapter 3, my preliminary data imply that positive identification of the causative 
pathogen to produce HMB-PP and elevated frequencies of Vγ9/Vδ2 T cells might be 
negative predictors of clinical outcome.  Due to the limited number of patient 
samples analyzed in the present study, we need to recruit more patient samples to 
improve the validity and accuracy of the results related to clinical outcome. External 
validation is also needed. Moreover, other clinically important outcomes such as the 
function of peritoneal membrane and the speed of responses (rapid vs. delayed) to 
antibiotics should be considered in future researches. Apart from confirming these 
findings, it is also important to concentrate on understanding why elevated 
frequencies of Vγ9/Vδ2 T cells are a negative predictor of clinical outcome. 
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6.2.2 Immune fingerprints for different bacteria species  
The immune response to different bacteria differs greatly. My data in Chapter 4 
suggest that the identification of pathogen-specific fingerprints is feasible. However, 
more patient samples are needed in order to reach sufficient statistical power.  
Moreover, the performance of diagnostic laboratories and their ability to positively 
identify bacteria by microbiological culture varies greatly between different centres, 
as well as the spectrum of micro-organisms patients become infected with (20, 169-
171). Our findings will have to be confirmed in independent centres. Instead of 
merely identifying the immune fingerprints for different bacteria species, it is also 
important to find out possible underlying mechanisms in future studies. 
 
6.2.3 Sequential measurement of acute peritonitis samples  
Serial sampling of acute peritonitis samples (day 1-5) can reflect the dynamic aspects 
of PD-associated peritonitis. The serial samples can be examined for changes of 
leukocyte subpopulations and the function of these cells, thus providing superior 
information about the peritoneal immune defence mechanisms and outcome 
prediction. 
 
6.2.4 The crosstalk between γδ T cells and mesothelial cells 
In Chapter 5, my data show that resting HPMC are potent suppressors of γδ T cell 
cytokine production and proliferation in the presence of HMB-PP. The inhibition 
was likely mediated by HPMC-derived TGF-β. However, additional studies are 
necessary to better define the precise functions of HPMC-derived TGF-β. Moreover, 
HPMC were shown to release other anti-inflammatory cytokines such as 
prostaglandin E2 (196), which inhibit the cytokine production and cytotoxicity of 
Vγ9/Vδ2 T-cell lines (224). Prostaglandin E2 may also play a role in regulation of γδ 
T-cell responses to HMB-PP by HPMC. Last but not least, it will be interesting to 
evaluate whether γδ T cells can reciprocally affect the physiological function of 
HPMC.  
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Abstract
Human blood Vc9/Vd2 T cells, monocytes and neutrophils share a responsiveness toward inflammatory chemokines and are
rapidly recruited to sites of infection. Studying their interaction in vitro and relating these findings to in vivo observations in
patients may therefore provide crucial insight into inflammatory events. Our present data demonstrate that Vc9/Vd2 T cells
provide potent survival signals resulting in neutrophil activation and the release of the neutrophil chemoattractant CXCL8
(IL-8). In turn, Vc9/Vd2 T cells readily respond to neutrophils harboring phagocytosed bacteria, as evidenced by expression
of CD69, interferon (IFN)-c and tumor necrosis factor (TNF)-a. This response is dependent on the ability of these bacteria to
produce the microbial metabolite (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), requires cell-cell contact of
Vc9/Vd2 T cells with accessory monocytes through lymphocyte function-associated antigen-1 (LFA-1), and results in a TNF-a
dependent proliferation of Vc9/Vd2 T cells. The antibiotic fosmidomycin, which targets the HMB-PP biosynthesis pathway,
not only has a direct antibacterial effect on most HMB-PP producing bacteria but also possesses rapid anti-inflammatory
properties by inhibiting cd T cell responses in vitro. Patients with acute peritoneal-dialysis (PD)-associated bacterial
peritonitis – characterized by an excessive influx of neutrophils and monocytes into the peritoneal cavity – show a selective
activation of local Vc9/Vd2 T cells by HMB-PP producing but not by HMB-PP deficient bacterial pathogens. The cd T cell-
driven perpetuation of inflammatory responses during acute peritonitis is associated with elevated peritoneal levels of cd T
cells and TNF-a and detrimental clinical outcomes in infections caused by HMB-PP positive microorganisms. Taken together,
our findings indicate a direct link between invading pathogens, neutrophils, monocytes and microbe-responsive cd T cells
in early infection and suggest novel diagnostic and therapeutic approaches.
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Introduction
The cellular immune system consists of an ‘innate’ arm of
phagocytes and antigen-presenting cells, and an ‘adaptive’ arm of
antigen-specific lymphocytes capable of developing immunological
memory. Yet, there is increasing evidence of considerable crosstalk
between the two [1]. Innate responses directly influence the shape
and outcome of adaptive T cell responses, and vice versa specialized
T cell subsets feedback to innate cells [2]. Among these
interactions, the regulation of neutrophil-mediated inflammatory
responses by Th17 cells has received enormous attention over the
past few years [3], and with the emergence of novel T cell subsets
additional networks are being proposed so that each polarized T
cell eventually pairs with an innate counter player [4–7].
The necessity to integrate complex signals in order to mount the
most effective defense is best illustrated by the existence of
‘unconventional’ T cells bridging the classical divide between
innate and adaptive immunity, such as natural killer T cells,
mucosal-associated invariant T cells, intestinal intraepithelial
CD8aa+ T cells and dendritic epidermal cd T cells [8–14]. These
often tissue-associated lymphocytes are characterised by restricted
T cell receptor (TCR) repertoires that allow them to respond
rapidly to a limited range of conserved structures. Unconventional
T cells readily assume a plethora of effector functions, ranging
PLoS Pathogens | www.plospathogens.org 1 May 2011 | Volume 7 | Issue 5 | e1002040
from sentinel tasks and targeted killing to engaging with
keratinocytes, fibroblasts, phagocytes and antigen-presenting cells
as well as other lymphocyte.
cd T cells expressing a Vc9/Vd2 TCR – Vc2/Vd2 according
to an alternative nomenclature – are only found in humans and
higher primates and differ fundamentally from all other conven-
tional and unconventional T cells [15]. Activated Vc9/Vd2 T cells
produce a range of cytokines, kill infected and transformed target
cells, regulate survival and differentiation of monocytes and
maturation of dendritic cells, provide B cell help and present
antigens to CD4+ and CD8+ T cells [11,12,16,17]. They expand
considerably in many infections, at times to .50% of all
circulating T cells within a few days [18], and respond selectively
in a non-MHC restricted manner to the microbial metabolite (E)-
4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) [19].
HMB-PP is an intermediate of the non-mevalonate pathway of
isoprenoid biosynthesis that is present in many bacteria and in
malaria parasites but not in humans [17–19]. The rapid and
sensitive response of Vc9/Vd2 T cells to a broad range of
pathogens evokes cardinal features of innate immunity. Indeed,
HMB-PP fulfills Janeway’s criteria for a ‘pathogen-associated
molecular pattern’ in that it is (i) invariant among different species;
(ii) a product of a pathway unique to micro-organisms; and (iii)
essential in microbial physiology [17]. Yet, HMB-PP recognition is
not mediated via germline-encoded pattern recognition receptors
but involves the re-arranged Vc9/Vd2 TCR [20–22].
Bacteria that possess the non-mevalonate pathway and hence
produce HMB-PP comprise some of the most detrimental human
pathogens such as the causative agents of cholera, diphtheria,
plague, tuberculosis and typhoid, but also numerous commensal
and opportunistic species in the mucosal flora, skin and feces
[19,23]. In all these micro-organisms, HMB-PP is an essential
intracellular metabolite, and it is not clear whether and how it is
released by invading bacteria and becomes visible to the immune
system as soluble molecule. Indeed, earlier studies with mycobac-
teria suggested that uptake of whole bacteria by monocytes,
macrophages, or DCs may be required for the recognition by
Vc9/Vd2 T cells [24–27]. Neutrophils are the first immune cells
infiltrating the site of infection and the main phagocytes
responsible for early pathogen clearance, and growing evidence
points toward a crucial role of cd T cells in regulating neutrophil
responses in mouse models of infection, hypersensitivity and
autoimmunity [8,12]. Yet, the interplay between cd T cells and
neutrophils has not been addressed in detail [28,29]. Our present
data demonstrate that Vc9/Vd2 T cells readily respond to
neutrophils harboring phagocytosed bacteria, and that this
response is strictly dependent on the ability of these bacteria to
produce HMB-PP and cell-cell contact of Vc9/Vd2 T cells with
accessory monocytes. The majority of circulating Vc9/Vd2 T cells
shows migration properties similar to monocytes [30], suggesting
that these two cell types are co-recruited to the site of
inflammation and interact with each other at early stages of
infection [17,31]. Our present findings thus indicate a direct link
between invading pathogens, neutrophils, monocytes and
microbe-responsive cd T cells, and suggest novel diagnostic and
therapeutic approaches in acute infection.
Results
Human cd T cells induce neutrophil survival and
activation
Neutrophils are short-lived phagocytes that undergo spontane-
ous apoptosis in vitro unless rescued by survival signals. We
previously demonstrated that activated human Vc9/Vd2 T cells
induce monocytes to survive and differentiate into inflammatory
dendritic cells [31]. Here, HMB-PP stimulated Vc9/Vd2 T cells
had a similar survival effect on autologous neutrophils and readily
rescued them from undergoing apoptosis (Figure 1). This effect
was selective and dependent on the number of Vc9/Vd2 T cells
and the concentration of HMB-PP. An increase in neutrophil
survival could already be observed at ratios of only 1 cd T cell per
100 neutrophils and at HMB-PP concentrations as low as 0.1–
1 nM. Activation of Vc9/Vd2 T cells in these cultures was
confirmed by upregulation of CD69 and secretion of interferon
(IFN)-c (Figure S1 in Text S1). The low cd T cell numbers and
HMB-PP concentrations needed to promote neutrophil survival in
vitro are likely to have physiologic relevance.
Activated neutrophils mobilize intracellular stores of CD11b to
the cell surface and shed CD62L, thus enhancing their potential to
undergo firm adhesions with endothelial cells and extravasate at
the site of inflammation. In line with their anti-apoptotic effect on
neutrophils, Vc9/Vd2 T cells induced upregulation of CD11b and
loss of CD62L in surviving neutrophils in an HMB-PP dependent
manner (Figure 2A). Importantly, synthetic HMB-PP alone did
not have any activity on neutrophils in the absence of cd T cells
(Figure 1, Figure 2 and data not shown).
Rapid recruitment of neutrophils involves the chemotactic
action of CXCL8 (IL-8) produced at the site of inflammation, and
increased endothelial permeability mediated by tumor necrosis
factor (TNF)-a. Analysis of the supernatants from the above
experiments revealed that co-cultures of neutrophils and HMB-PP
stimulated Vc9/Vd2 T cells produced considerable amounts of
both CXCL8 and TNF-a, in a dose-dependent manner and at
levels comparable to lipopolysaccharide (LPS) stimulated neutro-
phils (Figure 2B). Another cytokine implicated in neutrophil
recruitment is IL-17, which in a number of infection models is
readily produced by murine cd T cells [8]. While activated Vc9/
Vd2 T cells readily produce TNF-a, IFN-c and granulocyte/
macrophage colony-stimulating factor (GM-CSF) [31,32], we were
unable to detect IL-17 in our co-cultures indicating that under the
conditions tested human cd T cells failed to secrete relevant levels
of IL-17 (data not shown). This is reminiscent of recent findings
Author Summary
The immune system of all jawed vertebrates harbors three
distinct lymphocyte populations – ab T cells, cd T cells and
B cells – yet only higher primates including humans
possess so-called Vc9/Vd2 T cells, an enigmatic cd T cell
subset that uniformly responds to the majority of bacterial
pathogens. For reasons that are not understood, this
responsiveness is absent in all other animals although they
too are constantly exposed to a plethora of potentially
harmful micro-organisms. We here investigated how Vc9/
Vd2 T cells respond to live microbes by mimicking
physiological conditions in acute disease. Our experiments
demonstrate that Vc9/Vd2 T cells recognize a small
common molecule released when invading bacteria
become ingested and killed by other white blood cells.
The stimulation of Vc9/Vd2 T cells at the site of infection
amplifies the inflammatory response and has important
consequences for pathogen clearance and the develop-
ment of microbe-specific immunity. However, if triggered
at the wrong time or the wrong place, this rapid reaction
toward bacteria may also lead to inflammation-related
damage. These findings improve our insight into the
complex cellular interactions in early infection, identify
novel biomarkers of diagnostic and predictive value and
highlight new avenues for therapeutic intervention.
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that human ab T cells including human Th17 cells modulate
neutrophils (which lack the IL-17 receptor C chain) in an IL-17–
independent manner through a combination of TNF-a, IFN-c and
GM-CSF [33]. In our cultures, blocking experiments demonstrat-
ed that TNF-a played a key role in the cd T cell-mediated effect
on neutrophils, as judged by a partial inhibition of neutrophil
survival and a reduction of CD11b expression in the presence of
soluble TNF-a receptor (sTNFR), while neutralizing antibodies
against GM-CSF and IFN-c had no significant effect (Figure 3).
Taken together, these data show that Vc9/Vd2 T cells become
activated by soluble HMB-PP in the presence of autologous
neutrophils and that they provide potent stimulatory signals
inducing neutrophil survival and activation. The interaction of the
two cell types leads to the rapid release of the pro-inflammatory
mediators CXCL8 and TNF-a into the microenvironment,
thereby potentially maintaining neutrophil influx at the site of
infection.
Vc9/Vd2 T cells respond to neutrophils harboring
phagocytosed bacteria
Under physiological conditions, invading pathogens are rapidly
taken up by newly recruited neutrophils. We therefore tested
whether Vc9/Vd2 T cells respond to neutrophils harboring
phagocytosed bacteria in a similar manner as they respond to
soluble HMB-PP. In order to do this, we set up triple cultures
consisting of neutrophils, monocytes and Vc9/Vd2 T cells,
mimicking physiological conditions at the site of infection.
Human neutrophils readily took up green fluorescent protein
(GFP) expressing Escherichia coli, Listeria innocua and Mycobacterium
smegmatis, with .95% of the neutrophils being GFP+ within
30 min (Figure 4A and data not shown). Triple co-cultures of
neutrophils harboring different strains of M. smegmatis with
autologous Vc9/Vd2 T cells and monocytes led to rapid cd T
cell activation, as evidenced by upregulation of CD69 and
expression of TNF-a and IFN-c within 20 hours (Figure 4B and
data not shown). Activation profiles were similar to those seen in
control cultures with non-infected neutrophils in the presence of
synthetic HMB-PP, demonstrating that Vc9/Vd2 T cells respond
to bacterial degradation products released or presented by
neutrophils. For the sake of clarity and simplicity all activation
data in the following sections are shown as proportion of CD69+
TNF-a+ cd T cells in the cultures although the cells were always
co-stained for IFN-c as well. The proportion of CD69+ IFN-c+
and TNF-a+ IFN-c+ cd T cells followed essentially the same
pattern throughout this study and led to the same conclusions.
The Vc9/Vd2 T cell response to phagocytosed bacteria
depends on the ability of bacteria to produce HMB-PP
In order to investigate the correlation between the ability of
bacteria to produce HMB-PP and their capacity to stimulate Vc9/
Vd2 T cells, we designed experiments to distinguish a specific cd T
cell response to HMB-PP from a possible background stimulation
by the plethora of other microbial compounds acting via pattern
recognition receptors. Thus, we generated a M. smegmatis
transfectant stably expressing a second copy of the gene encoding
HMB-PP synthase (gcpE) and hence overproducing HMB-PP
compared to the parental wildtype (wt) strain [34] (Figure S2 in
Text S1). As a second bacterial model we utilized HMB-PP
producing and HMB-PP deficient strains of the non-pathogenic
Gram-positive bacterium Listeria innocua [35,36] (Figure S3 in Text
S1).
Compared with M. smegmatis wt bacteria, higher levels of Vc9/
Vd2 T cell activation were observed when using M. smegmatis-gcpE+
(Figure 5). Furthermore, considerable Vc9/Vd2 T cell activation
was seen with phagocytosed L. innocua-gcpE+, a strain in which
HMB-PP artificially accumulates, but not with the naturally
HMB-PP deficient L. innocua wt strain that was .1006 less potent
(Figure 5). The double transfectant L. innocua-gcpE+lytB+, in which
HMB-PP becomes converted into the downstream reaction
products isopentenyl pyrophosphate (IPP) and dimethylallyl
pyrophosphate (DMAPP), resulted in no detectable Vc9/Vd2 T
cell activation (data not shown). These data demonstrate that the
Figure 1. HMB-PP stimulated Vc9/Vd2 T cells induce neutrophil survival. Dose-dependent survival of neutrophils incubated with LPS, and of
neutrophils (PMN) co-cultured with Vc9/Vd2 T cells at various ratios in the presence of HMB-PP at different concentrations. Neutrophils were analyzed
after 20 hours in culture; dot plots depict representative annexin-V and fixable live/dead stainings for live CD32 CD15+ neutrophils cultured under
the indicated conditions. Data shown are mean percentages (%) + SEM of live cells from independent experiments using three different donors.
doi:10.1371/journal.ppat.1002040.g001
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response of Vc9/Vd2 T cells to neutrophils harboring phagocy-
tosed bacteria depends on the ability of these bacteria to produce
HMB-PP and suggest that phagocytosis and subsequent degrada-
tion of bacteria in neutrophils leads to either presentation of
HMB-PP on the cell surface or the release of soluble HMB-PP into
the microenvironment.
Crosstalk with monocytes provides essential help for the
Vc9/Vd2 T cell response to phagocytosed bacteria
Vc9/Vd2 T cells, monocytes and neutrophils share a
responsiveness toward inflammatory chemokines and are the
earliest leukocytes recruited to sites of infection. Vc9/Vd2 T cell
responses in vitro are greatly facilitated by contact with monocytes
as ‘feeder cells’, which most likely act by ‘presenting’ HMB-PP to
Vc9/Vd2 T cells and by providing contact-dependent signals [17].
In support of our previous observation of a substantial HMB-PP
dependent crosstalk between Vc9/Vd2 T cells and monocytes
leading to optimum cd T cell activation [31], the response of Vc9/
Vd2 T cells to neutrophils harboring phagocytosed L. innocua-gcpE+
was largely dependent on the presence of monocytes. Omission of
monocytes from the co-cultures resulted in greatly reduced
expression levels of CD69, TNF-a and IFN-c, compared to triple
co-cultures (Figure 6A and data not shown), suggesting that
monocytes provide essential help for the recognition of bacteria by
Vc9/Vd2 T cells and increase the sensitivity of the response
especially at low HMB-PP concentrations.
We speculated that this accessory effect might have stemmed
from contact-dependent interactions of monocytes with either
neutrophils or cd T cells and tested this hypothesis in transwell
cultures where neutrophils harboring phagocytosed L. innocua-
gcpE+ in the lower chamber were separated from Vc9/Vd2 T cells
in the upper chamber. As shown in Figure 6B, cell-cell contact
between monocytes and Vc9/Vd2 T cells was crucial for the
response to phagocytosed bacteria, while no contact was needed
between Vc9/Vd2 T cells and neutrophils, and neither between
Figure 2. HMB-PP stimulated Vc9/Vd2 T cells induce neutrophil
activation and production of pro-inflammatory mediators. (A)
Dose-dependent up-regulation of CD11b and shedding of CD62L by
neutrophils incubated with LPS as positive control, and of neutrophils
co-cultured with Vc9/Vd2 T cells at various ratios in the presence of
HMB-PP at different concentrations. Neutrophils were analyzed after
20 hours in culture; histograms depict representative CD11b and CD62L
stainings for live CD32 CD15+ neutrophils cultured under the indicated
conditions. Data shown are mean fluorescence intensities (MFI) + SEM
from independent experiments using three different donors. (B) Dose-
dependent secretion of CXCL8 and TNF-a into the culture supernatant
of neutrophils incubated with LPS as positive control, and of
neutrophils co-cultured with Vc9/Vd2 T cells at various ratios in the
presence of HMB-PP at different concentrations. Supernatants were
analyzed after 20 hours by ELISA. Data shown are mean levels (pg/ml) +
SEM from independent experiments using three different donors.
doi:10.1371/journal.ppat.1002040.g002
Figure 3. HMB-PP stimulated Vc9/Vd2 T cells induce neutrophil
survival and activation through TNF-a. Neutrophils were co-
cultured with Vc9/Vd2 T cells for 20 hours at a ratio of 5:1, in the
absence or presence of 10 nM HMB-PP. Soluble cytokines were blocked
by the addition of sTNFR, anti-GM-CSF or anti-IFN-c. Data shown are
mean values + SEM for neutrophil survival and expression of CD11b by
live neutrophils, as determined in independent experiments using three
different donors.
doi:10.1371/journal.ppat.1002040.g003
Neutrophil-gd T Cell Crosstalk in Early Infection
PLoS Pathogens | www.plospathogens.org 4 May 2011 | Volume 7 | Issue 5 | e1002040
monocytes and neutrophils. These data indicate that upon
phagocytosis of HMB-PP+ bacteria, neutrophils release soluble
factors that efficiently stimulate Vc9/Vd2 T cells, while monocytes
provide important contact-dependent accessory signals.
Upon phagocytosis of HMB-PP+ bacteria neutrophils
release HMB-PP into the culture supernatant
Since neutrophils harboring bacteria were able to stimulate
Vc9/Vd2 T cells in a transwell system, we next examined whether
cell-free culture supernatants derived from infected neutrophils
stimulated Vc9/Vd2 T cells in a similar manner. Indeed, Vc9/
Vd2 T cells readily responded to supernatants from neutrophils
harboring L. innocua-gcpE+ but not from neutrophils harboring L.
innocua wt bacteria, as evidenced by expression of CD69, TNF-a
and IFN-c (Figure 6C and data not shown). Importantly, short-
term pre-treatment of L. innocua-gcpE+ supernatants with shrimp
alkaline phosphatase abrogated the bioactivity on Vc9/Vd2 T
cells completely (Figure 6C), evoking the known sensitivity of
mycobacterial HMB-PP to dephosphorylation and the relative
inactivity of the dephosphorylated products [37–39]. Control
experiments confirmed that alkaline phosphatase affected the
response of Vc9/Vd2 T cells to synthetic HMB-PP but not to the
phosphatase-resistant diphosphonate analogue, HMB-PCP [40],
demonstrating that the presence of alkaline phosphatase in the
cultures had no inhibitory effect on the cells’ ability to express
CD69, TNF-a and IFN-c (Figure 6D and data not shown). We
conclude that upon phagocytosis of HMB-PP+ bacteria neutro-
phils release soluble HMB-PP into the microenvironment where it
becomes accessible to monocytes and Vc9/Vd2 T cells.
The Vc9/Vd2 T cell response to phagocytosed bacteria is
HMB-PP dependent but largely independent of other
pathogen-associated molecular patterns
In order to assess the clinical relevance of our findings, we
expanded our panel of bacteria by including clinical isolates of
pathogens that are frequently associated with community- and
hospital-acquired infections and pose serious threats to public
health (Table S1 in Text S1). Of note, neutrophils harboring
HMB-PP+ pathogens but not neutrophils harboring HMB-PP2
pathogens induced in Vc9/Vd2 T cells the co-expression of
CD69, TNF-a and IFN-c (Figure 7A and data not shown). This
Figure 4. Vc9/Vd2 T cells respond to bacteria upon phagocy-
tosis by neutrophils. (A) Resting neutrophils or neutrophils after
phagocytosis of M. smegmatis-gfp+ stably expressing GFP, at a
multiplicity of infection (MOI) of 10. Cells were counter-stained with
DAPI and imaged by fluorescence microscopy. Data shown are
representative from independent experiments using two different
donors. (B) Activation of Vc9/Vd2 T cells co-cultured for 20 hours with
neutrophils in the absence (medium) or in the presence of 10 nM HMB-
PP, or co-cultured with neutrophils harboring M. smegmatis-gcpE+
overexpressing HMB-PP synthase. Data shown are representative from
independent experiments using three different donors.
doi:10.1371/journal.ppat.1002040.g004
Figure 5. Vc9/Vd2 T cells show enhanced responses to
phagocytosed bacteria that overproduce HMB-PP. Dose-depen-
dent activation of Vc9/Vd2 T cells by neutrophils harboring genetically
engineered transfectants of M. smegmatis (upper panel) or L. innocua
(lower panel), in which HMB-PP accumulates intracellularly, compared
to the parental wildtype strains (wt). Data shown are mean frequencies
of CD69+ TNF-a+ Vc9/Vd2 T cells 6 SEM after 20 hours in culture, as
determined in independent experiments using three different donors.
Error bars for MOIs depict mean values 6 SEM for the true colony-
forming unit (CFU) counts of the bacterial inocula used.
doi:10.1371/journal.ppat.1002040.g005
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response was largely independent of the presence of other
pathogen-associated molecular patterns such as LPS as both
Gram-negative (Acinetobacter baumannii, Enterobacter cloacae, Klebsiella
pneumoniae, Pseudomonas aeruginosa) and Gram-positive bacteria (M.
smegmatis) capable of producing HMB-PP stimulated Vc9/Vd2 T
cells equally. Direct addition of alkaline phosphatase to these co-
cultures abrogated the HMB-PP dependent cytokine responses,
confirming soluble HMB-PP as common Vc9/Vd2 T cell
stimulator in these species (Figure 7A, Figure S4 in Text S1).
The bioactivity of culture supernatants harvested after 5 hours
from neutrophils harboring the above bacteria corresponded to
levels of 0.1–10 nM HMB-PP, as titrated against a HMB-PP
standard (data not shown). Residual levels of CD69 expression
after phosphatase treatment may have been due to incomplete
degradation of HMB-PP and to indirect stimulation of Vc9/Vd2
T cells by other microbial compounds such as LPS acting on
neutrophils or monocytes [41,42]. In contrast to HMB-PP
producing species, HMB-PP deficient Gram-negative (Chryseobac-
terium indologenes) and Gram-positive bacteria (Enterococcus faecalis, L.
innocua, Staphylococcus aureus) did not elicit Vc9/Vd2 T cells
responses above background as demonstrated by the complete
lack of TNF-a (Figure 7A, Figure S4 in Text S1) and IFN-c (data
not shown). These findings illustrate the extraordinary specificity
Vc9/Vd2 T cells for HMB-PP, even in the abundant presence of
other microbial products and despite high levels of monocyte and/
or neutrophil-derived mediators such as IL-1b, IL-6 and CXCL8
that were present in our triple co-cultures regardless of the HMB-
PP status of the phagocytosed bacteria (data not shown).
Vc9/Vd2 T cells proliferate in response to phagocytosed
bacteria in a TCR, LFA-1 and TNF-a dependent manner
cd T cells expand rapidly in acute bacterial infections [18]. We
therefore tested whether phagocytosed pathogens could induce
expansion of 5-(and 6-)carboxyfluorescein diacetate succinimidyl
ester (CFSE)-labeled Vc9/Vd2 T cells. As shown in Figure 7B,
Vc9/Vd2 T cells proliferated considerably in the presence of
supernatants derived from neutrophils harboring HMB-PP+
Enterobacter cloacae but not from neutrophils harboring HMB-PP2
Chryseobacterium indologenes or Staphylococcus aureus. Similarly to the
immediate up-regulation of CD69, TNF-a and IFN-c, the
proliferation of Vc9/Vd2 T cells in response to Enterobacter cloacae
was HMB-PP dependent and could be abrogated by alkaline
phosphatase. Expanding Vc9/Vd2 T cells also up-regulated the
high affinity IL-2 receptor, CD25 (Figure 7B) and became
responsive to exogenously added IL-2, which enhanced the
proliferative response even further (data not shown). Blocking
Figure 6. Vc9/Vd2 T cells respond, in a monocyte-dependent manner, to phosphatase-sensitive molecules released from
phagocytosed bacteria. (A) Activation of Vc9/Vd2 T cells by neutrophils harboring L. innocua wt or L. innocua-gcpE+ bacteria, in the presence (cd-
mo) or absence (cd) of monocytes. Data shown are mean frequencies of CD69+ TNF-a+ Vc9/Vd2 T cells + SEM after 20 hours in culture, as determined
in independent experiments using three different donors. (B) Activation of Vc9/Vd2 T cells in the top chamber of a transwell plate separated from
neutrophils (N) harboring L. innocua-gcpE+ in the bottom chamber, in the presence or absence of monocytes (mo). Data shown are mean frequencies
of CD69+ TNF-a+ Vc9/Vd2 T cells + SEM after 20 hours in culture, as determined in independent experiments using three different donors.
(C) Activation of Vc9/Vd2 T cells co-cultured for 20 hours with monocytes in the presence of supernatants from neutrophils harboring L. innocua wt
or L. innocua-gcpE+ bacteria that had been pretreated or not with alkaline phosphatase (AP). Data shown are representative from independent
experiments using two different donors. (D) Activation of Vc9/Vd2 T cells co-cultured for 20 hours with monocytes in the presence of 1 nM HMB-PP
or 100 mM HMB-PCP pretreated or not with alkaline phosphatase (AP). Data shown are representative from independent experiments using two
different donors.
doi:10.1371/journal.ppat.1002040.g006
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experiments demonstrated a crucial requirement of soluble and
contact-dependent signals for optimum stimulation of Vc9/Vd2 T
cells. TNF-a was recently implicated in Vc9/Vd2 T cell
proliferation in response to IPP and IL-2 [43], and blocking of
lymphocyte function-associated antigen-1 (LFA-1, CD11a/CD18)
efficiently disrupted cluster formation with monocytes [31]. Here,
both Vc9/Vd2 T cell proliferation and CD25 up-regulation in
response to supernatants derived from neutrophils harboring
HMB-PP+ Klebsiella pneumoniae (Figure 7B) or Enterobacter cloacae
(data not shown) were readily inhibited by sTNFR and anti-
CD11a antibodies but not by anti-IFN-c antibodies. Finally,
addition of anti-Vc9 antibodies completely abrogated the Vc9/
Vd2 T cell proliferation in response to HMB-PP (data not shown)
and Enterobacter cloacae supernatants (Figure S7 in Text S1),
confirming a requirement for the TCR [44]. Taken together,
our findings demonstrate that Vc9/Vd2 T cells are rapidly
activated by a broad range of HMB-PP producing pathogens,
leading to TCR, LFA-1 and TNF-a dependent cd T cell
expansion.
Acute infections caused by HMB-PP producing bacteria
are characterized by elevated numbers of activated cd T
cells
We next addressed whether the dichotomy between HMB-PP+
and HMB-PP2 pathogens in their potential to trigger cd T cells in
vitro is replicated under physiological conditions in vivo. As clinical
correlate for HMB-PP+ and HMB-PP2 infections, we analyzed
episodes of acute bacterial infections in peritoneal dialysis (PD)
patients, in whom the peritoneal catheter affords continuous and
non-invasive access to the inflammatory infiltrate (Table S2 in Text
S1). PD-associated peritonitis is characterized by a considerable
influx of neutrophils and monocytes into the peritoneal cavity
[45,46], where the two cell types may become targets for local or
infiltrating cd T cells [31,47]. Here, in a total of 24 newly recruited
patients examined on the first day of acute peritonitis (i.e. before
administration of antibiotics), both the total number and the
frequency of peritoneal Vc9/Vd2 T cells were elevated in HMB-
PP+ infections compared to HMB-PP2 infections, suggesting
increased recruitment and/or proliferation in response to
Figure 7. Vc9/Vd2 T cells respond to HMB-PP producing Gram+ and Gram2 bacteria but not to HMB-PP deficient bacteria. (A) Dose-
dependent activation of Vc9/Vd2 T cells by neutrophils harboring clinical isolates of a range of different bacteria: Gram2 HMB-PP+, Enterobacter
cloacae (two different isolates tested, A and B) and Klebsiella pneumoniae; Gram2 HMB-PP2, Chryseobacterium indologenes; and Gram+ HMB-PP2,
Enterococcus faecalis and Staphylococcus aureus; in the presence or absence of alkaline phosphatase (AP). Data shown are mean frequencies of CD69+
TNF-a+ Vc9/Vd2 T cells 6 SEM after 20 hours in culture, as determined in independent experiments using 3–5 donors. Error bars for MOIs depict
mean values6 SEM for the true CFU counts of the bacterial inocula used. (B) Proliferation after 5 days in culture and CD25 expression of CFSE-labeled
Vc9/Vd2 T cells in response to supernatants from neutrophils harboring clinical isolates of the indicated bacteria, in the presence or absence of
alkaline phosphatase (AP), soluble TNF-a receptor (sTNFR) or blocking antibodies against IFN-c or CD11a. Data shown are representative of
independent experiments using cells from at least two different donors.
doi:10.1371/journal.ppat.1002040.g007
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HMB-PP released by bacteria (Figure 8). Moreover, local activation
was evidenced by higher percentages of Vc9/Vd2 T cells expressing
CD69 in the HMB-PP+ patient group. In contrast, we did not see
any significant differences in the numbers and frequencies of
peritoneal neutrophils, monocytes/macrophages and total CD3+ T
cells, regardless of the HMB-PP status of the causative pathogen
(Figure S5 in Text S1). Similarly, while the proportion of Vc9/Vd2
T cells within peritoneal CD3+ T cells was clearly elevated in HMB-
PP+ infections, CD4+ and CD8+ T cells showed no such bias (Figure
S6 in Text S1).
Episodes of peritonitis caused by HMB-PP producing
bacteria are associated with poor clinical outcome
As Medzhitov stated recently, ‘‘inflammation is beneficial in
appropriate amounts but can easily become detrimental when
excessive because of its tissue-damaging potential’’ [48]. PD
patients constitute a particularly vulnerable group where inflam-
matory events can have profound consequences [49–51]. We
speculated that local activation of cd T cells may contribute to
inflammation-related damage and tested whether the occurrence
of clinical complications in PD patients depends on the capacity of
the causative pathogen to produce HMB-PP. Our analysis of 26
patients treated at the University Hospital of Wales, Cardiff, UK,
demonstrated that infections with HMB-PP+ bacteria were
associated with worse outcomes, evidenced as higher mortality
rates and higher incidences of technique failure (i.e., cessation of
therapy due to catheter removal, transfer to hemodialysis or
patient death), while HMB-PP2 bacteria caused milder disease
(Figure 9). Of note, we were able to validate this pattern in two
larger and entirely independent cohorts treated in Australia
(ANZDATA Registry) and at the University Hospital of North
Staffordshire, Stoke-on-Trent, UK (Figure 9). In order to rule out
that this pattern was not due to differences in Gram staining (and
hence endotoxin-related), we divided the group of HMB-PP+
bacteria further into Gram+ and Gram2 species. Our outcome
analysis demonstrates that even within the Gram+ group, bacteria
capable of producing HMB-PP were associated with worse
outcomes compared to HMB-PP2 pathogens (Figure 9), suggest-
ing that the HMB-PP producing capacity of the causative
pathogen might be of predictive value for the clinical outcome
from bacterial peritonitis (Table S3 in Text S1).
Peritoneal cd T cell frequencies and TNF-a levels might
predict clinical outcome in peritonitis patients
In order to identify potentially useful diagnostic and prognostic
biomarkers of inflammation severity and outcomes from bacterial
infection, we measured a large number of immunological
parameters. These analyses identified elevated frequencies of
peritoneal Vc9/Vd2 T cells on day 1 as possible predictor of
subsequent technique failure within three months after infection
Figure 8. Vc9/Vd2 T cell numbers and CD69 expression are
elevated in acute peritonitis caused by HMB-PP bacteria. Total
numbers and frequencies of Vc9/Vd2 T cells (% of total cells and % of all
CD3+ T cells), and expression of CD69 on peritoneal Vc9/Vd2 T cells in
patients with PD-associated peritonitis on day 1 (the day of hospital
admission with a cloudy effluent, i.e. before commencement of
antibiotic therapy), depending on whether or not the causative
pathogen was capable of producing HMB-PP.
doi:10.1371/journal.ppat.1002040.g008
Figure 9. Episodes of peritonitis caused by HMB-PP producing
bacteria are associated with poor clinical outcome. Cumulative
patient survival (left) and cumulative technique survival (right) of
patients with acute bacterial peritonitis, grouped into infections with
Gram+ HMB-PP2 (blue), Gram+ HMB-PP+ (green) or Gram2 HMB-PP+
pathogens (red); episodes caused by Gram2 HMB-PP2 pathogens were
not recorded in the patient databases. Top, PD patients admitted at the
University Hospital of Wales, Cardiff, with acute peritonitis (day 1, i.e.
first presentation with a cloudy bag). Middle, Australian PD patients
from the ANZDATA registry with first-time peritonitis. Bottom, PD
patients with first-time peritonitis treated at the University Hospital of
North Staffordshire, Stoke-on-Trent, UK. Comparisons were made using
log-rank tests.
doi:10.1371/journal.ppat.1002040.g009
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(Table 1). Similarly, expression of the activation marker HLA-DR
by peritoneal Vc9/Vd2 T cells on the day of admission was
associated with increased mortality. No other parameters tested
including the numbers and frequencies of neutrophils, monocytes
or CD4+ and CD8+ T cells reached statistical significance (data
not shown). Among soluble factors in peritoneal effluent, only
elevated levels of TNF-a on day 1 indicated higher rates of
technique failure and mortality (Table 1), while no such
correlation was seen for other cytokines and chemokines, including
GM-CSF, IFN-c, IL-1b, IL-2, IL-6, IL-10, IL-12p70, IL-17, IL-
22, CXCL8, CXCL10 and sIL-6R (data not shown).
Pre-treatment of bacteria with fosmidomycin blocks
HMB-PP production and abrogates cd T cell responses
Our findings of a rapid cd T cell response to neutrophil-
engulfed HMB-PP producing pathogens and its potential detri-
mental consequence in episodes of acute peritonitis may not only
be of diagnostic and predictive value for affected patients, they also
highlight possible new avenues of therapeutic intervention in
bacterial infections. HMB-PP is an intermediate of the non-
mevalonate pathway of isoprenoid biosynthesis, in which the first
enzymatic step catalyzed by 1-deoxy-D-xylulose-5-phosphate
reductoisomerase (Dxr) can be inhibited by fosmidomycin (Figure
S8A in Text S1), a natural antibiotic produced by Streptomyces
lavendulae [52,53]. We therefore speculated that the effect of
fosmidomycin pre-treatment of bacteria may serve a dual purpose
in treating acute infections: by directly inhibiting an essential
pathway in a broad range of pathogens and by abrogating HMB-
PP driven inflammatory responses.
Tests with selected clinical isolates of common pathogens
demonstrated that the majority of HMB-PP+ bacteria (Enterobacter
cloacae, Klebsiella pneumoniae, Pseudomonas aeruginosa) was susceptible to
overnight treatment with fosmidomycin (with the exception of
Acinetobacter baumannii as expected [54]), with a mean inhibitory
concentration (MIC) of 1–32 mg/ml depending on the strain
(Table S1 in Text S1). Of note, fosmidomycin also acted on
multidrug-resistant strains including bacteria harboring the
recently discovered ‘New Delhi’ metallo-b-lactamase 1 (NDM-1)
[55,56] (Davey MS, Tyrrell JM et al., submitted for publication). In
contrast to the efficient killing of most HMB-PP+ bacteria, the
HMB-PP2 bacteria Chryseobacterium indologenes, Enterococcus faecalis
and Staphylococcus aureus were not affected by fosmidomycin (Table
S1 in Text S1).
We next investigated the potential of short-term fosmidomycin
treatment to affect cd T cell activation by inhibiting the bacterial
HMB-PP biosynthesis. Prior exposure of bacteria to fosmidomycin
for 1 hour did not affect uptake by neutrophils as demonstrated
using Escherichia coli-gfp+ (Figure S8B in Text S1), and neither did it
affect gross bacterial viability as confirmed by re-plating treated
Enterobacter cloacae on antibiotic-free plates in order to overcome the
competitive inhibition by fosmidomycin (Figure 10A). Yet, pre-
incubation of Escherichia coli, Enterobacter cloacae and Klebsiella
pneumoniae with fosmidomycin for only 1 hour prior to phagocy-
tosis by neutrophils clearly abrogated their capacity to stimulate
Vc9/Vd2 T cells. This inhibitory effect on cd T cell responses was
evident both for activation of Vc9/Vd2 T cells in triple co-cultures
with neutrophils harboring fosmidomycin-treated bacteria
(Figure 10A and data not shown) as well as for activation (Figure
S8B in Text S1) and proliferation (Figure 10B) of Vc9/Vd2 T cells
in response to cell-free supernatants from neutrophils harboring
fosmidomycin-treated bacteria. Together these results indicate
that fosmidomycin not only has a direct antibacterial effect but
also possesses immediate anti-inflammatory properties by inhibit-
ing cd T cell-driven responses (Figure 11), thus making the non-
mevalonate pathway an attractive novel drug target for the
treatment of acute infection.
Table 1. Identification of immune markers of possible
predictive value for clinical outcome in 8 stable PD patients
and 29 PD patients with acute peritonitis (means 6 SD).
90th day technique failure
Stable
patients Survivors
Non-
survivors
Vc9+ (% of CD3+ T cells) 1.560.9 2.562.1 4.963.2*
TNF-a (pg/ml) 3.164.3 41.9653.3 128.4691.0*
90th day mortality
HLA-DR+ (% of Vd2+ T cells) 14.7610.5 11.5610.5 40.667.5***
TNF-a (pg/ml) 3.164.3 48.1660.4 148.7690.2*
Asterisks indicate significant differences between survivors and non-survivors.
doi:10.1371/journal.ppat.1002040.t001
Figure 10. Abrogation of HMB-PP dependent cd T cell
responses by fosmidomycin. (A) Activation of Vc9/Vd2 T cells co-
cultured for 20 hours with neutrophils harboring Enterobacter cloacae
pre-treated or not for 1 hour with the indicated concentrations of
fosmidomycin. The minimum inhibitory concentration (MIC) of fosmi-
domycin for this bacteria strain was 1 mg/ml, as determined by
microbroth dilution (Table S1 in Text S1). Data shown are frequencies
of CD69+ TNF-a+ Vc9/Vd2 T cells after 20 hours in culture, alongside
CFU counts of the original bacterial inocula after 1 hour treatment with
fosmidomycin, representative of independent experiments using cells
from two different donors. FACS plots show typical Vc9/Vd2 T cell
responses, representative of independent experiments using cells from
three different donors. (B) Proliferation after 5 days in culture of CFSE-
labeled Vc9/Vd2 T cells in response to supernatants from neutrophils
harboring Enterobacter cloacae pre-treated or not for 1 hour with
0.25 mg/ml fosmidomycin. Data shown are representative of indepen-
dent experiments using cells from two different donors.
doi:10.1371/journal.ppat.1002040.g010
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Discussion
Despite its relevance in early infection, the immediate crosstalk
of cd T cells, monocytes and neutrophils in the presence of
bacterial pathogens has not been addressed in detail. This is
particularly the case in humans who possess a unique cd T cell
population uniformly targeting an invariant non-self-metabolite,
HMB-PP. Previous reports already associated the activation of
Vc9/Vd2 T cells with the production of HMB-PP by microbes.
This link was mainly based on the observation that Vc9/Vd2 T
cell levels are often elevated in the blood of patients infected with
HMB-PP producing pathogens [18] and that bacterial extracts
prepared from those species activate Vc9/Vd2 T cells in vitro much
better than extracts prepared from HMB-PP deficient micro-
organisms [19,35,57]. Other investigators have speculated that
Vc9/Vd2 T cells respond in vivo toward infected host cells with
dysregulated isoprenoid metabolism leading to accumulation of
isopentenyl pyrophosphate (IPP) regardless of the presence or
absence of HMB-PP [58]. Here we unequivocally demonstrate
that Vc9/Vd2 T cells respond to live bacteria upon phagocytosis
by neutrophils, that this response is strictly HMB-PP dependent,
and that it is amplified by the presence of monocytes providing
crucial accessory signals. While it has remained puzzling how the
immune system actually ‘sees’ an intracellular metabolite that is
unlikely to be secreted or released by live micro-organisms, our
findings show that biologically relevant traces of HMB-PP escape
into the microenvironment after phagocytosis of extracellular
bacteria by neutrophils. These conditions are likely to occur
during the acute stage of the infection when Vc9/Vd2 T cells and
monocytes are co-recruited to the site of inflammation [17] where
they encounter neutrophils engaged in clearing invading patho-
gens (Figure 11).
The present findings explain how HMB-PP may become
released at the site of infection. However, the molecular
mechanism of HMB-PP recognition by Vc9/Vd2 T cells remains
poorly understood. Our observation that monocytes were required
for Vc9/Vd2 T cell responses to phagocytosed bacteria offers
important clues. Monocytes and monocyte-derived macrophages
or DCs were shown before to provide accessory help and may
constitute a pivotal trigger for Vc9/Vd2 T cell responses to
different bacterial pathogens. In the case of direct infection of
monocytic cells, HMB-PP derived from intracellular bacteria may
reach the cell surface bound to a presenting molecule [24,25,27].
In the case of extracellular bacteria, monocytes may take up or
bind soluble HMB-PP released by professional phagocytes and
present it to Vc9/Vd2 T cells (Figure 11). The HMB-PP
presenting pathway remains elusive but may involve cell surface
F1-ATPase [59], together with tight cell-cell interactions via LFA-
1/ICAM-1 [31,60], while it is independent of MHC class I, MHC
class II, b2-microglobulin or CD1 [61]. Of note, any chemical
modification of the molecular structure of HMB-PP abrogates its
bioactivity by several magnitudes, such that the closely related
natural metabolites IPP and DMAPP are .10,000 times less
active in vitro [39,40,62,63]. This is supported by our previous
[35,64,65] and present demonstration that HMB-PP deficient
bacteria (but which produce IPP and DMAPP) fail to stimulate
cytokine production by Vc9/Vd2 T cells. Treatment with
fosmidomycin or alkaline phosphatase abrogated the Vc9/Vd2
T cell responses to HMB-PP producing bacteria and emphasized
the importance of HMB-PP for the induction of IFN-c and
TNF-a. However, fosmidomycin or alkaline phosphatase treated
cultures as well as cultures involving HMB-PP deficient bacteria
did show residual levels of CD69 expression, in line with a role for
direct or indirect sensing of microbial TLR ligands [41,42,66] that
is likely to amplify the overall response. In this respect it is
intriguing that our present study identified a crucial role for TNF-
a in supporting Vc9/Vd2 T cell proliferation, a cytokine which is
readily produced not only by activated Vc9/Vd2 T cells
themselves but also by neutrophils and monocytes exposed to
Figure 11. HMB-PP dependent interaction between cd T cells, neutrophils and monocytes in acute microbial infection. Local secretion
of inflammatory chemokines leads to extravasation of neutrophils, monocytes and cd T cells toward the site of infection. Upon phagocytosis of
invading microbes, neutrophils release traces of HMB-PP into the microenvironment where it becomes ‘visible’ to cd T cells. cd T cells recognize HMB-
PP in the context of a yet unidentified presenting molecule ‘X’ and contact-dependent signals provided by monocytes. Crosstalk between the three
different cell types triggers the production of pro-inflammatory cytokines such as TNF-a, which drives local cd T cell expansion, and chemokines such
as CXCL8, which recruits further neutrophils to the site of infection. Activated cd T cells also provide survival and activation signals such as TNF-a for
newly arriving neutrophils and monocytes. This cd T cell-driven inflammatory reaction can be interrupted at various check-points as demonstrated in
the present study.
doi:10.1371/journal.ppat.1002040.g011
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microbial compounds such as LPS. This is in stark contrast to
other cytokines produced by innate immune cells such as IFN-a
and IFN-b which may induce upregulation of CD69 on Vc9/Vd2
T cells but fail to co-stimulate Vc9/Vd2 T cell proliferation [32].
Taken together, we identified an inflammatory crosstalk of Vc9/
Vd2 T cells, neutrophils and monocytes in the presence of HMB-
PP producing bacteria that can be manipulated at various check-
points: (i) the antibiotic fosmidomycin abrogates the microbial
HMB-PP production and thus renders bacterial pathogens
invisible for Vc9/Vd2 T cells; (ii) alkaline phosphatase degrades
free HMB-PP released by neutrophils into the microenvironment;
(iii) blocking antibodies against the TCR prevent the recognition of
HMB-PP by Vc9/Vd2 T cells; (iv) blocking antibodies against
CD11a disrupt the LFA-1/ICAM-1 dependent contact between
cd T cells and monocytes needed for cd T cell stimulation; (v) and
sTNFR neutralizes soluble TNF-a which is released by all three
cell types in response to microbial ligands and acts as growth factor
for Vc9/Vd2 T cells and survival factor for neutrophils (Figure 11).
How does the HMB-PP dependent crosstalk of Vc9/Vd2 T
cells, monocytes and neutrophils in vitro translate into the situation
in vivo in acutely infected patients? Studies in patients with systemic
inflammatory response syndrome suggested a significant role for
Vc9/Vd2 T cells as early responders after severe insult and
identified a correlation between Vc9/Vd2 T cell activation and
clinical scores [67]. Our own findings in patients with PD-related
peritonitis support this notion and demonstrate that the capacity of
the causative pathogen to produce HMB-PP and local infiltrates of
activated Vc9/Vd2 T cells on day 1 are indicative of acute
inflammatory responses and may predict the subsequent clinical
outcome from infection. It is becoming increasingly clear that the
nature of the infection is a major determinant of outcome, and
future interventions may well have to focus on subgroups of
patients with different forms of infection [68]. A careful re-analysis
of peritonitis outcomes from validated registry data [69–76]
confirms that HMB-PP+ bacteria cause clinically more severe
infection and emphasizes the need to pay more attention to
detailed host-pathogen interactions. Bacterial infection remains a
leading cause of morbidity and mortality worldwide, not the least
due to the alarming spread of antibiotic-resistant pathogens that is
posing an enormous challenge on clinical practice, public
healthcare and biomedical research [55,56]. In most cases,
antimicrobial treatment is largely empirical as microbiological
culture results are typically not available for 2–3 days. Moreover,
many times no organism can be identified, with rates of culture-
negative infections occasionally reaching 50% [77]. In contrast,
laboratory analyses of immune cells and/or soluble mediators may
provide valuable information within a few hours and both aid
diagnosis and refine treatment. In this respect, fosmidomycin or
related HMB-PP inhibitors might constitute useful combination
partners for antibiotic therapy especially in critical cases such as
acute peritonitis or sepsis where the intervention has to commence
before the nature of the causative pathogen is known, and where
activated Vc9/Vd2 T cells may contribute to poor clinical
outcome. Fosmidomycin targets an essential pathway in a broad
range of pathogens [54,78,79] and simultaneously abrogates Vc9/
Vd2 T cell responses [80,81]. Of note, the inhibitory effect of
fosmidomycin on the Vc9/Vd2 T cell bioactivity was detectable
after only 1 hour of treatment and well below its MIC, i.e. under
conditions that would easily be achievable in patients. Other ways
of specifically manipulating cd T cell mediated responses may
include the use of anti-cd TCR antibodies or cd TCR antagonists
such as BrH-PCP [82]. Given the importance of TNF-a for cd T
cell proliferation and the association of peritoneal TNF-a levels
with morbidity and mortality, one may also advocate the use of
TNF-a blocking reagents for the treatment of acute PD-related
peritonitis [83].
Taken together our experiments demonstrate that Vc9/Vd2 T
cells recognize with HMB-PP a small common molecule released
by the majority of invading bacteria when they become
phagocytosed by neutrophils. Stimulation of Vc9/Vd2 T cells
at the site of infection is likely to amplify the local inflammatory
response with important consequences for pathogen clearance
and the development of microbe-specific immunity. However, if
triggered at the wrong time or the wrong place, this rapid
reaction toward most bacteria may also lead to inflammation-
related damage and detrimental clinical outcome. These findings
improve our insight into the complex cellular interactions in early
infection, identify novel biomarkers of possible diagnostic and
predictive value and highlight new avenues for therapeutic
intervention.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki and under local ethical guidelines
(Bro Taf Health Authority, Wales). The study was approved by the
South East Wales Local Ethics Committee under reference
number 04WSE04/27. All patients provided written informed
consent for the collection of samples and subsequent analysis.
Patients
The Cardiff study population included 39 adult patients who
were receiving PD at the University Hospital of Wales, Cardiff,
UK, and were admitted with acute peritonitis between September
2008 and October 2010 (Table S2 in Text S1). Eight stable
patients with no infection in the previous 3 months were included
in this study as non-infected controls. In addition, microbiological
and survival data were obtained from all 739 adult patients who
were receiving PD between 1987 and 2008 at the University
Hospital of North Staffordshire, Stoke-on-Trent, UK; and from all
2,542 Australian adult patients from the Australia and New
Zealand Dialysis Transplant (ANZDATA) Registry who were
receiving PD between 2003 and 2008 (Table S2 in Text S1).
Diagnosis of acute peritonitis was based on the presence of
abdominal pain and cloudy peritoneal effluent with .100 WBC/
mm3. Infections were grouped into culture-positive and culture-
negative episodes, according to the result of the microbiological
analysis of the effluent. Bacteria species identified in culture-
positive infections were grouped into HMB-PP+ and HMB-PP2,
based on the presence or absence of HMB-PP in the microbial
metabolism [17,19]. Endpoints of outcome analyses were 14th and
90th day mortality and technique failure (catheter removal,
transfer to hemodialysis, and/or patient death). In order to rule
out a history of previous antibiotic treatment as a potentially
confounding factor, outcome studies were restricted to patients
with first-episode peritonitis, excluding cases of fungal infection or
unrecorded culture results.
Bacteria culture
Bacteria strains used in this study are listed in Table S1 in Text
S1. Mycobacterium smegmatis strains were grown aerobically at 37uC
in liquid Lemco medium (Oxoid) supplemented with 10 mg/ml
peptone, 5 mg/ml NaCl and 0.25% Tween 80 (Sigma), or on solid
Lemco plates with 15 mg/ml agar (Fisher). Listeria innocua strains
were grown aerobically at 37uC in liquid brain heart infusion
medium (Oxoid) or on agar plates. Escherichia coli laboratory strains
and multi-drug resistant clinical isolates of Acinetobacter baumannii,
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Chryseobacterium indologenes, Enterobacter cloacae, Enterococcus faecalis,
Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus aureus
were grown in liquid LB broth and on solid Columbia blood agar
(Oxoid). Where appropriate, antibiotics were added to the
medium: M. smegmatis-gcpE+, 100 mg/ml hygromycin B; L.
innocua-gcpE+, 7.5 mg/ml chloramphenicol; E. coli-gfp+, 100 mg/ml
ampicillin (all from Sigma). Bacterial susceptibilities to fosmido-
mycin were determined by microbroth dilution method, according
to the Clinical and Laboratory Standards Institute guidelines [84].
A log 2 dilution series of 0.06 to 128 mg/ml allowed the
identification of the minimal inhibitory concentration (MIC)
where bacterial growth was absent. No defined break points have
been acknowledged for fosmidomycin [85], therefore resistance
was defined as concentrations .128 mg/ml.
Cell isolation
Peritoneal cells were harvested from chilled overnight dwell
effluents [31,47]; cell-free supernatants were stored at 270uC.
PBMC were isolated from peripheral blood of healthy volunteers
using Lymphoprep (Axis-Shield). Vc9+ T cells (.98%) were
purified from PBMC using monoclonal antibodies (mAbs) against
Vc9-PE-Cy5 (Immu360; Beckman-Coulter) and anti-PE microbe-
ads (Miltenyi). Monocytes (.98%) were purified using anti-CD14
microbeads (Miltenyi). Neutrophils (.95%) used for bacterial
phagocytosis were isolated from peripheral blood using a
Lymphoprep gradient followed by dextran sedimentation [86].
Remaining erythrocytes were lysed with ammonium chloride
solution (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA), and
neutrophils were washed in HBSS without Mg2+ and Ca2+ (Sigma)
and resuspended to a final cell concentration of 26106/ml in
HBSS with Mg2+ and Ca2+ (Sigma) supplemented with 10%
human serum. Neutrophils (.98%) used in Vc9/Vd2 T cell co-
culture experiments were isolated from peripheral blood by initial
dextran sedimentation followed by centrifugation through discon-
tinuous Percoll gradients [87]. The cell culture medium used
throughout this study was RPMI-1640 with 2 mM L-glutamine,
1% sodium pyruvate, 50 mg/ml penicillin/streptomycin and 10%
fetal calf serum (Invitrogen).
Phagocytosis of live bacteria
Single colonies were grown in culture broth for 18 hours, and
bacteria were washed in PBS and resuspended in HBSS with Mg2+
and Ca2+ supplemented with 10% human serum. Freshly isolated
neutrophils were incubated with bacteria at a multiplicity of
infection (MOI) of 0.1–100 bacteria per neutrophil for 30–60 min
at 37uC, with gentle shaking. In some experiments, bacteria were
pre-treated with 0.5–25 mg/ml fosmidomycin for 1 hour prior to
phagocytosis. Actual MOIs of all bacterial inocula used were
determined by plating out serial dilutions on agar plates and
expressed as colony forming units (CFU) per neutrophil. Non-
phagocytosed bacteria were washed off three times. For micro-
scopic analyses, neutrophils harboring GFP-expressing bacteria
were washed, counterstained with DAPI (Sigma) and fixed in 2%
paraformaldehyde. Images were acquired on a Nikon Eclipse 80i
fluorescence microscope equipped with a Nikon DXM 1200F
camera and processed with Adobe Photoshop. For the generation
of cell-free supernatants, neutrophils pre-incubated with bacteria
as described above were cultured for 5 hours in complete RPMI-
1640. Supernatants were then harvested and cells removed by
centrifugation at 12,000 g for 10 min. Samples were stored at
220uC and thawed a maximum of 5 times. For some experiments,
neutrophil supernatants were treated with 0.015 U/ml shrimp
alkaline phosphatase for 30 min at 37uC.
Triple co-cultures of neutrophils, monocytes and cd T
cells
Unless indicated otherwise, neutrophils were co-cultured for
20 hours in complete RPMI-1640 medium (further supplemented
with 8 mg/ml colistin (Sigma) for assays involving multi-drug
resistant clinical isolates) with autologous monocytes and cd T cells
at a ratio of 10 neutrophils and 1 monocyte per 1 cd T cell
(10:1:1), in the absence or presence of 0.015 U/ml shrimp alkaline
phosphatase (Roche). Proliferation assays using cd T cells that had
been pre-labeled with CFSE (Molecular Probes) were incubated
for 4–6 days. Controls included co-cultures in the absence or
presence of 1–100 nM synthetic HMB-PP [40] or 1–100 ng/ml
LPS from Salmonella abortus equi (Sigma). In transwell experiments,
neutrophils were separated from cd T cells by 0.4 mm pore
polycarbonate membranes (Fisher Scientific). Cell-free superna-
tants derived from neutrophils after phagocytosis of bacteria were
tested in monocyte-cd T cell co-cultures (1:1) at a dilution of 1 in 3.
Blocking reagents used were anti-IFN-c (25718; R&D Systems);
anti-CD11a (TS1/22) from Dr Ruggero Pardi (DIBIT-Scientific
Institute San Raffaele, Milano, Italy); and sTNFR p75-IgG1 fusion
protein (Enbrel; Amgen); alone or in combination at 10 mg/ml
each. Anti-TCR-Vc9 (Immu360; Beckman Coulter) was used at
1.25 mg/ml.
Flow cytometry
Cells were acquired on an eight-color FACSCanto II (BD
Biosciences) and analyzed with FloJo 7.6 (TreeStar), using
monoclonal antibodies against CD3 (UCHT1), CD15 (HI98),
CD25 (M-A251), CD62L (DREG-56), CD69 (FN50), CD86
(2331) and HLA-DR (L243) from BD Biosciences; TCR-Vc9
(Immu360) and CD40 (mAB89) from Beckman Coulter; and
CD11b (ICRF44) and CD14 (61D3) from eBioscience; together
with appropriate isotype controls. Cells of interest were gated
based on their appearance in side scatter and forward scatter area/
height, exclusion of live/dead staining (fixable Aqua; Invitrogen)
and surface staining: CD32 CD142 CD15+ neutrophils, CD32
CD14+ CD152 monocytes, and CD3+ Vc9+ cd T cells. Apoptotic
cells were identified using Annexin V (BD Biosciences). For
detection of intracellular cytokines, 10 mg/ml brefeldin A (Sigma)
was added to cultures 5 hours prior to harvesting. Surface-stained
cells were labeled using the Fix & Perm kit (eBioscience) and
monoclonal antibodies against IFN-c (45.15; BD Biosciences) and
TNF-a (188; Beckman Coulter).
Culture supernatants and effluent samples
Soluble cytokines in cell culture supernatants were detected
using ELISA kits for IL-1b, IL-6 and IL-17 (R&D Systems); and
IFN-c, TNF-a and CXCL8 (BD Biosciences). All samples were
measured in duplicate on a Dynex MRX II reader. Cell-free
peritoneal effluents were analyzed on a SECTOR Imager 600
(Meso Scale Discovery) for TNF-a, GM-CSF, IFN-c, IL-1b, IL-2,
IL-6, IL-10, IL-12p70, CXCL8 (IL-8) and soluble IL-6 receptor
(sIL-6R). In addition, IL-17, IL-22 and CXCL10 in peritoneal
effluents were measured in duplicate on a Dynex MRX II reader,
using conventional kits (R&D Systems).
Statistical analysis
Data were analyzed using two-tailed Student’s t-tests (GraphPad
Prism 4.0), and considered significant as indicated in the figures
and tables: *, p,0.05; **, p,0.01; ***, p,0.001. Cumulative
survival curves as a function of time were generated using the
Kaplan-Meier approach and compared using the log rank test
(SPSS 16.0).
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Table S1.  Bacteria strains used in the present study.   
Strain Relevant feature Gram HMB-PP Fosmidomycin MIC (g/ml) 
Escherichia coli [Clontech, Cambridge, UK]    
E. coli wt Parental laboratory strain BL21 − + ND 
E. coli-gfp+ BL21 expressing GFP (pAcGFP) − + ND 
Mycobacterium smegmatis [ref. 34]    
M. smegmatis wt Parental laboratory strain mc2155 + + ND 
M. smegmatis-gfp+ mc2155 expressing GFP (pFLAME7) + + ND 
M. smegmatis-gcpE+ mc2155 expressing GcpE from M. tuberculosis + +++ ND 
Listeria innocua [refs. 35,36]    
L. innocua wt Parental laboratory strain APC + − ND 
L. innocua-gfp+ APC expressing GFP + − ND 
L. innocua-gcpE+ APC expressing GcpE from Bacillus subtilis + +++ ND 
L. innocua-gcpE+/lytB+ APC expressing GcpE, LytB from B. subtilis + + ND 
Clinical isolates [this study]    
Acinetobacter baumannii  Strain 48-694D − + > 128 
Chryseobacterium 
indologenes Strain S281 − − > 128 
Enterobacter cloacae ‘A’ Strain 48-12346 − + 1 
Enterobacter cloacae ‘B’ Strain 69-7329 − + 1 
Enterococcus faecalis Strain IQA 7/09 + − > 128 
Klebsiella pneumoniae  Strain WCH7 − + 32 
Pseudomonas aeruginosa  Strain 75-3755A − + 8 
Staphylococcus aureus  Strain S288 + − > 128 
ND, not determined 
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Table S2.  Characteristics of all patients analyzed in the present study. 
 Stable Acute peritonitis 
 Cardiff (UK) 
Cardiff 
(UK) 
Stoke-on-Trent 
(UK) 
ANZDATA 
(Australia) 
Total number 8 39 385  2,424 
Study period 2008-2010 2008-2010 1987-2008 2003-2008 
Age (mean ± SD) 61.4 ± 19.5 66.3 ± 11.3 57.0 ± 16.0 58.4 ± 16.7 
Women (%) 37.5 35.9 43.1 44.8 
Days on PD (mean ± SD) 1088.5 ± 936.2 1106.1 ± 984.9 532.0 ± 581.9 738.7 ± 502.5 
14th day mortality (%) − 2.6 3.6 1.2 
14th day technique failure (%) − 12.5 9.6 13.4 
90th day mortality (%) − 10.3 8.8 1.8 
90th day technique failure (%) − 28.2 19.0 16.8 
Culture-positive infections (%) − 64.1 61.5 85.8 
HMB-PP+ organisms among 
positively identified species (%) − 50.0 26.4 38.6 
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Table S3.  Odds ratios for risk of technique failure and mortality within 90 days after infection, depending on the causative pathogen.  
90th day technique 
failure 
 
Stoke-on-Trent
(UK) 
p value ANZDATA (Australia) p value 
ANZDATA + 
Stoke-on-Trent
combined 
p value 
Reference: 
culture-negative  1.0  1.0  1.0  
HMB-PP– 2.0 * 0.8 n.s. 1.0 n.s. 
HMB-PP+ 7.4 *** 3.4 *** 4.1 *** 
Reference: 
HMB-PP–  1.0  1.0  1.0  
Gram+ HMB-PP+ 3.1 n.s. 2.0 0.066 2.1 * 
Gram– HMB-PP+ 3.8 *** 4.3 ** 4.0 *** 
       
90th day mortality       
Reference: 
culture-negative  1.0  1.0  1.0  
HMB-PP– 2.1 n.s. 2.3 n.s. 1.3 n.s. 
HMB-PP+ 6.3 *** 5.4 * 2.8 ** 
Reference: 
HMB-PP–  1.0  1.0  1.0  
Gram+ HMB-PP+ 2.9 n.s. 2.8 n.s. 2.4 n.s. 
Gram– HMB-PP+ 3.0 * 2.4 ** 2.2 ** 
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Figure S1.  Activation of  T cells and dose-dependent secretion of IFN- in neutrophil- T cell 
co-cultures.  Expression of CD69 by V9+ CD3+ T cells was determined after 20 hours in culture by 
flow cytometry; supernatants were analyzed after 20 hours by ELISA.  Data shown are mean values 
+ SEM from independent experiments using three different donors.   
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Figure S2.  Isoprenoid biosynthesis in the Mycobacterium strains used in the present study.  
M. smegmatis possess a fully functional non-mevalonate pathway and hence is capable of producing 
HMB-PP.  Transfection of M. smegmatis with an additional copy of gcpE from M. tuberculosis leads to 
a 2-3 fold accumulation of HMB-PP compared to the wildtype [35].  
Abbreviations: CDP-ME, 4-diphosphocytidyl-2-C-methyl-D-erythritol; CDP-MEP, 4-diphosphocytidyl-
2-C-methyl-D-erythritol 2-phosphate; DMAPP, dimethylallyl pyrophosphate; DOXP, 1-deoxy-D-
xylulose 5-phosphate; HMB-PP, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate; IPP, isopentenyl 
pyrophosphate; MEcPP, 2-C-methyl-D-erythritol 2,4-cyclopyrophosphate; MEP, 2-C-methyl-D-
erythritol 4-phosphate. 
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Figure S3.  Isoprenoid biosynthesis in the Listeria strains used in the present study.  L. innocua 
utilizes the mevalonate pathway (left) but also possesses a rudimentary non-mevalonate pathway (right) 
leading to the production of MEcPP but not of HMB-PP.  Transfection of the wildtype strain with a 
copy of the gcpE (ispG) gene from Bacillus subtilis confers the ability to produce and accumulate 
HMB-PP; co-transfection of L. innocua gcpE+ with the lytB (ispH) gene from B. subtilis rescues the 
non-mevalonate pathway in L. innocua and leads to intermediate HMB-PP levels due to reduction of 
HMB-PP into IPP and DMAPP [36,37]. 
Abbreviations: CDP-ME, 4-diphosphocytidyl-2-C-methyl-D-erythritol; CDP-MEP, 4-diphosphocytidyl-
2-C-methyl-D-erythritol 2-phosphate; DMAPP, dimethylallyl pyrophosphate; DOXP, 1-deoxy-D-
xylulose 5-phosphate; HMB-PP, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate; HMG-CoA, 
3-hydroxy-3-methylglutaryl-coenzyme A; IPP, isopentenyl pyrophosphate; MEcPP, 2-C-methyl-D-
erythritol 2,4-cyclopyrophosphate; MEP, 2-C-methyl-D-erythritol 4-phosphate; P, phosphate. 
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Figure S4.  V9/V2 T cells respond to alkaline phosphatase-sensitive molecules released by 
phagocytosed HMB-PP producing bacteria.  Activation of  T cells by neutrophils harboring a 
range of different bacteria: Gram− HMB-PP+, Acinetobacter baumannii, Enterobacter cloacae (two 
different strains tested), Klebsiella pneumoniae and Pseudomonas aeruginosa; Gram+ HMB-PP+, 
Mycobacterium smegmatis; Gram− HMB-PP−, Chryseobacterium indologenes; and Gram+ HMB-PP−, 
Enterococcus faecalis, Listeria innocua and Staphylococcus aureus; in the presence or absence of 
alkaline phosphatase (AP).  Data shown are representative from independent experiments using 2-5 
different donors. 
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Figure S5.  Neutrophil, monocytes and T cells in acute peritonitis are not influenced by the 
HMB-PP status of the causative pathogen.  Total numbers and frequencies of peritoneal CD15+ 
neutrophils, CD14+ monocytes/macrophages and CD3+ T cells in patients with PD-associated peritonitis 
on day 1 (the day of hospital admission with a cloudy effluent, i.e. before commencement of antibiotic 
therapy), depending on whether or not the causative pathogen was capable of producing HMB-PP. 
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Figure S6.  CD4+ and CD8+ T cells in acute peritonitis are not influenced by the HMB-PP status 
of the causative pathogen.  Proportion of CD4+ and CD8+ T cells within all peritoneal CD3+ T cells in 
patients with PD-associated peritonitis on day 1 (the day of hospital admission with a cloudy effluent, 
i.e. before commencement of antibiotic therapy), depending on whether or not the causative pathogen 
was capable of producing HMB-PP. 
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Figure S7.  The V9/V2 T cells response to HMB-PP producing bacteria is TCR dependent.  
Proliferation after 5 days in culture of CFSE-labeled V9/V2 T cells in response to supernatants from 
neutrophils harboring Enterobacter cloacae, in the presence or absence of soluble TNF- receptor 
(sTNFR) or antibodies against CD11a or TCR-V9.  Data shown are representative of independent 
experiments using cells from two different donors. 
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Figure S8.  Fosmidomycin abrogates HMB-PP dependent  T cell responses to phagocytosed 
bacteria but does not affect bacterial uptake by neutrophils.  (A) Overview of the non-mevalonate 
pathway of isoprenoid biosynthesis.  The bacterial genes encoding the enzymes indicated are 
highlighted in blue.  Fosmidomycin blocks HMB-PP production by inhibiting the second step of the 
pathway.  DOXP, 1-deoxy-D-xylulose 5-phosphate; MEP, 2-C-methyl-D-erythritol 4-phosphate; 
CDP-ME, 4-diphosphocytidyl-2-C-methyl-D-erythritol; CDP-MEP, 4-diphosphocytidyl-2-C-methyl-D-
erythritol 2-phosphate; MEcPP, 2-C-methyl-D-erythritol 2,4-cyclopyrophosphate; IPP, isopentenyl 
pyrophosphate; DMAPP, dimethylallyl pyrophosphate.  (B) Phagocytosis by neutrophils of E. coli-gfp+ 
that had been pre-treated or not for 1 hour with 50 g/ml fosmidomycin (control, neutrophils only).  
GFP fluorescence was determined 1 hour later.  Neutrophil supernatants were collected after 5 hours 
and added to  T cell-monocyte co-cultures for 20 hours.  Data shown are representative of 
independent experiments using cells from two different donors. 
